Mammalian and human nerves control organs and muscles. Artificially stimulating the nerves elicits desired organ and muscle responses. Accessing the nerves to selectively control these responses from outside the body, without invasive implants or needles penetrating the dermis, muscle or fat tissue is desired.
A Topical Nerve Stimulator and Sensor (TNSS) device described in the related U.S. Patent Application Serial No. PCT/US 14/40240 filed May 30, 2014 is used to stimulate nerves. A TNSS may apply electrode generated electric field(s) in a low frequency to dermis in the proximity of a nerve. The TNSS also includes hardware and logic for high frequency (GHz) communication to mobile devices.
A wireless system including a TNSS device is described herein. Its components, features and performance characteristics are set forth in the following technical description. Advantages of a wireless TNSS system over existing transcutaneous electrical nerve stimulation devices are:
fine control of all stimulation parameters from a remote device such as a smartphone, either directly by the user or by stored programs;
multiple electrodes of a TNSS can form an array to shape an electric field in the tissues;
multiple TNSS devices can form an array to shape an electric field in the tissues;
multiple TNSS devices can stimulate multiple structures, coordinated by a smartphone;
selective stimulation of nerves and other structures at different locations and depths in a volume of tissue;
mechanical, acoustic or optical stimulation in addition to electrical stimulation;
transmitting antenna of TNSS device can focus beam of electromagnetic energy within tissues in short bursts to activate nerves directly without implanted devices;
inclusion of multiple sensors of multiple modalities, including but not limited to position, orientation, force, distance, acceleration, pressure, temperature, voltage, light and other electromagnetic radiation, sound, ions or chemical compounds, making it possible to sense electrical activities of muscles (EMG, EKG), mechanical effects of muscle contraction, chemical composition of body fluids, location or dimensions or shape of an organ or tissue by transmission and receiving of ultrasound;
TNSS devices are expected to have service lifetimes of days to weeks and their disposability places less demand on power sources and battery requirements;
combination of stimulation with feedback from artificial or natural sensors for closed loop control of muscle contraction and force, position or orientation of parts of the body, pressure within organs, and concentrations of ions and chemical compounds in the tissues;
multiple TNSS devices can form a network with each other, with remote controllers, with other devices, with the internet and with other users;
collection of large amounts of data from one or many TNSS devices and one or many users regarding sensing and stimulation, collected and stored locally or through the internet;
analysis of large amounts of data to detect patterns of sensing and stimulation, apply machine learning, and improve algorithms and functions;
creation of databases and knowledge bases of value;
convenience;
power management that utilizes both hardware and software functions will be critical to the convenience factor and widespread deployment of TNSS device.
Referring to
Referring to
If the action potential reaches a junction, known as a synapse, with another nerve cell, the transient change in membrane voltage results in the release of chemicals known as neuro-transmitters that can initiate an action potential in the other cell. This provides a means of rapid electrical communication between cells, analogous to passing a digital pulse from one cell to another.
If the action potential reaches a synapse with a muscle cell it can initiate an action potential that spreads over the surface of the muscle cell. This voltage change across the membrane of the muscle cell opens ion channels in the membrane that allow ions such as sodium, potassium and calcium to flow across the membrane, and can result in contraction of the muscle cell.
Increasing the voltage across the membrane of a cell below −70 millivolts is known as hyper-polarization and reduces the probability of an action potential being generated in the cell. This can be useful for reducing nerve activity and thereby reducing unwanted symptoms such as pain and spasticity
The voltage across the membrane of a cell can be changed by creating an electric field in the tissues with a stimulator. It is important to note that action potentials are created within the mammalian nervous system by the brain, the sensory nervous system or other internal means. These action potentials travel along the body's nerve “highways”. The TNSS creates an action potential through an externally applied electric field from outside the body. This is very different than how action potentials are naturally created within the body.
Electric Fields that can Cause Action Potentials
Referring to
Referring to
Formation of Electric Fields by Stimulators
The location and magnitude of the electric potential applied to the tissues by electrodes provides a method of shaping the electrical field. For example, applying two electrodes to the skin, one at a positive electrical potential with respect to the other, can produce a field in the underlying tissues such as that shown in the cross-sectional diagram,
The diagram in
Referring to
Referring to
It is the change in electric field that will cause an action potential to be created in a nerve cell, provided sufficient voltage and the correct orientation of the electric field occurs. More complex three-dimensional arrangements of tissues with different electrical properties can result in more complex three-dimensional electric fields, particularly since tissues have different electrical properties and these properties are different along the length of a tissue and across it, as shown in Table 1.
Modification of Electric Fields by Tissue
An important factor in the formation of electric fields used to create action potentials in nerve cells is the medium through which the electric fields must penetrate. For the human body this medium consists of various types of tissue including bone, fat, muscle, and skin. Each of these tissues possesses different electrical resistivity or conductivity and different capacitance and these properties are anisotropic. They are not uniform in all directions within the tissues. For example, an axon has lower electrical resistivity along its axis than perpendicular to its axis. The wide range of conductivities is shown in Table 1. The three-dimensional structure and resistivity of the tissues will therefore affect the orientation and magnitude of the electric field at any given point in the body.
Modification of Electric Fields by Multiple Electrodes
Applying a larger number of electrodes to the skin can also produce more complex three-dimensional electrical fields that can be shaped by the location of the electrodes and the potential applied to each of them. Referring to
Applying multiple electrodes to a part of the body with complex tissue geometry will thus result in an electric field of a complex shape. The interaction of electrode arrangement and tissue geometry can be modeled using Finite Element Modeling, which is a mathematical method of dividing the tissues into many small elements in order to calculate the shape of a complex electric field. This can be used to design an electric field of a desired shape and orientation to a particular nerve.
High frequency techniques known for modifying an electric field, such as the relation between phases of a beam, cancelling and reinforcing by using phase shifts, may not apply to application of electric fields by TNSSs because they use low frequencies. Instead, the present system uses beam selection to move or shift or shape an electric field, also described as field steering or field shaping, by activating different electrodes, such as from an array of electrodes, to move the field. Selecting different combinations of electrodes from an array may result in beam or field steering. A particular combination of electrodes may shape a beam and/or change the direction of a beam by steering. This may shape the electric field to reach a target nerve selected for stimulation.
Activation of Nerves by Electric Fields
Usually in the past selectivity in activating nerves has required electrodes to be implanted surgically on or near nerves. Using electrodes on the surface of the skin to focus activation selectively on nerves deep in the tissues has many advantages. These include avoidance of surgery, avoidance of the cost of developing complex implants and gaining regulatory approval for them, and avoidance of the risks of long-term implants.
The features of the electric field that determine whether a nerve will be activated to produce an action potential can be modeled mathematically by the Activating Function described by Rattay (Rattay F. The basic mechanism for the electrical stimulation of the nervous system. Neuroscience Vol. 89, No. 2, pp. 335-346, 1999). The electric field can produce a voltage, or extracellular potential, within the tissues that varies along the length of a nerve. If the voltage is proportional to distance along the nerve, the first order spatial derivative will be constant and the second order spatial derivative will be zero. If the voltage is not proportional to distance along the nerve, the first order spatial derivative will not be constant and the second order spatial derivative will not be zero. The Activating Function is proportional to the second-order spatial derivative of the extracellular potential along the nerve. If it is sufficiently greater than zero at a given point it predicts whether the electric field will produce an action potential in the nerve at that point. This prediction may be input to a nerve signature.
In practice this means that electric fields that are varying sufficiently greatly in space or time can produce action potentials in nerves. These action potentials are also most likely to be produced where the orientation of the nerves to the fields change, either because the nerve or the field changes direction. The direction of the nerve can be determined from anatomical studies and imaging studies such as MRI scans. The direction of the field can be determined by the positions and configurations of electrodes and the voltages applied to them, together with the electrical properties of the tissues.
As a result it is possible to activate certain nerves at certain tissue locations selectively while not activating others.
To accurately control an organ or muscle, the nerve to be activated must be accurately selected. This selectivity may be improved by using the system described herein, and described herein as a nerve signature, in several ways, as follows:
Improved algorithms to control the effects when a nerve is stimulated, for example, by measuring the resulting electrical or mechanical activity of muscles and feeding back this information to modify the stimulation and measuring the effects again. Repeated iterations of this process can result in optimizing the selectivity of the stimulation, either by classical closed loop control or by machine learning techniques such as pattern recognition and artificial intelligence;
Improving nerve selectivity by labeling or tagging nerves chemically; for example, introduction of genes into some nerves to render them responsive to light or other electromagnetic radiation can result in the ability to activate these nerves and not others when light or electromagnetic radiation is applied from outside the body;
Improving nerve selectivity by the use of electrical conductors to focus an electric field on a nerve; these conductors might be implanted, but could be passive and much simpler than the active implantable medical devices currently used;
Improving nerve selectivity by the use of reflectors or refractors, either outside or inside the body, to focus a beam of electromagnetic radiation on a nerve. If these reflectors or refractors are implanted, they may be passive and much simpler than the active implantable medical devices currently used;
Improving nerve selectivity by the use of feedback from the person upon whom the stimulation is being performed; this may be an action taken by the person in response to a physical indication such as a muscle activation or a feeling from one or more nerve activations;
Improving nerve selectivity by the use of feedback from sensors associated with the TNSS, or separately from other sensors, that monitor electrical activity associated with the stimulation; and
Improving nerve selectivity by the combination of feedback from both the person or sensors and the TNSS that may be used to create a unique profile of the user's nerve physiology for selected nerve stimulation.
Potential applications of electrical stimulation to the body are shown in
Logic Components
Referring to
Master Control Program
The primary responsibility of the MCP 910 is to coordinate the activities and communications among the various control programs, the Data Manager 920, the User 932, and the external ecosystem and to execute the appropriate response algorithms in each situation. The MCP 910 accomplishes electric field shaping and/or beam steering by providing an electrode activation pattern to the TNSS device 934 to selectively stimulate a target nerve. For example, upon notification by the Communications Controller 930 of an external event or request, the MCP 910 is responsible for executing the appropriate response, working with the Data Manager 920 to formulate the correct response and actions. It integrates data from various sources such as Sensors 938 and external inputs such as TNSS devices 934, and applies the correct security and privacy policies, such as encryption and HIPAA required protocols. It will also manage the User Interface (UI) 912 and the various Application Program Interfaces (APIs) 914 that provide access to external programs.
The MCP is also responsible for effectively managing power consumption by the TNSS device through a combination of software algorithms and hardware components that may include, among other things: computing, communications, and stimulating electronics, antenna, electrodes, sensors, and power sources in the form of conventional or printed batteries.
Communications Controller
The communications controller is responsible for receiving inputs from the User 932, from a plurality of TNSS devices 934, and from 3rd party apps 936 via communications sources such as Internet or cellular networks. The format of such inputs will vary by source and must be received, consolidated, possibly reformatted, and packaged for the Data Manager 920.
User inputs may consist of simple requests for activation of TNSS devices 934 to status and information concerning the User's 932 situation or needs. TNSS devices 934 will provide signaling data that may consist of voltage readings, TNSS 934 status data, responses to control program inquiries, and other signals. The Communications Controller 930 is also responsible for sending data and control requests to the plurality of TNSS devices 934. 3rd party applications 936 can send data, requests, or instructions for the Master Control Program 910 or User 932 via Internet or cellular networks. The Communications Controller 930 is also responsible for communications via the cloud where various software applications reside.
Data Manager
The Data Manager (DM) 920 has primary responsibility for the storage and movement of data to and from the Communications Controller 930, Sensors 938, Actuators 940, and the Master Control Program 910. The DM 920 has the capability to analyze and correlate any of the data under its control. It provides logic to select and activate nerves. Examples of such operations upon the data include: statistical analysis and trend identification; machine learning algorithms; signature analysis and pattern recognition, correlations among the data within the Data Warehouse 926, the Therapy Library 922, the Tissue Models 924, and the Electrode Placement Models 928, and other operations. There are several components to the data that is under its control as described in the following paragraphs.
The Data Warehouse (DW) 926 is where incoming data is stored; examples of this data can be real-time measurements from TNSS devices 934 or from Sensors (938), data streams from the Internet, or control and instructional data from various sources. The DM 920 will analyze data, as specified above, that is held in the DW 926 and cause actions, including the export of data, under MCP 910 control. Certain decision making processes implemented by the DM 920 will identify data patterns both in time, frequency, and spatial domains and store them as signatures for reference by other programs. Techniques like EMG, even multi-electrode EMG, gather a lot of data that is the sum of hundreds to thousands of individual motor units and the normal procedure is to perform complex decomposition analysis on the total signal to attempt to tease out individual motor units and their behavior. The DM 920 will perform big data analysis over the total signal and recognize patterns that relate to specific actions or even individual nerves or motor units. This analysis can be performed over data gathered in time from an individual, or over a population of TNSS Users.
The Therapy Library 922 contains various control regimens for the TNSS devices 934. Regimens specify the parameters and patterns of pulses to be applied by the TNSS devices 934. The width and amplitude of individual pulses may be specified to stimulate nerve axons of a particular size selectively without stimulating nerve axons of other sizes. The frequency of pulses applied may be specified to modulate some reflexes selectively without modulating other reflexes. There are preset regimens that may be loaded from the Cloud 942 or 3rd party apps 936. The regimens may be static read-only as well as adaptive with read-write capabilities so they can be modified in real-time responding to control signals or feedback signals or software updates. Referring to
The Tissue Models 924 are specific to the electrical properties of particular body locations where TNSS devices 934 may be placed. As noted previously, electric fields for production of action potentials will be affected by the different electrical properties of the various tissues that they encounter. Tissue Models 924 are combined with regimens from the Therapy Library 922 and Electrode Placement Models 928 to produce desired actions. Tissue Models 924 may be developed by MRI, Ultrasound or other imaging or measurement of tissue of a body or particular part of a body. This may be accomplished for a particular User 932 and/or based upon a body norm. One such example embodiment of a desired action is the use of a Tissue Model 924 together with a particular Electrode Placement Model 928 to determine how to focus the electric field from electrodes on the surface of the body on a specific deep location corresponding to the pudendal nerve in order to stimulate that nerve selectively to reduce incontinence of urine. Other example embodiments of desired actions may occur when a Tissue Model 924 in combination with regimens from the Therapy Library 22 and Electrode Placement Models 928 produce an electric field that stimulates a sacral nerve. Many other embodiments of desired actions follow for the stimulation of other nerves.
Electrode Placement Models 928 specify electrode configurations that the TNSS devices 934 may apply and activate in particular locations of the body. For example, a TNSS device 934 may have multiple electrodes and the Electrode Placement Model 928 specifies where these electrodes should be placed on the body and which of these electrodes should be active in order to stimulate a specific structure selectively without stimulating other structures, or to focus an electric field on a deep structure. An example embodiment of an electrode configuration is a 4 by 4 set of electrodes within a larger array of multiple electrodes, such as an 8 by 8 array. This 4 by 4 set of electrodes may be specified anywhere within the larger array such as the upper right corner of the 8 by 8 array. Other example embodiments of electrode configurations may be circular electrodes that may even consist of concentric circular electrodes. The TNSS device 934 may contain a wide range of multiple electrodes of which the Electrode Placement Models 928 will specify which subset will be activated. These Electrode Placement Models 928 complement the regimens in the Therapy Library 922 and the Tissue Models 924 and are used together with these other data components to control the electric fields and their interactions with nerves, muscles, tissues and other organs. Other examples may include TNSS devices 934 having merely one or two electrodes, such as but not limited to those utilizing a closed circuit.
Sensor/Actuator Control
Independent sensors 938 and actuators 940 can be part of the TNSS system. Its functions can complement the electrical stimulation and electrical feedback that the TNSS devices 934 provide. An example of such a sensor 938 and actuator 940 include, but are not limited to, an ultrasonic actuator and an ultrasonic receiver that can provide real-time image data of nerves, muscles, bones, and other tissues. Other examples include electrical sensors that detect signals from stimulated tissues or muscles. The Sensor/Actuator Control module 950 provides the ability to control both the actuation and pickup of such signals, all under control of the MCP 910.
Application Program Interfaces
The MCP 910 is also responsible for supervising the various Application Program Interfaces (APIs) that will be made available for 3rd party developers. There may exist more than one API 914 depending upon the specific developer audience to be enabled. For example many statistical focused apps will desire access to the Data Warehouse 926 and its cumulative store of data recorded from TNSS 934 and User 932 inputs. Another group of healthcare professionals may desire access to the Therapy Library 922 and Tissue Models 924 to construct better regimens for addressing specific diseases or disabilities. In each case a different specific API 914 may be appropriate.
The MCP 910 is responsible for many software functions of the TNSS system including system maintenance, debugging and troubleshooting functions, resource and device management, data preparation, analysis, and communications to external devices or programs that exist on the smart phone or in the cloud, and other functions. However, one of its primary functions is to serve as a global request handler taking inputs from devices handled by the Communications Controller 930, external requests from the Sensor Control Actuator Module (950), and 3rd party requests 936.
Examples of High Level Master Control Program (MCP) functions are set forth in the following paragraphs.
The manner in which the MCP handles these requests is shown in
User Request: The RH 960 will determine which of the plurality of User Requests 961 is present such as: activation; display status, deactivation, or data input, e.g. specific User condition. Shown in
TNSS/Sensor Inputs: The RH 960 will perform data analysis over TNSS 934 or Sensor inputs 965. As shown at block 966, it employs data analysis, which may include techniques ranging from DSP decision making processes, image processing algorithms, statistical analysis and other algorithms to analyze the inputs. In
3rd Party Apps: Applications can communicate with the MCP 910, both sending and receiving communications. A typical communication would be to send informational data or commands to a TNSS 934. The RH 960 will analyze the incoming application data, as shown at block 972.
Referring to
One arrangement is to integrate a wide variety of these functions into an SOC, system on chip 1000. Within this is shown a control unit 1002 for data processing, communications, transducer interface and storage and one or more stimulators 1004 and sensors 1006 that are connected to electrodes 1008. An antenna 1010 is incorporated for external communications by the control unit. Also present is an internal power supply 1012, which may be, for example, a battery. An external power supply is another variation of the chip configuration. It may be necessary to include more than one chip to accommodate a wide range of voltages for data processing and stimulation. Electronic circuits and chips will communicate with each other via conductive tracks within the device capable of transferring data and/or power.
The TNSS interprets a data stream from the control device, such as that shown in
The TNSS receives sensory signals from the tissue and translates them to a data stream that is recognized by the control device, such as the example in
Application to Bladder Control
Bladder function may be modified directly or indirectly using the principles described above. Referring to
In other cases, electrical stimulation of these sensory nerves causes action potentials that travel to the spinal cord 1100 where they reduce the activity in motor nerves from the spinal cord to the sphincter, allowing relaxation of the sphincter. This form of neuromodulation can reduce unwanted contraction of the sphincter and provide useful function such as reduced straining to pass urine, an improved stream of urine and more complete bladder emptying, for example in a condition known as Fowler's Syndrome.
In other cases, electrical stimulation of sacral sensory nerves 1110 causes action potentials that travel to the spinal cord 1100 where they increase the activity in nerves from the spinal cord to the internal and external urethral sphincters, producing contraction of these sphincter muscles that surround the exit of the bladder. In other cases, electrical stimulation of motor axons in the pudendal nerve 1130 to the external urethral sphincter muscle can produce contraction of that muscle. Whether the contraction of the sphincters is produced indirectly, as a reflex response to stimulation of sensory nerves, or directly, as a response to stimulation of motor nerves, it can reduce incontinence or leaking of urine, for example during straining, coughing or sneezing. This may benefit some people with stress incontinence.
Electrodes can be applied to the skin on the back of the penis in proximity to the dorsal penile nerve 1140, or to the skin on or near the back of the clitoris in proximity to the dorsal clitoral nerve, at the base of the spine or other sites around the pelvis in proximity to the sacral nerves 1120 or their branches and tributaries or the pudendal nerves 1130 or their branches and tributaries, or the back of the lower leg adjacent to the posterior tibial nerve 1150.
The electrodes are typically used in pairs to apply electrical stimuli in the form of square waves having amplitudes of between 20 and 100 volts, pulse widths of between 100 and 500 microseconds, and a pulse repetition rate of between 3 and 30 pulses per second.
Non-invasive methods of directing or focusing electrical stimulation from electrodes on the surface of the skin towards nerves deeper in the body may also be used to allow selective stimulation of deep nerves such as the sacral nerves 1120 or pudendal nerves 1130 without the need for surgical implantation of electrodes or stimulators.
The electrodes on the surface of the skin are connected to or part of a Topical Nerve Stimulator and Sensor (TNSS) 934 (
Operation
The stimulator may be operated voluntarily by the user or may be operated automatically in response to signals from sensors in the TNSS or elsewhere in a TNSS system shown in
Voluntary Operation by the User for Control of Over Active Bladder or Urge Incontinence
As the bladder 1204 fills, there are usually signals transmitted by sensory nerves 1211 to the brain 1209 resulting in awareness by the user of a sensation of bladder fullness, or an urge to pass urine, or a fear of incontinence; these sensations may or may not be associated with contraction of the bladder.
When these sensations are felt, the user can press a button on the TNSS 934 (
The TNSS 934 (
The TNSS 934 (
Voluntary Operation by the User for Control of Stress Incontinence
When a user becomes aware that they are about to engage in an activity such as straining, coughing or sneezing that may cause stress incontinence, the user can press a button on the TNSS 934 or a control device 1206 to cause electrical stimulation of sacral sensory or motor nerves to produce reflex or direct activation of the urethral sphincters. The contraction of these sphincters may reduce stress incontinence.
Automatic Operation for Control of Over Active Bladder or Urge Incontinence
In some cases it will be possible to control the urge to empty the bladder automatically, without the intervention of the user. The normal feedback to cause the TNSS 934 to be activated for this purpose comes from the user's perception of an urge to urinate, which is communicated to the control device 1206 as described previously. There is a plurality of other non-invasive portable methods of obtaining feedback that can control the bladder in parallel with or separately from this feedback. For example, the TNSS 934 may include an acoustic transceiver that can send an acoustic pulse into the body and detect acoustic echoes from the pelvic region indicating bladder position, shape or volume, or a sensor of bladder pressure may transmit a signal to the TNSS 934 or control device 1206.
The TNSS 934 will then automatically stimulate bladder nerves as described above to inhibit bladder contraction before the user becomes aware of the urge. This automatic mode of operation will make use of the various feedback loops shown in
Automatic Operation for Control of Stress Incontinence
In some cases it will be possible to reduce stress incontinence automatically, without the intervention of the user. The normal feedback to cause the TNSS 934 to be activated for this purpose comes from the user's awareness that they are about the engage in an activity that may cause stress incontinence. There is a plurality of other methods of obtaining feedback that can control the sphincters in parallel with or separately from this feedback. For example, sensors and associated pattern recognition software may detect a pattern of activity indicating an impending sneeze, cough or episode of straining. The control device 1206 and TNSS 934 will then automatically stimulate nerves to cause sphincter contraction and reduce stress incontinence.
Adaptive Operation
With training using data from one or many individuals, software in the TNSS 934 or in the control device 1206 or in other computing systems available via the internet may use machine learning to recognize patterns in time or space and improve determination of when incontinence is about to occur.
There may be additional functions in addition to the operations described above. These include logging functions, incorporating data from the cloud, and data from other sensors and sources.
Upon activation of the TNSS 934 one or more of the following functions can occur.
The user's activation profile is recorded by the TNSS 934 and shared with the control device 1206. The activation profile consists of a User ID, stimulation signal identifier and stimulus parameters, date and time of day, and if the user interface permits, user conditions at the time of activation. Historical data can be gathered and analyzed for the user's benefit.
The control device 1206 and/or the TNSS 934 may accept data from other users via the Internet. Types of data may be instructions from a healthcare professional, population data, statistical analyses and trend data relative to the individual user or across populations. This data can be passed through to the user, or cause actions to be taken, such as alarms or notifications.
Data can be gathered from other sensors, from other sensors, which may be located in the TNSS 1401, in the control device, and other patches, or in other devices, on a continuous basis or only when the TNSS 934 is activated. When the TNSS 934 is activated, these data can be used to alter or modify the stimulation signals that the TNSS 934 transmits to the user. An example would be an acoustic transceiver that may be implemented in MEMS that can both transmit and receive acoustic data to create acoustic images of the bladder and pelvic region. This would allow the TNSS 934 to gather image data of the pelvic region over time and learn the state of bladder, as compared to historical conditions.
This application claims priority to and the benefit of the filing date of United States provisional patent application Ser. No. 62/119,134 filed Feb. 21, 2015. This application also claims priority to and the benefit of the filing date as a continuation-in-part application of U.S. utility patent application Ser. No. 14/893,946 filed Nov. 25, 2015, which claims priority to and the benefit of the filing date as a national stage application of PCT patent application serial no. PCT/US14/40240, filed May 30, 2014, which in turn claims priority to U.S. provisional patent application Ser. No. 61/828,981, filed May 30, 2013.
Number | Name | Date | Kind |
---|---|---|---|
4277980 | Coats et al. | Jul 1981 | A |
4532930 | Crosby et al. | Aug 1985 | A |
4542753 | Brenman et al. | Sep 1985 | A |
4549556 | Tarjan et al. | Oct 1985 | A |
4553549 | Pope et al. | Nov 1985 | A |
4590949 | Pohndorf | May 1986 | A |
4614395 | Peers-Trevarton | Sep 1986 | A |
4658835 | Pohndorf | Apr 1987 | A |
4677989 | Robblee | Jul 1987 | A |
4690144 | Rise et al. | Sep 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4706682 | Stypulkowski et al. | Nov 1987 | A |
4717581 | Robblee | Jan 1988 | A |
4759228 | Butler et al. | Jul 1988 | A |
4800898 | Hess et al. | Jan 1989 | A |
4817628 | Zealear et al. | Apr 1989 | A |
4881526 | Johnson et al. | Nov 1989 | A |
4883666 | Sabel et al. | Nov 1989 | A |
4919148 | Muccio | Apr 1990 | A |
4940453 | Cadwell | Jul 1990 | A |
4959532 | Owechko | Sep 1990 | A |
5031621 | Grandjean et al. | Jul 1991 | A |
5035242 | Franklin et al. | Jul 1991 | A |
5047005 | Cadwell | Sep 1991 | A |
5092332 | Lee et al. | Mar 1992 | A |
5092835 | Schurig et al. | Mar 1992 | A |
5095905 | Klepinski | Mar 1992 | A |
5211657 | Yamada et al. | May 1993 | A |
5265608 | Lee et al. | Nov 1993 | A |
5381801 | McShane et al. | Jan 1995 | A |
5476494 | Edell et al. | Dec 1995 | A |
5501703 | Holsheimer et al. | Mar 1996 | A |
5569307 | Schulman et al. | Oct 1996 | A |
5575813 | Edell et al. | Nov 1996 | A |
5584869 | Heck et al. | Dec 1996 | A |
5597381 | Rizzo, III | Jan 1997 | A |
5603726 | Schulman et al. | Feb 1997 | A |
5609616 | Schulman et al. | Mar 1997 | A |
5628769 | Saringer | May 1997 | A |
5643330 | Holsheimer et al. | Jul 1997 | A |
5679340 | Chappel | Oct 1997 | A |
5713922 | King | Feb 1998 | A |
5738625 | Gluck | Apr 1998 | A |
5741314 | Daly et al. | Apr 1998 | A |
5792209 | Varner | Aug 1998 | A |
5795790 | Schinstine et al. | Aug 1998 | A |
5824022 | Zilberman et al. | Oct 1998 | A |
5830651 | Cauley et al. | Nov 1998 | A |
5837236 | Dinsmore | Nov 1998 | A |
5853370 | Chance et al. | Dec 1998 | A |
5871534 | Messick et al. | Feb 1999 | A |
5876425 | Gord et al. | Mar 1999 | A |
5891437 | Pietropaolo et al. | Apr 1999 | A |
5916870 | Lee et al. | Jun 1999 | A |
5921245 | O'Donnell, Jr. | Jul 1999 | A |
5922012 | Sakano | Jul 1999 | A |
5937318 | Warner, Jr. et al. | Aug 1999 | A |
5938691 | Schulman et al. | Aug 1999 | A |
5948428 | Lee et al. | Sep 1999 | A |
5987361 | Mortimer | Nov 1999 | A |
5989445 | Wise et al. | Nov 1999 | A |
5992769 | Wise et al. | Nov 1999 | A |
6002960 | Sternberger et al. | Dec 1999 | A |
6011018 | Crabtree et al. | Jan 2000 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6058331 | King | May 2000 | A |
6060048 | Cherksey | May 2000 | A |
6060054 | Staerz | May 2000 | A |
6066084 | Edrich et al. | May 2000 | A |
6067474 | Schulman et al. | May 2000 | A |
6085115 | Weaver et al. | Jul 2000 | A |
6096537 | Chappel | Aug 2000 | A |
6119071 | Gorenflo et al. | Sep 2000 | A |
6120538 | Rizzo, III et al. | Sep 2000 | A |
6140116 | Dinsmore | Oct 2000 | A |
6178349 | Kieval | Jan 2001 | B1 |
6203792 | Filbin | Mar 2001 | B1 |
6204053 | Dinsmore | Mar 2001 | B1 |
6258353 | Isacson et al. | Jul 2001 | B1 |
6264950 | Staerz | Jul 2001 | B1 |
6265175 | Gage et al. | Jul 2001 | B1 |
6270831 | Kumar et al. | Aug 2001 | B2 |
6277372 | Fraser et al. | Aug 2001 | B1 |
6284245 | Edge | Sep 2001 | B1 |
6288527 | Sugihara et al. | Sep 2001 | B1 |
6294383 | Isacson et al. | Sep 2001 | B1 |
6304784 | Allee et al. | Oct 2001 | B1 |
6304787 | Kuzma et al. | Oct 2001 | B1 |
6359550 | Brisebois et al. | Mar 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6379393 | Mavroidis et al. | Apr 2002 | B1 |
6392118 | Hammang et al. | May 2002 | B1 |
6392550 | Najor | May 2002 | B1 |
6393327 | Scribner | May 2002 | B1 |
6415186 | Chim et al. | Jul 2002 | B1 |
6421232 | Sallam | Jul 2002 | B2 |
6427083 | Owen et al. | Jul 2002 | B1 |
6444205 | Dinsmore et al. | Sep 2002 | B2 |
6472181 | Mineau-Hanschke | Oct 2002 | B1 |
6510347 | Borkan | Jan 2003 | B2 |
6517833 | Edge | Feb 2003 | B2 |
6533732 | Urmey | Mar 2003 | B1 |
6537200 | Leysieffer et al. | Mar 2003 | B2 |
6546291 | Merfeld et al. | Apr 2003 | B2 |
6561975 | Pool et al. | May 2003 | B1 |
6565503 | Leysieffer et al. | May 2003 | B2 |
6575894 | Leysieffer et al. | Jun 2003 | B2 |
6599695 | Gage et al. | Jul 2003 | B2 |
6640118 | Van Heerden et al. | Oct 2003 | B2 |
6640121 | Telischi et al. | Oct 2003 | B1 |
RE38323 | Sugihara et al. | Nov 2003 | E |
6647297 | Scribner | Nov 2003 | B2 |
6690974 | Archer et al. | Feb 2004 | B2 |
6697674 | Leysieffer | Feb 2004 | B2 |
6727696 | Kruspe et al. | Apr 2004 | B2 |
6744367 | Forster | Jun 2004 | B1 |
6788976 | Gesotti | Sep 2004 | B2 |
6795737 | Gielen et al. | Sep 2004 | B2 |
6807445 | Baumann et al. | Oct 2004 | B2 |
6839596 | Nelson et al. | Jan 2005 | B2 |
6850802 | Holsheimer | Feb 2005 | B2 |
6879855 | Schulman et al. | Apr 2005 | B2 |
6884122 | Robinson et al. | Apr 2005 | B2 |
6892097 | Holsheimer | May 2005 | B2 |
6893812 | Woltering et al. | May 2005 | B2 |
6894616 | Forster | May 2005 | B1 |
6902547 | Aves et al. | Jun 2005 | B2 |
6931273 | Groenewegen et al. | Aug 2005 | B2 |
6949251 | Dalal et al. | Sep 2005 | B2 |
6970745 | Scribner | Nov 2005 | B2 |
6976998 | Rizzo et al. | Dec 2005 | B2 |
7001608 | Fishman et al. | Feb 2006 | B2 |
7003335 | Briancon | Feb 2006 | B2 |
7010351 | Firlik et al. | Mar 2006 | B2 |
7027873 | Pajunk et al. | Apr 2006 | B2 |
7030411 | Krulevitch et al. | Apr 2006 | B2 |
7037603 | Lasater | May 2006 | B2 |
7047080 | Palanker et al. | May 2006 | B2 |
7058455 | Huie, Jr. et al. | Jun 2006 | B2 |
7079882 | Schmidt | Jul 2006 | B1 |
7101542 | Vallera et al. | Sep 2006 | B1 |
7106190 | Owens | Sep 2006 | B1 |
7107104 | Keravel et al. | Sep 2006 | B2 |
7115071 | Sunbeck | Oct 2006 | B1 |
7117034 | Kronberg | Oct 2006 | B2 |
7120499 | Thrope et al. | Oct 2006 | B2 |
7127301 | Okandan et al. | Oct 2006 | B1 |
7155278 | King et al. | Dec 2006 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7174223 | Dalton et al. | Feb 2007 | B2 |
7181288 | Rezai et al. | Feb 2007 | B1 |
7191018 | Gielen et al. | Mar 2007 | B2 |
7193414 | Kruspe et al. | Mar 2007 | B2 |
7206632 | King | Apr 2007 | B2 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7218216 | Uehran | May 2007 | B1 |
7218964 | Hill et al. | May 2007 | B2 |
7228178 | Carroll et al. | Jun 2007 | B2 |
7228727 | Discenzo | Jun 2007 | B2 |
7239918 | Strother et al. | Jul 2007 | B2 |
7249998 | van Esbroeck et al. | Jul 2007 | B2 |
7283867 | Strother et al. | Oct 2007 | B2 |
7297420 | Jiang | Nov 2007 | B2 |
7299034 | Kates | Nov 2007 | B2 |
7308303 | Whitehurst et al. | Dec 2007 | B2 |
7308317 | Okandan et al. | Dec 2007 | B1 |
7333851 | Echauz et al. | Feb 2008 | B2 |
7337004 | Classen et al. | Feb 2008 | B2 |
7349169 | Lee et al. | Mar 2008 | B2 |
RE40209 | Sugihara et al. | Apr 2008 | E |
7376467 | Thrope et al. | May 2008 | B2 |
7384145 | Hetling et al. | Jun 2008 | B2 |
7392093 | Khan | Jun 2008 | B2 |
7398255 | Lauer et al. | Jul 2008 | B2 |
7415309 | McIntyre | Aug 2008 | B2 |
7420760 | Zhang et al. | Sep 2008 | B2 |
7422564 | Parsons et al. | Sep 2008 | B2 |
7435443 | Jiang | Oct 2008 | B2 |
7435585 | Tykocinski et al. | Oct 2008 | B2 |
7437193 | Parramon et al. | Oct 2008 | B2 |
7437196 | Wyler et al. | Oct 2008 | B2 |
7483747 | Gliner et al. | Jan 2009 | B2 |
7499745 | Littrup et al. | Mar 2009 | B2 |
7499748 | Moffitt et al. | Mar 2009 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7519419 | Jiang et al. | Apr 2009 | B2 |
7529582 | DiLorenzo | May 2009 | B1 |
7553307 | Bleich et al. | Jun 2009 | B2 |
7555343 | Bleich | Jun 2009 | B2 |
7561919 | Shalev et al. | Jul 2009 | B2 |
7565199 | Sheffield et al. | Jul 2009 | B2 |
7565200 | Wyler et al. | Jul 2009 | B2 |
7571002 | Thrope et al. | Aug 2009 | B2 |
7571006 | Gordon et al. | Aug 2009 | B2 |
7578819 | Bleich et al. | Aug 2009 | B2 |
7584004 | Caparso et al. | Sep 2009 | B2 |
7587238 | Moffitt et al. | Sep 2009 | B2 |
7598031 | Liew | Oct 2009 | B2 |
7599737 | Yomtov et al. | Oct 2009 | B2 |
7620456 | Gliner et al. | Nov 2009 | B2 |
7622303 | Soykan et al. | Nov 2009 | B2 |
7636597 | Gross et al. | Dec 2009 | B2 |
7643874 | Nitzan et al. | Jan 2010 | B2 |
7657308 | Miles et al. | Feb 2010 | B2 |
7658707 | Topolev | Feb 2010 | B2 |
7662558 | Liew | Feb 2010 | B2 |
7676274 | Hung et al. | Mar 2010 | B2 |
7680526 | McIntyre et al. | Mar 2010 | B2 |
7684866 | Fowler et al. | Mar 2010 | B2 |
7689285 | Garabet | Mar 2010 | B2 |
D613868 | Lhuillery et al. | Apr 2010 | S |
7699768 | Kishawi et al. | Apr 2010 | B2 |
7704740 | Schindler et al. | Apr 2010 | B2 |
7706888 | Jolly | Apr 2010 | B2 |
7706893 | Hung et al. | Apr 2010 | B2 |
7711416 | Akkin et al. | May 2010 | B1 |
7715919 | Osorio et al. | May 2010 | B2 |
7715924 | Rezai et al. | May 2010 | B2 |
7725196 | Machado et al. | May 2010 | B2 |
7732407 | Hunter | Jun 2010 | B2 |
7738968 | Bleich | Jun 2010 | B2 |
7738969 | Bleich | Jun 2010 | B2 |
7740631 | Bleich et al. | Jun 2010 | B2 |
7747318 | John et al. | Jun 2010 | B2 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7756584 | Sheffield et al. | Jul 2010 | B2 |
7769462 | Meadows et al. | Aug 2010 | B2 |
7769470 | Rezai et al. | Aug 2010 | B1 |
7798982 | Zets et al. | Sep 2010 | B2 |
7799021 | Leung et al. | Sep 2010 | B2 |
7801603 | Westlund et al. | Sep 2010 | B2 |
7813809 | Strother et al. | Oct 2010 | B2 |
7819801 | Miles et al. | Oct 2010 | B2 |
7819869 | Godara et al. | Oct 2010 | B2 |
7831305 | Gliner | Nov 2010 | B2 |
7844340 | Pawlowicz, III | Nov 2010 | B2 |
7877136 | Moffitt et al. | Jan 2011 | B1 |
7892180 | Epley | Feb 2011 | B2 |
7894911 | Greenberg et al. | Feb 2011 | B2 |
7894914 | Stahmann et al. | Feb 2011 | B2 |
7899542 | Cowan et al. | Mar 2011 | B2 |
7914842 | Greenberg et al. | Mar 2011 | B1 |
7917231 | Farah et al. | Mar 2011 | B2 |
7918802 | Urmey | Apr 2011 | B2 |
7922676 | Daskal et al. | Apr 2011 | B2 |
7943632 | Katzman et al. | May 2011 | B2 |
7945330 | Gliner et al. | May 2011 | B2 |
7947448 | Couillard-Despres et al. | May 2011 | B2 |
RE42449 | Forster | Jun 2011 | E |
7959577 | Schmitz et al. | Jun 2011 | B2 |
7963915 | Bleich | Jun 2011 | B2 |
7967751 | Goscha et al. | Jun 2011 | B2 |
7974689 | Volpe et al. | Jul 2011 | B2 |
7981144 | Geist et al. | Jul 2011 | B2 |
7988688 | Webb et al. | Aug 2011 | B2 |
7991475 | Tang et al. | Aug 2011 | B1 |
7991480 | Stahmann et al. | Aug 2011 | B2 |
7992521 | Bocquier | Aug 2011 | B2 |
8000782 | Gharib et al. | Aug 2011 | B2 |
8000796 | Tass et al. | Aug 2011 | B2 |
8000804 | Wessendorf et al. | Aug 2011 | B1 |
8010202 | Shah et al. | Aug 2011 | B2 |
8014868 | Greenberg et al. | Sep 2011 | B2 |
8014878 | Greenberg et al. | Sep 2011 | B2 |
8025632 | Einarsson | Sep 2011 | B2 |
8027716 | Gharib et al. | Sep 2011 | B2 |
8033996 | Behar | Oct 2011 | B2 |
8060210 | Carroll | Nov 2011 | B1 |
8065012 | Firlik et al. | Nov 2011 | B2 |
8067173 | Liew | Nov 2011 | B2 |
8073526 | Graham et al. | Dec 2011 | B2 |
8073546 | Sheffield et al. | Dec 2011 | B2 |
8075556 | Betts | Dec 2011 | B2 |
8078252 | Kipke et al. | Dec 2011 | B2 |
8090446 | Fowler et al. | Jan 2012 | B2 |
8092398 | Weinberg et al. | Jan 2012 | B2 |
8095209 | Flaherty | Jan 2012 | B2 |
8101358 | Liew | Jan 2012 | B2 |
8110358 | Liew | Feb 2012 | B2 |
8114019 | Miles et al. | Feb 2012 | B2 |
8114597 | Liew | Feb 2012 | B2 |
8116875 | Osypka et al. | Feb 2012 | B2 |
8126562 | Fowler et al. | Feb 2012 | B2 |
8131376 | Faraji et al. | Mar 2012 | B1 |
8133674 | Liew | Mar 2012 | B2 |
8133675 | Liew | Mar 2012 | B2 |
8135472 | Fowler et al. | Mar 2012 | B2 |
8137258 | Dennis et al. | Mar 2012 | B1 |
8137284 | Miles et al. | Mar 2012 | B2 |
8140152 | John et al. | Mar 2012 | B2 |
8140162 | Jiang et al. | Mar 2012 | B1 |
8140170 | Rezai et al. | Mar 2012 | B2 |
8148072 | Liew | Apr 2012 | B2 |
8155757 | Neisz et al. | Apr 2012 | B1 |
8160713 | Greenberg et al. | Apr 2012 | B2 |
8162846 | Epley | Apr 2012 | B2 |
8165685 | Knutson et al. | Apr 2012 | B1 |
8170676 | Greenberg et al. | May 2012 | B2 |
8174371 | Schwieger | May 2012 | B2 |
8180453 | Greenberg et al. | May 2012 | B2 |
8180460 | Nevsmith et al. | May 2012 | B2 |
8192357 | Miles et al. | Jun 2012 | B2 |
8195300 | Gliner et al. | Jun 2012 | B2 |
8195307 | Vilims | Jun 2012 | B2 |
8200338 | Grennberg et al. | Jun 2012 | B2 |
8215773 | Gibson-Horn et al. | Jul 2012 | B2 |
8216135 | Goscha et al. | Jul 2012 | B2 |
8226661 | Balling et al. | Jul 2012 | B2 |
8228202 | Buchner et al. | Jul 2012 | B2 |
8239036 | Shah et al. | Aug 2012 | B2 |
8255044 | Miles et al. | Aug 2012 | B2 |
8257922 | Liew | Sep 2012 | B2 |
8260428 | Fink et al. | Sep 2012 | B2 |
8260439 | DiUbaldi et al. | Sep 2012 | B2 |
8280516 | Graupe | Oct 2012 | B2 |
8301266 | Zilberman et al. | Oct 2012 | B1 |
8303516 | Schmitz et al. | Nov 2012 | B2 |
8308665 | Harry et al. | Nov 2012 | B2 |
8313443 | Tom | Nov 2012 | B2 |
8323320 | Lowry et al. | Dec 2012 | B2 |
8328354 | Li et al. | Dec 2012 | B2 |
8332037 | Imran | Dec 2012 | B2 |
8332044 | McIntyre | Dec 2012 | B2 |
8346367 | Carroll | Jan 2013 | B2 |
8352022 | Akkin et al. | Jan 2013 | B2 |
8359083 | Clark et al. | Jan 2013 | B2 |
8364257 | Van Den Eerenbeemd | Jan 2013 | B2 |
8364258 | Della Rocca et al. | Jan 2013 | B2 |
8374698 | Ok et al. | Feb 2013 | B2 |
8374701 | Hyde et al. | Feb 2013 | B2 |
8382656 | Brown | Feb 2013 | B1 |
8386032 | Bachinski et al. | Feb 2013 | B2 |
8386053 | Kornet | Feb 2013 | B2 |
8388678 | Singhal et al. | Mar 2013 | B2 |
8391970 | Tracey et al. | Mar 2013 | B2 |
8391986 | Graupe et al. | Mar 2013 | B2 |
8391987 | Faraji et al. | Mar 2013 | B2 |
8396556 | Libbus et al. | Mar 2013 | B2 |
8403841 | Miles et al. | Mar 2013 | B2 |
8406886 | Gaunt et al. | Mar 2013 | B2 |
8412328 | Whelan et al. | Apr 2013 | B2 |
8412335 | Gliner et al. | Apr 2013 | B2 |
8417345 | Machado et al. | Apr 2013 | B2 |
8419653 | Bleich et al. | Apr 2013 | B2 |
8428732 | Nishida et al. | Apr 2013 | B2 |
8428738 | Valencia | Apr 2013 | B2 |
8428739 | Ahuja et al. | Apr 2013 | B2 |
8430882 | Lowry et al. | Apr 2013 | B2 |
8444640 | Demarais et al. | May 2013 | B2 |
8457764 | Ramachandran et al. | Jun 2013 | B2 |
8460167 | Chornenky et al. | Jun 2013 | B2 |
8463383 | Sakai et al. | Jun 2013 | B2 |
8473048 | Greenberg et al. | Jun 2013 | B2 |
8494640 | Peterson et al. | Jul 2013 | B2 |
8494642 | Cowan et al. | Jul 2013 | B2 |
8498717 | Lee et al. | Jul 2013 | B2 |
8498720 | Pellinen et al. | Jul 2013 | B2 |
8506613 | Webb et al. | Aug 2013 | B2 |
8509903 | York et al. | Aug 2013 | B2 |
8512235 | Miles et al. | Aug 2013 | B2 |
8515533 | Rofougaran | Aug 2013 | B2 |
8515543 | Greenberg et al. | Aug 2013 | B2 |
8517961 | Imran et al. | Aug 2013 | B2 |
8524311 | Greenberg et al. | Sep 2013 | B1 |
8532776 | Greenberg et al. | Sep 2013 | B2 |
8538537 | Hulvershorn et al. | Sep 2013 | B2 |
8543210 | Sharma | Sep 2013 | B2 |
8548600 | Deem et al. | Oct 2013 | B2 |
8554328 | Faraji et al. | Oct 2013 | B2 |
8554337 | Barolat | Oct 2013 | B2 |
8556838 | Moutray | Oct 2013 | B2 |
8560041 | Flaherty et al. | Oct 2013 | B2 |
8562521 | Miles et al. | Oct 2013 | B2 |
8565894 | Vetter et al. | Oct 2013 | B2 |
8568331 | Bertagnoli et al. | Oct 2013 | B2 |
8571665 | Moffitt et al. | Oct 2013 | B2 |
8579837 | Makower et al. | Nov 2013 | B1 |
8583238 | Heldman et al. | Nov 2013 | B1 |
8588918 | Bighetti | Nov 2013 | B2 |
8594798 | Osorio et al. | Nov 2013 | B2 |
8600514 | Carroll | Dec 2013 | B1 |
8608664 | Kunitake et al. | Dec 2013 | B2 |
8612002 | Faltys et al. | Dec 2013 | B2 |
8615308 | Hung et al. | Dec 2013 | B2 |
8617808 | Braesch-Andersen et al. | Dec 2013 | B2 |
8626265 | Hempel et al. | Jan 2014 | B2 |
8626305 | Nielsen et al. | Jan 2014 | B2 |
8628469 | Miles et al. | Jan 2014 | B2 |
8634930 | Dalal et al. | Jan 2014 | B2 |
8634932 | Ye et al. | Jan 2014 | B1 |
8639344 | Greenberg et al. | Jan 2014 | B2 |
8644900 | Balberg et al. | Feb 2014 | B2 |
8644937 | Greenberg et al. | Feb 2014 | B2 |
8644938 | Craggs | Feb 2014 | B2 |
8647346 | Bleich et al. | Feb 2014 | B2 |
8649845 | McIntyre et al. | Feb 2014 | B2 |
8649868 | Greenberg et al. | Feb 2014 | B2 |
8652129 | Wu et al. | Feb 2014 | B2 |
8652187 | Wells et al. | Feb 2014 | B2 |
8655455 | Mann et al. | Feb 2014 | B2 |
8660655 | Peterson et al. | Feb 2014 | B2 |
8666500 | Greenberg et al. | Mar 2014 | B2 |
8667971 | Makkar et al. | Mar 2014 | B2 |
8667972 | Makkar et al. | Mar 2014 | B2 |
8669058 | Liew | Mar 2014 | B2 |
8670837 | Daneshvar et al. | Mar 2014 | B2 |
8674838 | Konishi et al. | Mar 2014 | B2 |
8676274 | Li | Mar 2014 | B2 |
8682443 | Faraji et al. | Mar 2014 | B2 |
8698637 | Raichman | Apr 2014 | B2 |
8702685 | Schwartz et al. | Apr 2014 | B2 |
8706241 | Firlik et al. | Apr 2014 | B2 |
8708899 | Miles et al. | Apr 2014 | B2 |
8712517 | Jolly | Apr 2014 | B2 |
8712538 | Greenberg et al. | Apr 2014 | B2 |
8712549 | Zdeblick et al. | Apr 2014 | B2 |
8721637 | Zarins et al. | May 2014 | B2 |
8725251 | Della Rocca et al. | May 2014 | B2 |
8734339 | Rao et al. | May 2014 | B2 |
8740783 | Gharib et al. | Jun 2014 | B2 |
8740896 | Zarins et al. | Jun 2014 | B2 |
8744570 | Lee et al. | Jun 2014 | B2 |
8750957 | Tang et al. | Jun 2014 | B2 |
8753271 | Miles et al. | Jun 2014 | B1 |
8755896 | Humayun et al. | Jun 2014 | B2 |
8761889 | Wingeier et al. | Jun 2014 | B2 |
8774922 | Zarins et al. | Jul 2014 | B2 |
8774937 | Mercanzini et al. | Jul 2014 | B2 |
8777942 | Wu et al. | Jul 2014 | B2 |
8781603 | Ye et al. | Jul 2014 | B2 |
8784461 | Webb et al. | Jul 2014 | B2 |
8788064 | Mercanzini et al. | Jul 2014 | B2 |
8788065 | Rezai et al. | Jul 2014 | B2 |
8790338 | Asirvatham et al. | Jul 2014 | B2 |
8798756 | McClure et al. | Aug 2014 | B2 |
8801589 | Peterchev et al. | Aug 2014 | B2 |
8805467 | Yobas et al. | Aug 2014 | B2 |
8805517 | Radivojevic et al. | Aug 2014 | B2 |
8805521 | Carroll | Aug 2014 | B2 |
8821396 | Miles et al. | Sep 2014 | B1 |
8831750 | Ramachandran et al. | Sep 2014 | B2 |
8834545 | Stafford et al. | Sep 2014 | B2 |
8835163 | Zhao et al. | Sep 2014 | B2 |
8843201 | Heldman et al. | Sep 2014 | B1 |
8843204 | Garnham et al. | Sep 2014 | B2 |
8843210 | Simon et al. | Sep 2014 | B2 |
8849412 | Perryman et al. | Sep 2014 | B2 |
8855767 | Faltys et al. | Oct 2014 | B2 |
8862236 | Wolpaw et al. | Oct 2014 | B2 |
8864665 | Rotondo et al. | Oct 2014 | B2 |
8864759 | Godara et al. | Oct 2014 | B2 |
8866621 | Wolfe et al. | Oct 2014 | B2 |
8868164 | Kabakov et al. | Oct 2014 | B2 |
8868172 | Leyde et al. | Oct 2014 | B2 |
8868216 | Dunagan | Oct 2014 | B2 |
8870857 | Seymour et al. | Oct 2014 | B2 |
8874216 | Kim et al. | Oct 2014 | B2 |
8874239 | Greenberg et al. | Oct 2014 | B2 |
8880189 | Lipani | Nov 2014 | B2 |
8886324 | Beuter et al. | Nov 2014 | B2 |
8888773 | Chang et al. | Nov 2014 | B2 |
8892215 | Lipani | Nov 2014 | B2 |
8903494 | Goldwasser et al. | Dec 2014 | B2 |
8903501 | Perryman | Dec 2014 | B2 |
8909343 | Towe | Dec 2014 | B2 |
8909344 | Arle et al. | Dec 2014 | B2 |
8909345 | Danilov et al. | Dec 2014 | B1 |
8912149 | Rawat et al. | Dec 2014 | B1 |
8915846 | Miles et al. | Dec 2014 | B2 |
8915867 | Imran et al. | Dec 2014 | B2 |
8918178 | Simon et al. | Dec 2014 | B2 |
8921473 | Hyman | Dec 2014 | B1 |
8926959 | Deisseroth et al. | Jan 2015 | B2 |
8929990 | Moffitt et al. | Jan 2015 | B2 |
8932196 | Chornenky et al. | Jan 2015 | B2 |
8942797 | Bartol et al. | Jan 2015 | B2 |
8942812 | Machado et al. | Jan 2015 | B2 |
8942821 | Barolat | Jan 2015 | B2 |
8945004 | Miles et al. | Feb 2015 | B2 |
8945216 | Parker et al. | Feb 2015 | B2 |
8948884 | Ramachandran et al. | Feb 2015 | B2 |
8951193 | Ong et al. | Feb 2015 | B2 |
8954144 | Anderson et al. | Feb 2015 | B2 |
8954150 | Swanson et al. | Feb 2015 | B2 |
8954157 | Faraji et al. | Feb 2015 | B2 |
8954167 | Zarembo et al. | Feb 2015 | B2 |
8956387 | Naghavi et al. | Feb 2015 | B2 |
8958862 | Hetke et al. | Feb 2015 | B2 |
8958883 | Mueller et al. | Feb 2015 | B2 |
8958890 | Kipke et al. | Feb 2015 | B2 |
8965513 | Wingeier et al. | Feb 2015 | B2 |
8969532 | DeFrees et al. | Mar 2015 | B2 |
8972026 | Kipke et al. | Mar 2015 | B2 |
8974402 | Oddsson et al. | Mar 2015 | B2 |
8983593 | Bartol et al. | Mar 2015 | B2 |
8983601 | Fukamachi et al. | Mar 2015 | B2 |
8983628 | Simon et al. | Mar 2015 | B2 |
8983629 | Simon et al. | Mar 2015 | B2 |
8985057 | Woodward | Mar 2015 | B2 |
8986294 | Demarais et al. | Mar 2015 | B2 |
8992522 | Pellegrino et al. | Mar 2015 | B2 |
8996131 | Owen et al. | Mar 2015 | B1 |
8998894 | Mauch et al. | Apr 2015 | B2 |
9002458 | Pal et al. | Apr 2015 | B2 |
9002477 | Burnett | Apr 2015 | B2 |
9005191 | Azamian et al. | Apr 2015 | B2 |
9008784 | Chan et al. | Apr 2015 | B2 |
9014810 | Sauter-Starace et al. | Apr 2015 | B2 |
9014811 | Pal et al. | Apr 2015 | B2 |
9014823 | Simon et al. | Apr 2015 | B2 |
9019106 | Alameh et al. | Apr 2015 | B2 |
9020598 | Simon et al. | Apr 2015 | B2 |
9020612 | Danilov et al. | Apr 2015 | B1 |
9023037 | Zarins et al. | May 2015 | B2 |
9034640 | Matos et al. | May 2015 | B2 |
9037268 | Knight | May 2015 | B2 |
9042958 | Karmarkar et al. | May 2015 | B2 |
9043001 | Simon et al. | May 2015 | B2 |
9044596 | Mahadevan-Jansen et al. | Jun 2015 | B2 |
9044611 | Zhao et al. | Jun 2015 | B2 |
9056197 | Kishawi et al. | Jun 2015 | B2 |
9061097 | Holt et al. | Jun 2015 | B2 |
9061134 | Askin, III et al. | Jun 2015 | B2 |
9061135 | Keller et al. | Jun 2015 | B1 |
9072886 | Gaunt et al. | Jul 2015 | B2 |
9072889 | Guarraia et al. | Jul 2015 | B1 |
9072891 | Rao | Jul 2015 | B1 |
9084550 | Bartol et al. | Jul 2015 | B1 |
9084610 | Goshgarian et al. | Jul 2015 | B2 |
9084895 | Greenberg et al. | Jul 2015 | B2 |
9084900 | Hershey et al. | Jul 2015 | B2 |
9089341 | Chomas et al. | Jul 2015 | B2 |
9089687 | Lee et al. | Jul 2015 | B2 |
9089691 | Libbus et al. | Jul 2015 | B2 |
9095267 | Halpern et al. | Aug 2015 | B2 |
9095320 | Littrup et al. | Aug 2015 | B2 |
9095538 | Yu et al. | Aug 2015 | B2 |
9101279 | Ritchey et al. | Aug 2015 | B2 |
9113912 | Mehta et al. | Aug 2015 | B1 |
9114261 | Yonce | Aug 2015 | B2 |
9119628 | Mehta et al. | Sep 2015 | B1 |
9119964 | Marnfeldt | Sep 2015 | B2 |
9126197 | Orwar et al. | Sep 2015 | B2 |
9132058 | Imboden et al. | Sep 2015 | B2 |
9138579 | Wolpaw et al. | Sep 2015 | B2 |
9144677 | Garnham et al. | Sep 2015 | B2 |
9155887 | Miller, III et al. | Oct 2015 | B2 |
9158890 | Meredith et al. | Oct 2015 | B2 |
9162010 | Lenarz et al. | Oct 2015 | B2 |
9162064 | Faltys et al. | Oct 2015 | B2 |
9173585 | Tsampazis et al. | Nov 2015 | B2 |
9179850 | Wingeier et al. | Nov 2015 | B2 |
9179875 | Hua | Nov 2015 | B2 |
9189613 | Tuthill et al. | Nov 2015 | B1 |
9192757 | Seymour | Nov 2015 | B2 |
9192767 | Mercanzini et al. | Nov 2015 | B2 |
9199089 | Perryman et al. | Dec 2015 | B2 |
9205275 | Pan et al. | Dec 2015 | B2 |
9220897 | Perryman et al. | Dec 2015 | B2 |
9220899 | Cattaneo et al. | Dec 2015 | B2 |
9220900 | Libbus et al. | Dec 2015 | B2 |
9221177 | Herr et al. | Dec 2015 | B2 |
9227051 | Fisk et al. | Jan 2016 | B1 |
9227056 | Heldman et al. | Jan 2016 | B1 |
9254382 | Ahmad et al. | Feb 2016 | B2 |
9855427 | Bennett et al. | Jan 2018 | B2 |
9895546 | Jiang et al. | Feb 2018 | B2 |
10118040 | Zhu | Nov 2018 | B2 |
10342977 | Raghunathan | Jul 2019 | B2 |
10412828 | Yamakawa | Sep 2019 | B1 |
20010034477 | Mansfield | Oct 2001 | A1 |
20010055776 | Greenwalt | Dec 2001 | A1 |
20020009461 | Isacson | Jan 2002 | A1 |
20020019652 | Silva et al. | Feb 2002 | A1 |
20020031497 | Fraser | Mar 2002 | A1 |
20020034819 | Smith | Mar 2002 | A1 |
20020055779 | Andrews | May 2002 | A1 |
20020090722 | Dominko | Jul 2002 | A1 |
20020136705 | Dinsmore | Sep 2002 | A1 |
20020176849 | Slepian | Nov 2002 | A1 |
20030002297 | Nemtsev | Jan 2003 | A1 |
20030004547 | Owen | Jan 2003 | A1 |
20030049328 | Dalal | Mar 2003 | A1 |
20030088274 | Gliner | May 2003 | A1 |
20030097161 | Firlik | May 2003 | A1 |
20030100367 | Cooke | May 2003 | A1 |
20030104993 | Rueger | Jun 2003 | A1 |
20030109901 | Greatbatch | Jun 2003 | A1 |
20030125786 | Gliner | Jul 2003 | A1 |
20030149450 | Mayberg | Aug 2003 | A1 |
20030157712 | Daniel | Aug 2003 | A1 |
20030195441 | Firouzgar | Oct 2003 | A1 |
20030198664 | Sullivan | Oct 2003 | A1 |
20030232055 | Medzhitov | Dec 2003 | A1 |
20040005291 | Rogers | Jan 2004 | A1 |
20040014662 | Lindquist | Jan 2004 | A1 |
20040028613 | Quay | Feb 2004 | A1 |
20040030365 | Rubin | Feb 2004 | A1 |
20040038888 | Mercer et al. | Feb 2004 | A1 |
20040048279 | Olek et al. | Mar 2004 | A1 |
20040048373 | Gage et al. | Mar 2004 | A1 |
20040049134 | Tosaya | Mar 2004 | A1 |
20040054300 | Hung et al. | Mar 2004 | A1 |
20040062755 | Smith et al. | Apr 2004 | A1 |
20040064052 | Chance | Apr 2004 | A1 |
20040081652 | Zack | Apr 2004 | A1 |
20040093093 | Andrews | May 2004 | A1 |
20040097401 | Datta | May 2004 | A1 |
20040097839 | Epley | May 2004 | A1 |
20040102525 | Kozachuk | May 2004 | A1 |
20040106966 | Scribner | Jun 2004 | A1 |
20040121464 | Rathjen | Jun 2004 | A1 |
20040143170 | DuRousseau | Jul 2004 | A1 |
20040147975 | Popovic | Jul 2004 | A1 |
20040156826 | Dangond | Aug 2004 | A1 |
20040162583 | Bingham | Aug 2004 | A1 |
20040172100 | Humayun | Sep 2004 | A1 |
20040172102 | Leysieffer | Sep 2004 | A1 |
20040185557 | Smith et al. | Sep 2004 | A1 |
20040199235 | Younis | Oct 2004 | A1 |
20040212504 | Forcier et al. | Oct 2004 | A1 |
20040219184 | Brown et al. | Nov 2004 | A1 |
20040228831 | Belinka, Jr. | Nov 2004 | A1 |
20040229702 | Cooke | Nov 2004 | A1 |
20040230226 | Bingham | Nov 2004 | A1 |
20040243021 | Murphy | Dec 2004 | A1 |
20050003998 | Bertilsson | Jan 2005 | A1 |
20050015133 | Ibrahim | Jan 2005 | A1 |
20050020519 | Albiston | Jan 2005 | A1 |
20050020945 | Tosaya | Jan 2005 | A1 |
20050038473 | Tamarkin | Feb 2005 | A1 |
20050054096 | Piniella | Mar 2005 | A1 |
20050054907 | Page et al. | Mar 2005 | A1 |
20050070819 | Poux | Mar 2005 | A1 |
20050073649 | Spector | Apr 2005 | A1 |
20050107859 | Daglow et al. | May 2005 | A1 |
20050125044 | Tracey | Jun 2005 | A1 |
20050165323 | Montgomery | Jul 2005 | A1 |
20050203366 | Donoghue | Sep 2005 | A1 |
20050203601 | Palanker | Sep 2005 | A1 |
20050222631 | Dalal et al. | Oct 2005 | A1 |
20050226852 | Toda | Oct 2005 | A1 |
20050234370 | Beal | Oct 2005 | A1 |
20050267552 | Conquergood | Dec 2005 | A1 |
20050272097 | Calenoff | Dec 2005 | A1 |
20050273890 | Flaherty | Dec 2005 | A1 |
20050277918 | Shah | Dec 2005 | A1 |
20060034767 | Lum | Feb 2006 | A1 |
20060047326 | Wheeler | Mar 2006 | A1 |
20060049950 | Lockhart | Mar 2006 | A1 |
20060049957 | Surgenor | Mar 2006 | A1 |
20060058627 | Flaherty | Mar 2006 | A1 |
20060118035 | Lasater | Jun 2006 | A1 |
20060122458 | Bleich | Jun 2006 | A1 |
20060122529 | Tsau | Jun 2006 | A1 |
20060122864 | Gottesman | Jun 2006 | A1 |
20060140930 | Rodriguez | Jun 2006 | A1 |
20060149345 | Boggs, II | Jul 2006 | A1 |
20060161225 | Sormann | Jul 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060167564 | Flaherty | Jul 2006 | A1 |
20060171933 | Short | Aug 2006 | A1 |
20060184219 | Pajunk | Aug 2006 | A1 |
20060190056 | Fowler | Aug 2006 | A1 |
20060195146 | Tracey et al. | Aug 2006 | A1 |
20060195153 | Diubaldi et al. | Aug 2006 | A1 |
20060206167 | Flaherty | Sep 2006 | A1 |
20060206178 | Kim | Sep 2006 | A1 |
20060234376 | Mistry | Oct 2006 | A1 |
20060263336 | Caplan | Nov 2006 | A1 |
20060265037 | Kuzma | Nov 2006 | A1 |
20060281130 | Bock | Dec 2006 | A1 |
20070005106 | Adducci | Jan 2007 | A1 |
20070021803 | Deem | Jan 2007 | A1 |
20070043591 | Meretei | Feb 2007 | A1 |
20070049814 | Muccio | Mar 2007 | A1 |
20070049842 | Hill | Mar 2007 | A1 |
20070067004 | Boveja | Mar 2007 | A1 |
20070073361 | Goren | Mar 2007 | A1 |
20070088335 | Jolly | Apr 2007 | A1 |
20070100393 | Whitehurst | May 2007 | A1 |
20070102009 | Wong | May 2007 | A1 |
20070107071 | Couillard-Despres | May 2007 | A1 |
20070123778 | Kantorovich | May 2007 | A1 |
20070129769 | Bourget | Jun 2007 | A1 |
20070134657 | Poznansky | Jun 2007 | A1 |
20070135846 | Knudson | Jun 2007 | A1 |
20070165322 | Strom | Jul 2007 | A1 |
20070173893 | Pitts | Jul 2007 | A1 |
20070173903 | Goren | Jul 2007 | A1 |
20070179558 | Gliner | Aug 2007 | A1 |
20070180542 | Brinster | Aug 2007 | A1 |
20070192881 | Brinster | Aug 2007 | A1 |
20070203533 | Goren | Aug 2007 | A1 |
20070208212 | DiLorenzo | Sep 2007 | A1 |
20070208385 | Carroll | Sep 2007 | A1 |
20070219074 | Pride | Sep 2007 | A1 |
20070239211 | Lorincz | Oct 2007 | A1 |
20070249952 | Rubin | Oct 2007 | A1 |
20070276449 | Gunter | Nov 2007 | A1 |
20070282396 | Overstreet | Dec 2007 | A1 |
20070287613 | Adducci | Dec 2007 | A1 |
20070293893 | Stolen | Dec 2007 | A1 |
20070299483 | Strother | Dec 2007 | A1 |
20080002276 | Strom | Jan 2008 | A1 |
20080033520 | Jolly | Feb 2008 | A1 |
20080040951 | Kates | Feb 2008 | A1 |
20080057028 | Alitalo et al. | Mar 2008 | A1 |
20080064946 | Greenberg | Mar 2008 | A1 |
20080071321 | Boggs, II | Mar 2008 | A1 |
20080074794 | Lee | Mar 2008 | A1 |
20080077192 | Harry et al. | Mar 2008 | A1 |
20080095747 | Rutishauser | Apr 2008 | A1 |
20080097530 | Muccio | Apr 2008 | A1 |
20080120029 | Zelek et al. | May 2008 | A1 |
20080125870 | Carmichael | May 2008 | A1 |
20080133016 | Heinz | Jun 2008 | A1 |
20080139907 | Rao | Jun 2008 | A1 |
20080154335 | Thrope | Jun 2008 | A1 |
20080161879 | Firlik | Jul 2008 | A1 |
20080161882 | Firlik | Jul 2008 | A1 |
20080161887 | Hagen | Jul 2008 | A1 |
20080170234 | Kim | Jul 2008 | A1 |
20080170316 | Kim | Jul 2008 | A1 |
20080195163 | Scharmer | Aug 2008 | A1 |
20080200967 | Ponomarev | Aug 2008 | A1 |
20080208280 | Lindenthaler et al. | Aug 2008 | A1 |
20080215112 | Firlik | Sep 2008 | A1 |
20080221653 | Agrawal | Sep 2008 | A1 |
20080241208 | Shanley | Oct 2008 | A1 |
20080242607 | DeFrees | Oct 2008 | A1 |
20080243218 | Bottomley | Oct 2008 | A1 |
20080248959 | DeFrees | Oct 2008 | A1 |
20080249439 | Tracey | Oct 2008 | A1 |
20080253992 | DeFrees | Oct 2008 | A1 |
20080255582 | Harris | Oct 2008 | A1 |
20080262557 | Brown | Oct 2008 | A1 |
20080262584 | Bottomley | Oct 2008 | A1 |
20080274958 | DeFrees | Nov 2008 | A1 |
20080275546 | Storey | Nov 2008 | A1 |
20080280818 | DeFrees | Nov 2008 | A1 |
20080312538 | Shahar et al. | Dec 2008 | A1 |
20080318314 | Fulga et al. | Dec 2008 | A1 |
20090012586 | Kepecs | Jan 2009 | A1 |
20090012590 | Inman | Jan 2009 | A1 |
20090029912 | Gronthos | Jan 2009 | A1 |
20090036938 | Shipley | Feb 2009 | A1 |
20090036945 | Chancellor | Feb 2009 | A1 |
20090054800 | Martinerie | Feb 2009 | A1 |
20090054950 | Stephens | Feb 2009 | A1 |
20090076421 | Grant, Jr. | Mar 2009 | A1 |
20090076444 | Machado | Mar 2009 | A1 |
20090086015 | Larsen | Apr 2009 | A1 |
20090105149 | Albrechtsen | Apr 2009 | A1 |
20090112278 | Wingeier | Apr 2009 | A1 |
20090112279 | Wingeier | Apr 2009 | A1 |
20090118777 | Iki et al. | May 2009 | A1 |
20090118788 | Firlik | May 2009 | A1 |
20090124965 | Greenberg | May 2009 | A1 |
20090131995 | Sloan et al. | May 2009 | A1 |
20090132018 | DiUbaldi et al. | May 2009 | A1 |
20090149782 | Cohen | Jun 2009 | A1 |
20090149900 | Moffitt et al. | Jun 2009 | A1 |
20090157091 | Buysman | Jun 2009 | A1 |
20090171381 | Schmitz | Jul 2009 | A1 |
20090182393 | Bachinski | Jul 2009 | A1 |
20090201671 | Huntley | Aug 2009 | A1 |
20090214474 | Jennings | Aug 2009 | A1 |
20090215896 | Morseman | Aug 2009 | A1 |
20090220466 | Ratajczak | Sep 2009 | A1 |
20090226598 | Feng | Sep 2009 | A1 |
20090227025 | Nichols | Sep 2009 | A1 |
20090227831 | Burnett et al. | Sep 2009 | A1 |
20090227965 | Wijesiriwardana | Sep 2009 | A1 |
20090234265 | Reid, Jr. | Sep 2009 | A1 |
20090258048 | Ward | Oct 2009 | A1 |
20090270958 | Greenberg | Oct 2009 | A1 |
20090292338 | Gordon | Nov 2009 | A1 |
20090299439 | Mire et al. | Dec 2009 | A1 |
20090306728 | Wright | Dec 2009 | A1 |
20090306745 | Parker | Dec 2009 | A1 |
20090326612 | Distler | Dec 2009 | A1 |
20100004654 | Schmitz | Jan 2010 | A1 |
20100010550 | Ponomarev | Jan 2010 | A1 |
20100016732 | Wells | Jan 2010 | A1 |
20100035299 | DeFrees | Feb 2010 | A1 |
20100037755 | McMillen | Feb 2010 | A1 |
20100042180 | Mueller et al. | Feb 2010 | A1 |
20100042185 | Curtis | Feb 2010 | A1 |
20100045595 | Bakke | Feb 2010 | A1 |
20100047915 | Soykan | Feb 2010 | A1 |
20100092983 | Liew | Apr 2010 | A1 |
20100092984 | Liew | Apr 2010 | A1 |
20100094311 | Jolly et al. | Apr 2010 | A1 |
20100099786 | Dias | Apr 2010 | A1 |
20100112026 | Karp | May 2010 | A1 |
20100114195 | Burnes | May 2010 | A1 |
20100124745 | Liew | May 2010 | A1 |
20100124746 | Liew | May 2010 | A1 |
20100145427 | Gliner | Jun 2010 | A1 |
20100168739 | Wu | Jul 2010 | A1 |
20100179284 | Ward | Jul 2010 | A1 |
20100185042 | Schneider | Jul 2010 | A1 |
20100189712 | L'Heureux | Jul 2010 | A1 |
20100203520 | Liew | Aug 2010 | A1 |
20100204538 | Burnett et al. | Aug 2010 | A1 |
20100204777 | Storey | Aug 2010 | A1 |
20100211172 | Bellamkonda | Aug 2010 | A1 |
20100222630 | Mangrum | Sep 2010 | A1 |
20100222844 | Troosters | Sep 2010 | A1 |
20100241195 | Meadows | Sep 2010 | A1 |
20100268055 | Jung et al. | Oct 2010 | A1 |
20100268125 | Epley | Oct 2010 | A9 |
20100280570 | Sturm | Nov 2010 | A1 |
20100280571 | Sloan | Nov 2010 | A1 |
20100286067 | DeFrees | Nov 2010 | A1 |
20100292759 | Hahn | Nov 2010 | A1 |
20100298916 | Rabischong | Nov 2010 | A1 |
20100304864 | Johnson | Dec 2010 | A1 |
20100305674 | Zarembo | Dec 2010 | A1 |
20100310529 | Aizman | Dec 2010 | A1 |
20100324355 | Spitaels | Dec 2010 | A1 |
20100324626 | Lefkovitz | Dec 2010 | A1 |
20110009959 | Tiedtke | Jan 2011 | A1 |
20110014189 | Soula et al. | Jan 2011 | A1 |
20110022105 | Owen | Jan 2011 | A9 |
20110022131 | Giuliano | Jan 2011 | A1 |
20110028345 | Fang et al. | Feb 2011 | A1 |
20110040204 | Ivorra et al. | Feb 2011 | A1 |
20110040349 | Graupe | Feb 2011 | A1 |
20110059447 | Liew | Mar 2011 | A1 |
20110060266 | Streeter | Mar 2011 | A1 |
20110082531 | Swanson | Apr 2011 | A1 |
20110092863 | Kim | Apr 2011 | A1 |
20110098777 | Silverstone | Apr 2011 | A1 |
20110106207 | Cauller | May 2011 | A1 |
20110106219 | Cauller | May 2011 | A1 |
20110112352 | Pilla et al. | May 2011 | A1 |
20110118556 | Siegel | May 2011 | A1 |
20110124959 | Murison | May 2011 | A1 |
20110137189 | Kuo | Jun 2011 | A1 |
20110158444 | Waldmann | Jun 2011 | A1 |
20110177029 | DeFrees | Jul 2011 | A1 |
20110184269 | Sauter-Starace | Jul 2011 | A1 |
20110190882 | Parker | Aug 2011 | A1 |
20110195106 | McMurtrey | Aug 2011 | A1 |
20110196454 | Strand | Aug 2011 | A1 |
20110202120 | Ball et al. | Aug 2011 | A1 |
20110208226 | Fatone et al. | Aug 2011 | A1 |
20110218593 | Rubinstein et al. | Sep 2011 | A1 |
20110224565 | Ong | Sep 2011 | A1 |
20110224754 | Wei | Sep 2011 | A1 |
20110257501 | Huys et al. | Oct 2011 | A1 |
20110257504 | Hendricks | Oct 2011 | A1 |
20110262501 | Webster | Oct 2011 | A1 |
20110264178 | Mehregany | Oct 2011 | A1 |
20110268776 | Schapira | Nov 2011 | A1 |
20110270345 | Johnston | Nov 2011 | A1 |
20110270361 | Borsody | Nov 2011 | A1 |
20110295156 | Arturi | Dec 2011 | A1 |
20110301662 | Bar-Yoseph | Dec 2011 | A1 |
20110313270 | Pereira Neves | Dec 2011 | A1 |
20110319703 | Wiskerke | Dec 2011 | A1 |
20120016431 | Paul | Jan 2012 | A1 |
20120016440 | Muccio | Jan 2012 | A1 |
20120022616 | Garnham | Jan 2012 | A1 |
20120035684 | Thompson | Feb 2012 | A1 |
20120045487 | Lahann | Feb 2012 | A1 |
20120046702 | Gibson | Feb 2012 | A1 |
20120059389 | Larson | Mar 2012 | A1 |
20120064628 | Blick | Mar 2012 | A1 |
20120076830 | Sitharaman | Mar 2012 | A1 |
20120078327 | Sloan et al. | Mar 2012 | A1 |
20120089047 | Ryba et al. | Apr 2012 | A1 |
20120095166 | Ward | Apr 2012 | A1 |
20120095524 | Nelson | Apr 2012 | A1 |
20120101326 | Simon | Apr 2012 | A1 |
20120101413 | Beetel | Apr 2012 | A1 |
20120109233 | Lee et al. | May 2012 | A1 |
20120123508 | Wentz | May 2012 | A1 |
20120124470 | West | May 2012 | A1 |
20120130360 | Buckley | May 2012 | A1 |
20120134965 | Kim et al. | May 2012 | A1 |
20120136232 | Jeong | May 2012 | A1 |
20120143293 | Mauch et al. | Jun 2012 | A1 |
20120158095 | Jolly | Jun 2012 | A1 |
20120158104 | Huynh | Jun 2012 | A1 |
20120158113 | Jolly et al. | Jun 2012 | A1 |
20120158114 | Debruyne | Jun 2012 | A1 |
20120179076 | Bavelier | Jul 2012 | A1 |
20120185173 | Yamamoto | Jul 2012 | A1 |
20120191052 | Rao | Jul 2012 | A1 |
20120191086 | Moll | Jul 2012 | A1 |
20120197092 | Luo et al. | Aug 2012 | A1 |
20120197252 | Deem | Aug 2012 | A1 |
20120197374 | Vogt | Aug 2012 | A1 |
20120214737 | Marchionni | Aug 2012 | A1 |
20120221072 | Fukamachi | Aug 2012 | A1 |
20120226331 | Banna et al. | Sep 2012 | A1 |
20120237557 | Lewitus et al. | Sep 2012 | A1 |
20120238924 | Avni | Sep 2012 | A1 |
20120239363 | Durrani et al. | Sep 2012 | A1 |
20120244503 | Neveldine | Sep 2012 | A1 |
20120245534 | Jolly | Sep 2012 | A1 |
20120253236 | Snow | Oct 2012 | A1 |
20120259255 | Tomlinson | Oct 2012 | A1 |
20120259390 | Canion | Oct 2012 | A1 |
20120277825 | Mawson | Nov 2012 | A1 |
20120277842 | Kunis | Nov 2012 | A1 |
20120282228 | Bhasin | Nov 2012 | A1 |
20120283800 | Perryman | Nov 2012 | A1 |
20120296191 | McGrath | Nov 2012 | A1 |
20120296230 | Davis | Nov 2012 | A1 |
20120296444 | Greenberg | Nov 2012 | A1 |
20120302856 | Chang | Nov 2012 | A1 |
20120310140 | Kramer | Dec 2012 | A1 |
20120323288 | Anderson | Dec 2012 | A1 |
20130006322 | Tai | Jan 2013 | A1 |
20130012831 | Schmitz | Jan 2013 | A1 |
20130018240 | McCoy | Jan 2013 | A1 |
20130018444 | Glenn | Jan 2013 | A1 |
20130035745 | Ahmed | Feb 2013 | A1 |
20130041432 | Tucker et al. | Feb 2013 | A1 |
20130052712 | Cha | Feb 2013 | A1 |
20130053853 | Schmitz | Feb 2013 | A1 |
20130053934 | Gluckman | Feb 2013 | A1 |
20130066147 | Brown | Mar 2013 | A1 |
20130066216 | Park | Mar 2013 | A1 |
20130066391 | Hulvershorn | Mar 2013 | A1 |
20130066392 | Simon | Mar 2013 | A1 |
20130066395 | Simon | Mar 2013 | A1 |
20130072808 | Neves | Mar 2013 | A1 |
20130072835 | Harry et al. | Mar 2013 | A1 |
20130090542 | Kipke et al. | Apr 2013 | A1 |
20130090711 | Ramachandran | Apr 2013 | A1 |
20130101635 | Park et al. | Apr 2013 | A1 |
20130116685 | Deem et al. | May 2013 | A1 |
20130116744 | Blum | May 2013 | A1 |
20130122528 | Tyrell | May 2013 | A1 |
20130123568 | Hamilton | May 2013 | A1 |
20130123570 | Ly et al. | May 2013 | A1 |
20130131743 | Yamasaki | May 2013 | A1 |
20130131753 | Simon | May 2013 | A1 |
20130137955 | Kong et al. | May 2013 | A1 |
20130144143 | Kim et al. | Jun 2013 | A1 |
20130144369 | Elias | Jun 2013 | A1 |
20130144370 | Debruyne | Jun 2013 | A1 |
20130150653 | Borsody | Jun 2013 | A1 |
20130154838 | Alameh | Jun 2013 | A1 |
20130157229 | Lauritzen | Jun 2013 | A1 |
20130178765 | Mishelevich | Jul 2013 | A1 |
20130184792 | Simon | Jul 2013 | A1 |
20130184795 | Kipke et al. | Jul 2013 | A1 |
20130184799 | Kipke et al. | Jul 2013 | A1 |
20130204122 | Hendler et al. | Aug 2013 | A1 |
20130204317 | Sauter-Starace | Aug 2013 | A1 |
20130210041 | Anderberg | Aug 2013 | A1 |
20130218456 | Zelek | Aug 2013 | A1 |
20130231725 | Williams | Sep 2013 | A1 |
20130238066 | Boggs, II | Sep 2013 | A1 |
20130238074 | Zimmerling | Sep 2013 | A1 |
20130245480 | Crockford | Sep 2013 | A1 |
20130245486 | Simon et al. | Sep 2013 | A1 |
20130245711 | Simon | Sep 2013 | A1 |
20130245712 | Simon | Sep 2013 | A1 |
20130245717 | Stohl et al. | Sep 2013 | A1 |
20130245765 | Lowry et al. | Sep 2013 | A1 |
20130248226 | Sime | Sep 2013 | A1 |
20130253299 | Weber | Sep 2013 | A1 |
20130274540 | Pilla | Oct 2013 | A1 |
20130274658 | Steinke | Oct 2013 | A1 |
20130274842 | Gaunt | Oct 2013 | A1 |
20130280233 | Kahn et al. | Oct 2013 | A1 |
20130282001 | Hezi-Yamit | Oct 2013 | A1 |
20130282090 | Decre | Oct 2013 | A1 |
20130288233 | Murray | Oct 2013 | A1 |
20130289659 | Nelson | Oct 2013 | A1 |
20130289678 | Clark | Oct 2013 | A1 |
20130289686 | Masson | Oct 2013 | A1 |
20130296767 | Zarins et al. | Nov 2013 | A1 |
20130309278 | Peyman | Nov 2013 | A1 |
20130310909 | Simon | Nov 2013 | A1 |
20130317400 | Ferezy | Nov 2013 | A1 |
20130317580 | Simon | Nov 2013 | A1 |
20130324994 | Pellegrino et al. | Dec 2013 | A1 |
20130331869 | Runge et al. | Dec 2013 | A1 |
20130338729 | Spector | Dec 2013 | A1 |
20130341185 | Collaert et al. | Dec 2013 | A1 |
20140003696 | Taghva | Jan 2014 | A1 |
20140018792 | Gang et al. | Jan 2014 | A1 |
20140022162 | Yu et al. | Jan 2014 | A1 |
20140023999 | Greder | Jan 2014 | A1 |
20140024981 | Chun et al. | Jan 2014 | A1 |
20140025301 | Storm, Jr. et al. | Jan 2014 | A1 |
20140030735 | Merali et al. | Jan 2014 | A1 |
20140046423 | Rajguru | Feb 2014 | A1 |
20140051938 | Goldstein et al. | Feb 2014 | A1 |
20140058481 | Perryman et al. | Feb 2014 | A1 |
20140058483 | Zao et al. | Feb 2014 | A1 |
20140066924 | Azamian et al. | Mar 2014 | A1 |
20140073883 | Rao et al. | Mar 2014 | A1 |
20140074186 | Faltys et al. | Mar 2014 | A1 |
20140081682 | Perlmuter | Mar 2014 | A1 |
20140094674 | Nurmikko et al. | Apr 2014 | A1 |
20140099352 | Matheny | Apr 2014 | A1 |
20140107397 | Simon et al. | Apr 2014 | A1 |
20140107398 | Simon et al. | Apr 2014 | A1 |
20140114168 | Block et al. | Apr 2014 | A1 |
20140127171 | Nocera et al. | May 2014 | A1 |
20140128939 | Embrey et al. | May 2014 | A1 |
20140135607 | Lee et al. | May 2014 | A1 |
20140135680 | Peyman | May 2014 | A1 |
20140142374 | Makower et al. | May 2014 | A1 |
20140148649 | Miles et al. | May 2014 | A1 |
20140148871 | Southwell et al. | May 2014 | A1 |
20140148872 | Goldwasser et al. | May 2014 | A1 |
20140155811 | Gibson | Jun 2014 | A1 |
20140155973 | Grigsby et al. | Jun 2014 | A1 |
20140163580 | Tischendorf et al. | Jun 2014 | A1 |
20140163641 | Yao et al. | Jun 2014 | A1 |
20140163658 | Faraji et al. | Jun 2014 | A1 |
20140171807 | Akkin et al. | Jun 2014 | A1 |
20140180036 | Bukkapatnam et al. | Jun 2014 | A1 |
20140180196 | Stone et al. | Jun 2014 | A1 |
20140180365 | Perryman et al. | Jun 2014 | A1 |
20140187872 | Stivoric et al. | Jul 2014 | A1 |
20140194951 | Gong et al. | Jul 2014 | A1 |
20140197937 | Huang et al. | Jul 2014 | A1 |
20140200432 | Banerji et al. | Jul 2014 | A1 |
20140200466 | Sereno et al. | Jul 2014 | A1 |
20140200496 | Hyde et al. | Jul 2014 | A1 |
20140200681 | Kennedy et al. | Jul 2014 | A1 |
20140206947 | Isserow et al. | Jul 2014 | A1 |
20140207292 | Ramagem et al. | Jul 2014 | A1 |
20140213842 | Simon et al. | Jul 2014 | A1 |
20140213971 | Dolan et al. | Jul 2014 | A1 |
20140220555 | Chen et al. | Aug 2014 | A1 |
20140222125 | Glenn et al. | Aug 2014 | A1 |
20140225763 | Kavaler et al. | Aug 2014 | A1 |
20140228901 | Vogt | Aug 2014 | A1 |
20140228926 | Della Santina et al. | Aug 2014 | A1 |
20140235950 | Miles et al. | Aug 2014 | A1 |
20140236249 | Rao et al. | Aug 2014 | A1 |
20140236847 | Hamilton | Aug 2014 | A1 |
20140243616 | Johnson | Aug 2014 | A1 |
20140243932 | Libbus et al. | Aug 2014 | A1 |
20140249395 | Zhou et al. | Sep 2014 | A1 |
20140255461 | McMurtrey | Sep 2014 | A9 |
20140257063 | Ong et al. | Sep 2014 | A1 |
20140257437 | Simon et al. | Sep 2014 | A1 |
20140267123 | Ludwig | Sep 2014 | A1 |
20140275737 | Shore et al. | Sep 2014 | A1 |
20140276718 | Turovskiy et al. | Sep 2014 | A1 |
20140276760 | Bonyak et al. | Sep 2014 | A1 |
20140277031 | Ballakur et al. | Sep 2014 | A1 |
20140277033 | Taylor et al. | Sep 2014 | A1 |
20140277220 | Brennan et al. | Sep 2014 | A1 |
20140277237 | Maskara et al. | Sep 2014 | A1 |
20140277271 | Chan et al. | Sep 2014 | A1 |
20140277310 | Beetel et al. | Sep 2014 | A1 |
20140277582 | Leuthardt et al. | Sep 2014 | A1 |
20140288379 | Miles et al. | Sep 2014 | A1 |
20140296646 | Wingeier et al. | Oct 2014 | A1 |
20140300490 | Kotz et al. | Oct 2014 | A1 |
20140303525 | Sitharaman | Oct 2014 | A1 |
20140303548 | Jolly et al. | Oct 2014 | A1 |
20140304773 | Woods et al. | Oct 2014 | A1 |
20140309548 | Merz et al. | Oct 2014 | A1 |
20140316398 | Kelly et al. | Oct 2014 | A1 |
20140320289 | Raichman | Oct 2014 | A1 |
20140324120 | Bogie et al. | Oct 2014 | A1 |
20140330337 | Linke et al. | Nov 2014 | A1 |
20140336631 | Wu et al. | Nov 2014 | A1 |
20140336722 | Rocon De Lima et al. | Nov 2014 | A1 |
20140350041 | Yun et al. | Nov 2014 | A1 |
20140350633 | Gustafson et al. | Nov 2014 | A1 |
20140357453 | Tamanaha | Dec 2014 | A1 |
20140357933 | Lee et al. | Dec 2014 | A1 |
20140360511 | Mohler | Dec 2014 | A1 |
20140371547 | Gartenberg et al. | Dec 2014 | A1 |
20140371564 | Anikeeva et al. | Dec 2014 | A1 |
20140371622 | Hausman et al. | Dec 2014 | A1 |
20140375457 | Diaz | Dec 2014 | A1 |
20140378779 | Freeman et al. | Dec 2014 | A1 |
20140378789 | McKinley et al. | Dec 2014 | A1 |
20140378946 | Thompson et al. | Dec 2014 | A1 |
20140379045 | Rahimi et al. | Dec 2014 | A1 |
20140379049 | Mashiach et al. | Dec 2014 | A1 |
20150005607 | Cui et al. | Jan 2015 | A1 |
20150005680 | Lipani | Jan 2015 | A1 |
20150005840 | Pal et al. | Jan 2015 | A1 |
20150005841 | Pal et al. | Jan 2015 | A1 |
20150005851 | Bradley | Jan 2015 | A1 |
20150010607 | Francis et al. | Jan 2015 | A1 |
20150012079 | Goroszeniuk et al. | Jan 2015 | A1 |
20150016647 | Segovia Martinez | Jan 2015 | A1 |
20150017140 | Bhatia et al. | Jan 2015 | A1 |
20150018659 | Ware et al. | Jan 2015 | A1 |
20150032044 | Peyman | Jan 2015 | A9 |
20150032178 | Simon et al. | Jan 2015 | A1 |
20150032184 | Muccio | Jan 2015 | A1 |
20150038886 | Snow | Feb 2015 | A1 |
20150039055 | Wagner et al. | Feb 2015 | A1 |
20150049325 | Curtis | Feb 2015 | A1 |
20150051439 | Hillbratt | Feb 2015 | A1 |
20150051684 | Greenberg et al. | Feb 2015 | A1 |
20150057736 | Zachar | Feb 2015 | A1 |
20150059390 | Hayes | Mar 2015 | A1 |
20150062018 | Naidu et al. | Mar 2015 | A1 |
20150066126 | Marx et al. | Mar 2015 | A1 |
20150067422 | Hamilton | Mar 2015 | A1 |
20150073232 | Ahmad et al. | Mar 2015 | A1 |
20150073520 | Strahl et al. | Mar 2015 | A1 |
20150080709 | Chaturvedi | Mar 2015 | A1 |
20150080926 | Emery | Mar 2015 | A1 |
20150088030 | Taylor | Mar 2015 | A1 |
20150088223 | Blum et al. | Mar 2015 | A1 |
20150088224 | Goldwasser et al. | Mar 2015 | A1 |
20150088225 | Noble et al. | Mar 2015 | A1 |
20150102925 | Foldyna et al. | Apr 2015 | A1 |
20150105794 | Dhanasingh et al. | Apr 2015 | A1 |
20150105795 | Lenarz et al. | Apr 2015 | A1 |
20150112234 | McCaffrey et al. | Apr 2015 | A1 |
20150112321 | Cadouri | Apr 2015 | A1 |
20150112359 | Gillbe | Apr 2015 | A1 |
20150112360 | Pellinen et al. | Apr 2015 | A1 |
20150112404 | Holding et al. | Apr 2015 | A1 |
20150112405 | Brown et al. | Apr 2015 | A1 |
20150112408 | Kals | Apr 2015 | A1 |
20150119673 | Pellinen et al. | Apr 2015 | A1 |
20150119790 | Moffitt et al. | Apr 2015 | A1 |
20150119954 | Bhadra et al. | Apr 2015 | A2 |
20150119989 | Pimenta et al. | Apr 2015 | A1 |
20150126997 | Beetel et al. | May 2015 | A1 |
20150133761 | Vetter et al. | May 2015 | A1 |
20150133956 | Dayan et al. | May 2015 | A1 |
20150135840 | Sato et al. | May 2015 | A1 |
20150148643 | Small et al. | May 2015 | A1 |
20150148644 | Vaidyanathan et al. | May 2015 | A1 |
20150148736 | Jolly et al. | May 2015 | A1 |
20150148869 | Dorvall, II et al. | May 2015 | A1 |
20150148878 | Yoo et al. | May 2015 | A1 |
20150150508 | Glenn et al. | Jun 2015 | A1 |
20150157398 | Zarins et al. | Jun 2015 | A1 |
20150157851 | Sefkow et al. | Jun 2015 | A1 |
20150157854 | Hetke et al. | Jun 2015 | A1 |
20150157862 | Greenberg et al. | Jun 2015 | A1 |
20150164360 | Kipke et al. | Jun 2015 | A1 |
20150164401 | Toth et al. | Jun 2015 | A1 |
20150173673 | Toth et al. | Jun 2015 | A1 |
20150173918 | Herr et al. | Jun 2015 | A1 |
20150174403 | Pal et al. | Jun 2015 | A1 |
20150174418 | Tyler et al. | Jun 2015 | A1 |
20150182753 | Harris et al. | Jul 2015 | A1 |
20150190635 | Neuvonen et al. | Jul 2015 | A1 |
20150190636 | Simon et al. | Jul 2015 | A1 |
20150190637 | Simon et al. | Jul 2015 | A1 |
20150196767 | Ahmed | Jul 2015 | A1 |
20150201855 | Pellinen et al. | Jul 2015 | A1 |
20150202331 | Blumenfeld et al. | Jul 2015 | A1 |
20150202437 | Franke et al. | Jul 2015 | A1 |
20150209104 | Tran et al. | Jul 2015 | A1 |
20150209577 | Golestanirad et al. | Jul 2015 | A1 |
20150209586 | Silva et al. | Jul 2015 | A1 |
20150217125 | Chornenky et al. | Aug 2015 | A1 |
20150223731 | Sahin | Aug 2015 | A1 |
20150224300 | Hagr | Aug 2015 | A1 |
20150224330 | Kaib et al. | Aug 2015 | A1 |
20150230749 | Gharib et al. | Aug 2015 | A1 |
20150231396 | Burdick et al. | Aug 2015 | A1 |
20150235529 | Deschamps | Aug 2015 | A1 |
20150238104 | Tass | Aug 2015 | A1 |
20150238253 | Wu et al. | Aug 2015 | A1 |
20150238764 | Franke | Aug 2015 | A1 |
20150246072 | Bhatia et al. | Sep 2015 | A1 |
20150248470 | Coleman et al. | Sep 2015 | A1 |
20150251004 | Imran et al. | Sep 2015 | A1 |
20150254992 | Sethi | Sep 2015 | A1 |
20150257824 | Mauch | Sep 2015 | A1 |
20150272805 | Burnett et al. | Oct 2015 | A1 |
20150273206 | Monteiro | Oct 2015 | A1 |
20150283365 | Dacey, Jr. et al. | Oct 2015 | A1 |
20150284416 | Zhao | Oct 2015 | A1 |
20150290439 | Eldredge et al. | Oct 2015 | A1 |
20150290450 | Kolb et al. | Oct 2015 | A1 |
20150290464 | Monteiro | Oct 2015 | A1 |
20150290472 | Maguire et al. | Oct 2015 | A1 |
20150297104 | Chen et al. | Oct 2015 | A1 |
20150297444 | Tass | Oct 2015 | A1 |
20150297914 | Hamid et al. | Oct 2015 | A1 |
20150305667 | Durand | Oct 2015 | A1 |
20150305686 | Coleman et al. | Oct 2015 | A1 |
20150310762 | Seim et al. | Oct 2015 | A1 |
20150313498 | Coleman et al. | Nov 2015 | A1 |
20150313512 | Hausman et al. | Nov 2015 | A1 |
20150314017 | Zhao | Nov 2015 | A1 |
20150320560 | Mulliken et al. | Nov 2015 | A1 |
20150320588 | Connor | Nov 2015 | A1 |
20150321000 | Rosenbluth et al. | Nov 2015 | A1 |
20150321010 | Marnfeldt | Nov 2015 | A1 |
20150321017 | Perryman et al. | Nov 2015 | A1 |
20150322155 | Zhao | Nov 2015 | A1 |
20150328454 | Lambert | Nov 2015 | A1 |
20150328455 | Meadows et al. | Nov 2015 | A1 |
20150335288 | Toth et al. | Nov 2015 | A1 |
20150335876 | Jeffery et al. | Nov 2015 | A1 |
20150335877 | Jeffery et al. | Nov 2015 | A1 |
20150335883 | Halpern et al. | Nov 2015 | A1 |
20150335888 | Demers et al. | Nov 2015 | A1 |
20150343196 | Vasapollo | Dec 2015 | A1 |
20150343215 | De Ridder | Dec 2015 | A1 |
20150343242 | Tyler et al. | Dec 2015 | A1 |
20150354922 | Carriere | Dec 2015 | A1 |
20150359704 | Imboden et al. | Dec 2015 | A1 |
20150364018 | Mirov et al. | Dec 2015 | A1 |
20150374515 | Meijer et al. | Dec 2015 | A1 |
20150379880 | Sethi | Dec 2015 | A1 |
20160015962 | Maragheh et al. | Jan 2016 | A1 |
20170001003 | Pivonka et al. | Jan 2017 | A1 |
20170080216 | Pham | Mar 2017 | A1 |
20170209693 | An et al. | Jul 2017 | A1 |
20170224990 | Goldwasser et al. | Aug 2017 | A1 |
20170312512 | Creasey et al. | Nov 2017 | A1 |
20170312526 | Steinke et al. | Nov 2017 | A1 |
20170333695 | Kaplan et al. | Nov 2017 | A1 |
20180116877 | Ineichen | May 2018 | A1 |
20180133479 | Bennett et al. | May 2018 | A1 |
20180318585 | Pfeifer | Nov 2018 | A1 |
20200069941 | Campean et al. | Mar 2020 | A1 |
20200069942 | Campean et al. | Mar 2020 | A1 |
Number | Date | Country |
---|---|---|
101868279 | Oct 2010 | CN |
107362447 | Nov 2017 | CN |
2646779 | Jul 1993 | FR |
2011502707 | Jan 2011 | JP |
2012512682 | Jun 2012 | JP |
2013500080 | Jan 2013 | JP |
2013512076 | Apr 2013 | JP |
2009064641 | May 2009 | WO |
2011011748 | Jan 2011 | WO |
2011053607 | May 2011 | WO |
2012129574 | Sep 2012 | WO |
2015183620 | Apr 2016 | WO |
Entry |
---|
US 8,398,630 B2, 03/2013, Demarais et al. (withdrawn) |
US 8,613,701 B2, 12/2013, Rao et al. (withdrawn) |
US 8,652,133 B2, 02/2014, Zarins et al. (withdrawn) |
White, N, et al.; Overactive Bladder; Obstet Gynecol Clin North Am; 2016; 59-68; 43. |
Vigil, HR, et al.; Urinary tract infection in the neurogenic bladder; Transl Androl Urol; 2016; 72-87; 5. |
Su, X, et al.; Optimization of Neuromodulation for Bladder Control in a Rat Cystitis Model; Neuromodulation; 2016; 101-107; 19. |
Speer, LM, et al.; Chronic Pelvic Pain in Women; Am Fam Physician; 2016; 380-387; 93. |
Shah, P, et al.; Unique spatiotemporal neuromodulation of the lumbosacral circuitry shapes locomotor success after spinal cord injury; J Neurotrauma; 2016;Abstract, |
Sanford, MT, et al.; Neuromodulation in neurogenic bladder; Transl Androl Urol; 2016; 117-126; 5. |
Roth, TM; Safe Simultaneous Use of Sacral Neuromodulation and Vagal Nerve Stimulation; Female Pelvic Med Reconstr Surg; 2016; e1-2; 22;Abstract, |
Puccini, F, et al.; Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis; Int Urogynecol J; 2016; 347-354; 27. |
Penson, DF; Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladded and Urinary Retention; J Urol; 2016; 689; 195. |
Olivera, CK, et al.; Non-antimuscarinic treatment for overactive bladder: a systematic review; Am J Obstet Gynecol; 2016;Abstract. |
Noblett, K, et al.; Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder: Neurourol Urodyn: 2016: 246-251: 35. |
Musco, S, et al.; Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women With Overactive Bladder Syndrome; J Sex Med; 2016 |
Mason, MD, et al.; Prospective Evaluation of Sacral Neuromodulation in Children: Outcomes and Urodynamic Predictors of Success; J Urol; 2016. |
Manriquez, V, et al.; Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial: Eur J Obstet Gynecol Reprod Biol: 2016: 42531: 196. |
Lyon, TD, et al.; Pudendal but not tibial nerve stimulation inhibits bladder constractions induced by stimulation of pontine micturition center in cats; Am J Physiol Regul Integr Comp Physiol: 2016: R366-374: 310. |
Iqbal, F, et al.; Bilateral transcutaneous tibial nerve stimulation for chronic constipation; Colorectal Dis; 2016; 173-178; 18. |
Frokjaer, JB, et al.; Modulation of vagal tone enhances gastroduodenal motility and reduces somatic pain sensitivity; Neurogastroenterol Motil; 2016. |
Evers, J, et al.; Reversal of sensory deficit through sacral neuromodulation in an animal model fo fecal incontinence; Neurogastroenterol Motil; 2016;Abstract. |
Devane, LA, et al.; Acute lumbosacral nerve stimulation does not affect anorectal motor function in a rodent model; Neurogastroenterol Motil; 2016; 358-363; 28. |
Choudhary, M, et al.; Inhibitory effects of tibial nerve stimulation on bladder neurophysiology in rats; Springerplus; 2016; 35; 5. |
Cadish, LA, et al.; Stimulation latency and comparison of cycling regimens in women using sacral neuromodulation; Neurourol Urodyn; 2016;Abstract. |
Batla, A, et al.; Lower urinary tract dysfunction in patients with functional movement disorders; J Neurol Sci; 2016; 192-194; 361. |
Baron, M, et al.; [Does urinary sacral neuromodulation improve bowel symptoms other than fecal incontinence: A systematic review]; Prog Urol; 2016;Abstract. |
Zecca, C, et al.; Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis; Int Urogynecol J; 2015. |
Zariffa, J, et al.; A Phase-Based Electrical Plethysmography Approach to Bladder Volume Measurement; Ann Biomed Eng; 2015. |
Yamanishi, T, et al.; Neuromodulation for the Treatment of Lower Urinary Tract Symptoms; Low Urin Tract Symptoms; 2015; 121-132; 7. |
Williams, MJ, et al.; Self-Reported Medication Costs in Patients Receiving Sacral Neuromodulation for Overactive Bladder; Value Health; 2015; A352; 18. |
Wexner, SD, et al.; Current surgical strategies to treat fecal incontinence; Expert Rev Gastroenterol Hepatol; 2015; 1577-1589; 9;Abstract. |
Wenzler, DL, et al.; Proof of concept trial on changes in current perception threshold after sacral neuromodulation; Neuromodulation; 2015; 228-231; discussion 232; 18. |
Wein, AJ; Re: Results of a Prospective, Randomized, Multicenter Study Evaluating Sacral Neuromodulation with InterStim Therapy Compared to Standard Medical Therapy at 6-Months in Subjects with Mild Symptoms of Overactive Bladder; J Urol; 2015; 1051-1052; 194. |
Wark, HA, et al.; Restoration from acute urinary dysfunction using Utah electrode arrays implanted into the feline pudendal nerve; Neuromodulation; 2015; 317-323; 18. |
Veit-Rubin, N, et al.; [Overactive bladder syndrome—a public health challenge]; Rev Med Suisse; 2015; 2016-2021; 11;Abstract. |
Trevizol, AP, et al.; Trigeminal Nerve Stimulation (TNS) for the Treament of Irritable Bowel Syndrome in an Elderly Patient with Major Depressive Disorder: A Case Study; Brain Stimul; 2015; 1235-1236; 8. |
Tian, Y, et al.; Inhibitory Effect and Possible Mechanism of Intraurethral Stimulation on Overactive Bladder in Female Rats; Int Neurourol J; 2015; 151-157; 19. |
Thin, NN, et al.; Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence; Br J Surg; 2015; 349-358; 102. |
Tweel, WA, et al.; Neurogenic bladder in spinal cord injury patients; Res Rep Urol; 2015; 85-99; 7. |
Suskind, AM, et al.; Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention; Urology; 2015; 30-34;86. |
Su, X, et al.; Differentiation and interaction of tibial versus spinal nerve stimulation for micturition control in the rat; Neurourol Urodyn; 2015; 92-97; 34. |
Su, X, et al.; Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex; BMC Urol; 2015; 50; 15. |
Siegel, S, et al.; Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder; Neurourol Urodyn; 2015; 224-230; 34. |
Shvarts, PG, et al.; [The modern methods of the electical stimulation for the management of neurogenic disturbances of urination]; Vopr Kurortol Fizioter Lech Fiz Kult; 2015; 18-21; 92. |
Shi, P, et al.; Bladder response to acute sacral neuromodulation while treating rats in different phases of complete spinal cord injury: a preliminary study; Int Braz J Urol; 2015; 1194-1201; 41. |
Schurch, B, et al.; Dysfunction of lower urinary tract in patients with spinal cord injury; Handb Clin Neurol; 2015; 247-267; 130. |
Scheiner, DA, et al.; [Interstitial cystitis/bladder pain syndrom (IC/BPS)]; Praxis (Bern 1994); 2015; 909-918; 104. |
Sadiq, A, et al.; Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients; Curr Urol Rep; 2015; 44; 16. |
Saber-Khalaf, M, et al.; Sacral neuromodulation outcomes in male patients with chronic urinary retention; Neuromodulation; 2015; 329-334; discussion 334; 18. |
Rogers, MJ, et al.; Propranolol, but not naloxone, enhances spinal reflex bladder activity and reduces pudendal inhibition in cats; Am J Physiol Integr Comp Physiol; 2015; R42-49; 308. |
Rogers, MJ, et al.; Role of glycine in nociceptive and non-nocicpetive bladder reflexes and pudendal afferent inhibition of these reflexes in cats; Neurourol Urodyn; 2015;Abstract. |
Rimmer, CJ, et al.; Short-term Outcomes of a Randomized Pilot Trial of 2 Treatment Regimens of Transcutaneous Tibial Nerve Stimulation for Fecal Incontinence; Dis Colon Rectum; 2015; 974-982; 58. |
Reese, JN, et al.; Role of spinal metabotropic glutamate receptor 5 in pudendal inhibition of the nociceptive bladder reflex in cats; Am J Physiol Renal Physiol; 2015; F832-838; 308. |
Ramage, L, et al.; A systematic review of sacral nerve stimulation for low anterior resection syndrome; Colorectal Dis; 2015; 762-771; 17. |
Rahnama'l, MS, et al.; Evidence for prostaglandin E2 receptor expression in the intramural ganglia of the guinea pig urinary bladder; J Chem Neuroanat; 2015; 43-47; 64-65. |
Phe, V, et al.; How to define a refractory idiopathic overactive bladder?; Neurourol Urodyn; 2015; 42411; 34. |
Peyronnet, B, et al.; [Management of overactive bladder in women]; Prog Urol; 2015; 877-883; 25;Abstract. |
Peters, KM, et al.; Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients; Neurourol Urodyn; 2015;Abstract. |
Peters, KM, et al.; Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients; Low Urin Tract Symptoms; 2015; 77-83; 7. |
Patidar, N, et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: A preliminary report; J Pediatr Urol; 2015; 351.e351-356; 11. |
Parnell, BA, et al.; The effect of sacral neuromodulation on pudendal nerve function and female sexual function; Neurourol Urodyn; 2015; 456-460; 34. |
Panicker, JN, et al.; Lower urinary tract dysfunction in the neurological patient: clinical assessment and management; Lancet Neurol; 2015; 720-732; 14. |
Mishra, NN; Clinical presentation and treament of bladder pain syndrome/interstitial cystitis (BPS/IC) in India; Transl Androl Urol; 2015; 512-523; 4. |
Meissnitzer, T, et al.; CT-Guided Lead Placement for Selective Sacral Neuromodulation to Treat Lower Urinary Tract Dysfunctions; AJR Am J Roentgenol; 2015; 1139-1142; 205. |
Marinkovic, SP, et al.; Neuromodulation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up; Neuromodulation; 2015; 517-521; discussion 521; 18. |
Maeda, Y, et al.; Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement; Colorectal Dis; 2015; O74-87; 17. |
Lombardi, G, et al.; Sacral neuromodulation and female sexuality; Int Urogynecol J; 2015; 1751-1757; 26. |
Lin, YT, et al.; Effects of pudendal neuromodulation on bladder function in chronic spinal cord-injured rats; J Formos Med Assoc; 2015. |
Laudano, MA, et al.; Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries; J Urol; 2015; 449-453; 194. |
La, TH, et al.; Intermittent sacral neuromodulation for idiopathic urgency urinary incontinence in women; Neurourol Urodyn; 2015;Abstract. |
Kuo, TL, et al.; Pelvic floor spasm as a cause of voiding dysfunction; Curr Opin Urol; 2015; 311-316; 25. |
Kumsar, S, et al.; Effects of sacral neuromodulation on isolated urinary bladder function in a rat model of spinal cord injury; Neuromodulation; 2015; 67-74; discussion 74-65; 18. |
Kovacevic, M, et al.; Reflex neuromodulation of bladder function elicited by posterior tibial nerve stimulation in anesthetized rats; Am J Physiol Renal Physiol; 2015; F320-329; 308. |
Knowles, CH, et al.; Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial; Lancet; 2015; 1640-1648; 386. |
Karmarkar, R, et al.; Emergin drugs for overactive baldder; Expert Opin Emerg Drugs; 2015; 613-624; 20;Abstract. |
Karam, R, et al.; Real-Time Classification of Bladder Events for Effective Diagnosis and Treatment of Urinary Incontinence; IEEE Trans Biomed Eng; 2015. |
Joussain, C, et al.; Electrical managment of neurogenic lower urinary tract disorders; Ann Phys Rehabil Med; 2015; 245-250; 58. |
Jin, H, et al.; Electrical neuromodulation at acupoint ST36 normalizes impaired colonic motility induced by rectal distension in dogs; Am J Physiol Gastrointest Liver Physiol; 2015; G368-376; 309. |
Jimenez-Toscano, M, et al.; Efficacy and quality of life after transcutaneous posterior tibial neuromodulation for faecal incontinence; Colorectal Dis; 2015; 718-723; 17. |
Jesus, LE, et al.; Psychosocial and respiratory disease related to severe bladder dysfunction and non-monosymptomatic enuresis; J Pediatr Urol; 2015;Abstract. |
Horrocks, EJ, et al.; Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial); Health Technol Assess; 2015; 1-164; 19. |
Hoag, N, et al.; Underactive Bladder: Clinical Features, Urodynamic Parameters, and Treatment; Int Neurourol J; 2015; 185-189; 19. |
Hill, AJ, et al.; Resolution of Chronic Vulvar Pruritus With Replacement of a Neuromodulation Device; J Minim Invasive Gynecol; 2015; 889-891; 22. |
Heinze, K, et al.; [Neuromodulation—new techniques]; Urologe A; 2015; 373-377; 54. |
Hassouna, MM, et al.; Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective; Can Urol Assoc J; 2015; 242-247; 9. |
Hashim, H, et al.; Patient preferences for treating refractory overactive bladder in the UK; Int Urol Nephrol; 2015; 1619-1627; 47. |
Gupta, P, et al.; Percutaneous tibial nerve stimulation and sacral neuromodulation: an update; Curr Urol Rep; 2015; 4; 16. |
Gormley, EA, et al.; Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment; J Urol; 2015; 1572-1580; 193. |
Franzen, K, et al.; Surgery for urinary incontinence in women 65 years and older: a systematic review; Int Urogynecol J; 2015; 1095-1102; 26. |
Ford, AP, et al.; P2X3 receptors and sensitization of autonomic reflexes; Auton Neurosci; 2015; 16-24; 191. |
Ferroni; MC, et al.; Role of the brain stem in tibial inhibition of the micturition reflex in cats; Am J Physiol Renal Physiol; 2015; F242-250; 309. |
Drossaerts, J, et al.; Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation: Neurourol Urodyn: 2015:Abstract. |
Drossaerts, J, et al.; The value of urodynamic tools to guide patient selection in sacral neuromodulation; World J Urol; 2015; 1889-1895; 33. |
Drake, MJ; Management and rehabilitation of neurologic patients with lower urinary tract dysfunction; Handb Clin Neurol; 2015; 451-468; 130. |
Di Giovangiulio, M, et al.; The Neuromodulation of the Intestinal Immune System and its Relevance in Inflammatory Bowel Disease; Front Immunol; 2015; 590; 6. |
Desrosiers, L, et al.; Urogynecologic conditions: interstitial cystitis/painful bladder syndrome; FP Essent; 2015; 17-22; 430;Abstract. |
De Groat, WC, et al.; Impact of Bioelectronic Medicine on the Neural Regulation of Pelvic Visceral Function; Bioelectron Med; 2015; 25-36; 2015. |
Comiter, CV; Conscious Neuromodulation of the Bladder before Clinical Use; J Urol; 2015; 16-17; 194. |
Colaco, M, et al.; Current guidelines in the management of interstitial cystitis; Tranl Androl Urol; 2015; 677-683; 4. |
Chan, DK, et al.; Effective treatment of dyssynergic defecation using sacral neuromodulation in a patient with cerebral palsy; Female Pelvic Med Reconstr Surg; 2015; e27-29; 21;Abstract. |
Canbaz Kabay, S, et al.; Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients; 12-months results; Neurourol Urodyn; 2015;Abstract. |
Brown, ET, et al.; New evidence in the treatment of overactive bladder; Curr Opin Obstet Gynecol; 2015; 366-372; 27. |
Brink, TS, et al.; A Chronic, Conscious Large Animal Platform to Quantify Therapeutic Effects of Sacral Neuromodulation on Bladder Function; J Urol; 2015; 252-258; 194. |
Beusterien, K, et al.; Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder; Neurourol Urodyn; 2015;Abstract. |
Bertapelle, MP, et al.; Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System; World J Urol; 2015; 1109-1117; 33. |
Bayrak, O, et al.; Botulinum toxin injections for treating neurogenic detrusor overactivity; Turk J Urol; 2015; 221-227; 41. |
Banakhar, M, et al.; Sacral neuromodulation for Genitourinary Problems; Prog Neurol Surg; 2015; 192-199; 29;Abstract. |
Aoun, F, et al.; [Lower urinary tract dysfunction following radical hysterectomy]; Prog Urol; 2015; 1184-1190; 25;Abstract. |
Zheng, J, et al.; [Sacral Neuromodulation in the treatment of intractable constipation]; Zhonghua Wei Chang Wai Ke Za Zhi; 2015; 1175-1178; 17;Abstract. |
Zhao, X, et al.; Diffused and sustained inhibitory effects of intestinal electrical stimulation on intestinal motility mediated via sympathetic pathway; Neuromodulation; 2014; 373-379; discussion 380; 17. |
Zhang, N, et al.; Transcutaneous Neuromodulation at Posterior Tibial Nerve and ST36 for Chronic Constipation; Evid Based Complement Alternat Med; 2014; 560802; 2014. |
Zecca, C, et al.; Motor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practive; Eur J Neurol; 2014; 506-511; 21. |
Yang, G, et al.; Pudendal nerve stimulation and block by a wireless-controlled implantable stimulator in cats; Neuromodulation; 2014; 490-496; discussion 496; 17. |
Xiao, Z, et al.; Somatic modulation of spinal reflex bladder activity mediated by nociceptive bladder afferent nerve fibers in cats; Am J Physiol Renal Physiol; 2014; F673-679; 307. |
Xiao, Z, et al.; Role of spinal GABAA receptors in pudendal inhibition of nociceptive and nonnociceptive bladder reflexes in cats; Am J Physiol Renal Physiol; 2014; F781-789; 306. |
Wood, LN, et al.; Urinary incontinence in women; Bmj; 2014; g4531; 349. |
Withington, J, et al.; The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics databse; BJU Int; 2014; 268-277; 114. |
Wein, AJ; Re: inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; J Urol; 2014; 868-869; 191. |
Unger, CA, et al.; Fecal incontinence: the role of the urologist; Curr Urol Rep; 2014; 388; 15. |
Tang, H, et al.; Combination of sacral neuromodulation and tolterodine of treatment of idiopathic overactive bladder in women: a clinical trial; Urol J; 2014; 1800-1805; 11. |
Sillen, U, et al.; Effects of transcutaneous neuromodulation (TENS) on overactive bladder symptoms in children: a randomized controlled trial; J Pediatr Urol; 2014; 1100-1105; 10. |
Shalom, DF, et al.; Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity; Am J Obstet Gynecol; 2014; 561 e561-565; 211. |
Schwen, Z, et al.; Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats; Neurourol Urodyn; 2014; 1266-1271; 33. |
Possover, M; A novel implantation technique for pudendal nerve stimulation for treatment of overactive bladder and urgency incontinence; J Minim Invasive Gynecol; 2014; 888-892; 21. |
Pescatori, LC, et al.; Sphincteroplasty for anal incontinence; Gastroenterol Rep (Oxf); 2014; 92-97; 2. |
Peeters, K, et al.; Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction; BJU Int; 2014; 789-794; 113. |
Osman, NI, et al.; Fowler's syndrome—a cause of unexplained urinary retention in young women?; Nat Rev Urol; 2014; 87-98; 11;Abstract. |
Noblett, KL, et al.; Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction; Am J Obstet Gynecol; 2014; 99-106; 210. |
Nambiar, A, et al.; Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO); Neurourol Urodyn; 2014; S21-25; 33 Suppl. 3. |
Moon, KH, et al.; Prospective Trial of Sacral Neuromodulation for Refractory Overactive Bladder Syndrome in Korean Patients; Low Urin Tract Symptoms; 2014; 175-179; 6. |
Mehnert, U, et al.; The management of urinary incontinence in the male neurological patient; Curr Opin Urol; 2014; 586-592; 24. |
Mcnevin, MS, et al.; Outcomes associated with Interstim therapy for medically refractory fecal incontinence; Am J Surg; 2014; 735-737; discussion 737-788; 207. |
Mayr, CA, et al.; Cost-effectiveness of novel therapies for overactive bladder; Expert Rev Pharmacoecon Outcomes Res; 2014; 527-535; 14. |
Matsuta, Y, et al.; Poststimlation inhibition of the micturition reflex induced by tibial nerve stimulation in rats; Physiol Rep; 2014; e00205; 2. |
Mamopoulos, A, et al.; Active sacral neuromodulation during pregnancy: a unique case report; Am J Obstet Gynecol; 2014; e4-5; 211. |
Lowette, K, et al.; Role of corticosterone in the murine enteric nervous system during fasting; Am J Physiol Gastointest Liver Physiol; 2014; G905-913; 307. |
Lopez-Delgado, A, et al.; Effect on anal pressure of percutaneous posterior tibial nerve stimulation for faecal incontinence; Colorectal Dis; 2014; 533-537; 16. |
Lombardi, G, et al.; Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience; Spinal Cord; 2014; 241-245; 52. |
Lippmann, QK, et al.; Successful use of sacral neuromodulation in a 12-year-old with cerebral palsy and neurogenic bladder; Neuromodulation; 2014; 396-398; 17. |
Levy, RM; The evolving definition of neuromodulation, Neuromodulation; 2014; 207-210; 17. |
Levin, PJ, et al.; Psychosocial factors related to the use of InterStim(R) for the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2014; 272-275; 20;Abstract. |
Lee, YY; What's New in the Toolbox for Constipation and Fecal Incontinence?; Front Med (Lausanne); 2014; 5; 1. |
Laviana, A, et al.; Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome; Neurosurg Clin N Am; 2014; 33-46; 25. |
Kurpad, R, et al.; The evaluation and management of refractory neurogenic overactive bladder; Curr Urol Rep; 2014; 444; 15. |
Knupfer, SC, et al.; Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction; BMC Urol; 2014; 65; 14. |
Kessler, TM, et al., Urologists' referral attitude for sacral neuromodulationfor treating refractory idiopathic overactive bladder syndrome: discrete choice experiment; Neurourol Urodyn; 2014; 1240-1246; 33. |
Johnsen, NV, et al.; The role of electrical stimulation techniques in the management of the male patient with urgency incontinence; Curr Opin Urol; 2014; 560-565; 24. |
Jacobs, SA, et al.; Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet; Neurourol Urodyn; 2014; 488-492; 33. |
Hotouras, A, et al.; Prospective clinical audit of two neuromodulatory treatments for fecal incontinence: sacral nerve stimulation (SNS) and percutaneouls tibial nerve stimulation (PTNS); Surg Today; 2014; 2124-2130; 44. |
Hamann, MF, et al.; [Urinary incontinence in men and woman. Diagnostics and conservative therapy]; Urologe A; 2014; 1073-1084; quiz 1085-1076; 53. |
Grossi, U, et al.; Sacral neuromodulation for anorectal dysfunction secondary to congenital imperforate anus: report of two cases; Int J Colorectal Dis; 2014; 889-890; 29. |
Giarenis, I, et al.; Managing urinary incontinence: what works?; Climacteric; 2014; 26-33; 17 Suppl 2;Abstract. |
Foditsch, EE, et al.; Laparoscopic placement of a tined lead electrode on the pudendal nerve with urodynamic monitoring of bladder function during electrical stimulation: an acute experimental study in healthy female pigs; Springerplus; 2014; 309; 3. |
Faucheron, JL, et al.; Sacral neuromodulation for bowel dysfunction; Tech Coloproctol; 2014; 42433; 18. |
Falletto, E, et al.; Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group; Tech Coloproctol; 2014; 53-64; 18. |
Evers, J, et al.; Effects of stimulation frequency and intensity in sacral neuromodulation on anorectal inputs to the somatosensory cortex in an experimental model; Br J Surg; 2014; 1317-1328; 101. |
Elneil, S, et al.; Optimizing the duration of assessment of stage-1 sacral Neuromodulation in nonobstructive chronic urinary retention; neuromodulation; 2014; 66-70; discussion 70-61; 17. |
Duelund-Jakobsen, J, et al.; Baseline factors predictive of patient satisfaction with sacral neuromodulation for idiopathic fecal incontinence; Int J Colorectal Dis; 2014; 793-798; 29. |
Donon, L, et al.; [Sacral neuromodulation: results of a monocentric study of 93 patients]; Prog Urol; 2014; 1120-1131; 24;Abstract. |
Chen, ML, et al.; Electrical stimulation of somatic afferent nerves in the foot increases bladder capacity in healthy human subjects; J Urol; 2014; 1009-1013; 191. |
Chen, G, et al.; Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease; Spinal Cord; 2014;Abstract. |
Chandra, A, et al.; Neuromodulation of perineally transposed antropylorus with pudendal nerve anastomosis following total anorectal reconstruction in humans; Neurogastroenterol Motil; 2014; 1342-1348; 26. |
Carrington, EV, et al.; A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal incontinence and constipation; Neurogastroenterol Motil; 2014; 1222-1237; 26. |
Carlucci, L, et al.; Functional variability of sacral roots in bladder control; J Neurosurg Spine; 2014; 961-965; 21. |
Campin, L, et al.; [Urinary functional disorders bound to deep endometriosis and to its treatment: review of the literature]; J Gynecol Obstet Biol Reprod (Paris); 2014; 431-442; 43;Abstract. |
Burnstock, G; Purinergic signalling in the gastrointestinal tract and related organs in health and disease; Purinergic Signal; 2014; 18323; 10. |
Buhmann, H, et al.; [Update on fecal incontinence]; Praxis (Bern 1994); 2014; 1313-1321; 103. |
Gross, T, et al.; Transcutaneous Electrical Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review; Eur Urol; 2016;Abstract. |
Bouguen, G, et al.; Effects of transcutaneous tibial nerve stimulation on anorectal physiology in fecal incontinence: a double-blind placebo-controlled cross-over evaluation; Neurogastroenterol Motil; 2014; 247-254; 26. |
Banakhar, M, et al.; Effect of sacral neuromodulation on female sexual function and quality of life: Are they correlated?; Can Urol Assoc J; 2014; E762-767; 8. |
Balchandra, P, et al.; Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anitcholinerig treatment; Int Urogynecol J; 2014; 1059-1064; 25. |
Anger, JT, et al.; The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population; Neuromodulation; 2014; 72-74; discussion 74; 17. |
Amundsen, CL, et al.; The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial; Contemp Clin Trials; 2014; 272-283; 37 |
Abraham, N, et al.; Urgency after a sling: review of the management; Curr Urol Rep; 2014; 400; 15. |
Zhang, F, et al.; Neural pathways involved in sacral neuromodulation of reflex bladder activity in cats; Am J Physiol Renal Physiol; 2013; F710-717; 304. |
Yih, JM, et al.; Changes in sexual functioning in women after neuromodulation for voiding dysfunction; J Sex Med; 2016; 2477-2483; 10. |
Wein, AJ; Re: is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?; J Urol; 2013; 610-611; 189. |
Veeratterapillay, R, et al.; Augmentation cystoplasty: Contemporary indications, techniques and complications; Indian J Urol; 2013; 322-327; 29. |
Tirlapur, Sa, et al.; Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review; Acta Obstet Gynecol Scand; 2013; 881-887; 92 |
Thomas, GP, et al.; A pilot study of transcutaneous sacral nerve stimulation for faecal incontinence; Colorectal Dis; 2013; 1406-1409; 15. |
Thomas, GP, et al.; Sacral nerve stimulation for faecal incontinence secondary to congenital imperforate anus; Tech Coloproctol; 2013; 227-229; 17. |
Thin, NN, et al.; Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence; Br J Surg; 2013; 1430-1447; 100. |
Suskin, AM, et al.; Understanding the dissemination of sacral neuromodulation; Surg Innov; 2013; 625-630; 20. |
Su, X, et al., Role of the endogenous opioid system in modulation of urinary bladder activity by spinal nerve stimulation; Am J Physiol Renal Physiol; 2013; F52-60; 305. |
Su, X, et al.; Quantification of effectivenss of bilateral and unilateral neuromodulation in the rat bladder rhythmic contraction model; BMC Urol; 2013; 34; 13. |
Su, X, et al.; Neuromodulation attenuates bladder hyperactivity in a rat cystitis model; BMC Urol; 2013; 70; 13. |
Stephany, HA, et al.; Prospective evaluation of sacral nerve modulation in children with validated questionnaires; J Urol; 2013; 1516-1522; 190. |
Smits, MA, et al.; Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy; J Urol; 2013; 2148-2152; 190. |
Shi, P, et al.; Effects of acute sacral neuromodulation on bladder reflex in complete spinal cord injury rats; Neuromodulation; 2013; 583-589; discussion 589; 16. |
Sherif, H, et al.; Posterior tibial nerve stimulation as treatment for the overactive bladder; Arab J Urol; 2013; 131-135; 11. |
Sharma, A, et al.; Review of sacral neuromodulation for management of constipation; Surg Innov; 2013; 614-624; 20. |
Schwen, Z, et al.; Involvement of 5-HT3 receptors in pudendal inhibition of bladder overactivity in cats; Am J Physiol Renal Physiol; 2013; F663-671; 305. |
Schwen, Z, et al.; Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats; Am J Physiol Renal Physiol; 2013; F1663-1668; 305. |
Schuns, O, et al.; Development and characterization of [123]iodotiagabine for in-vivo GABA-transporter imaging; Nucl Med Commun; 2013; 175-179; 34;Abstract. |
Robinson, D, et al.; The medical management of refractory overactive bladder; Maturitas; 2013; 386-390; 74. |
Robinson, D, et al.; The management of overactive bladder refractory to medical therapy; Maturitas; 2013; 101-104; 75. |
Rashid, TG, et al.; Male incontinence: onabotulinum toxin A and sacral nerve stimulation; Curr Opin Urol; 2013; 545-551; 23. |
Rana, MV, et al.; Tripolar spinal cord stimulation for the treatment of abdominal pain associated with irritable bowel syndrome; Neuromodulation; 2013; 73-77; discussion 77; 16. |
Pucciani, F; A review on functional results of sphincter-saving surgery for rectal cancer: the anterior resection syndrome; Updates Surg; 2013; 257-263; 65. |
Peters, KM, et al.; Effect of Sacral Neuromodulation Rate on Overactive Bladder Symptoms: A Randomized Crossover Feasibility Study; Low Urin Tract Symptoms; 2013; 129-133; 5. |
Peters, KM, et al.; Does patient age impact outcomes of neuromodulation?; Neurourol Urodyn; 2013; 30-36; 32. |
Peters, KM, et al.; Clinical outcomes of sacral neuromodulation in patients with neurologic conditions; Urology; 2013; 738-743; 81. |
Peters, KM, et al.; Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study; J Urol; 2013; 2194-2201; 189. |
Peng, CW, et al.; Pudendal neuromodulation with a closed-loop control strategy to improve bladder functions in the animal study; Conf Proc IEEE Eng Med Biol Soc; 2013; 3626-3629; 2013. |
Osman, NI, et al.; Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches; Arab J Urol; 2013; 313-318; 11. |
Offiah, I, et al.; Interstitial cystitis/bladder pain syndrome: diagnosis and management; Int Urogynecol J; 2013; 1243-1256; 24. |
Schneider, MP, et al.; Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review; Eur Urol; 2015; 859-867; 68. |
Natalin, R, et al., Management of OAB in those over age 65; Curr Urol Rep; 2013; 379-385; 14. |
Murphy, AM, et al., Treatment of overactive bladder: what is on the horizon?; Int Urogynecol J; 2013; 42503; 24. |
Matsuta, Y, et al.; Effect of methysergide on pudendal inhibition of micturition reflex in cats; Exp Neurol; 2013; 250-258; 247. |
Matsuta, Y, et al.; Contribution of opioid and metabotropic glutamate receptor mechanisms to inhibition of bladder overactivity by tibial nerve stimulation; Am J Physiol Regul Integr Comp Physiol; 2013; R126-133; 305. |
Martinson, M, et al.; Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation; J Urol; 2013; 2010-216; 189. |
Mally, AD, et al.; Role of opioid and metabotropic glutamate 5 receptors in pudendal inhibition of bladder overactivity in cats; J Urol; 2013; 1574-1579; 189. |
Maher, RM, et al.; A novel externally applied neuromuscular stimulator for the treatment of stress urinary incontinence in women—a pilot study; Neuromodulation; 2013; 590-594; discussion 594; 16. |
Lombardi, G, et al.; Intravesical electrostimulation versus sacral neuromodulation for incomplete spinal cord patients suffering from neurogenic non-obstructive urinary retention; Spinal Cord; 2013; 571-578; 51. |
Kantartzis, KL, et al.; Cost-effectiveness of test phase implantation strategies for InterStim(R) sacral neuromodulation; Female Pelvic Med Reconstr Surg; 2013; 322-327; 19;Abstract. |
Kacker, R, et al.; Electrical and mechanical office-based neuromodulation; Urol Clin North Am; 2013; 581-589; 40. |
Jadav, AM, et al.; Does sacral nerve stimulation improve global pelvic function in women?; Colorectal Dis; 2013; 848-857; 15. |
Hyun, SJ, et al.; Comparative analysis between thoracic spinal cord and sacral neuromodulation in a rat spinal cord injury model: a preliminary report of a rat spinal cord stimulation model; Korean J Spine; 2013; 14-18; 10. |
Hull, T, et al.; Long-term durability of sacral stimulation therapy for chronic fecal incontinence; Dis Colon Rectum; 2013; 234-245; 56. |
Hersh, L, et al.; Clinical management of urinary incontinence in women; Am Fam Physician; 2013; 634-640; 87. |
Hellstrom, PA, et al.; Sacral nerve stimulation lead implantation using the O-arm; BMC Urol; 2013; 48; 13. |
Hassouna, M; Sacral neuromodulation for overactive bladder: Is it worth it?; Can Urol Assoc J; 2013; E454; 7. |
Gleason, JL, et al.; Sacral neuromodulation effects on periurethral sensation and urethral sphincter activity; Neurourol Urodyn; 2013; 476-479; 32. |
Gibbons, SJ et al.; Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics; Aliment Pharmacol Ther; 2013; 689-702; 38. |
Giarenis, I, et al.; Management of refractory overactive bladder; Minerva Ginecol; 2013; 41-52; 65;Abstract. |
Firoozi, F, et al.; Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged; J Urol; 2013; 594-597; 190. |
Ellsworth, P, et al.; Neurogenic detrusor overactivity: an update on management options; R I Med J (2013); 2013; 38-40; 96. |
Dudding, TC, et al.; Sacral nerve stimulation: an effective treatment for chronic functional anal pain?; Colorectal Dis; 2013; 1140-1144; 15. |
Davis, T, et al.; Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability; Can Urol Assoc J; 2013; 176-178; 7. |
Cornu, JN; Actual treatment of overactive bladder and urge urinary incontinence; Minerva Urol Nefrol; 2013; 21-35; 65;Abstract. |
Chiarioni, G, et al.; Neuromodulation for fecal incontinence: an effective surgical intervention; World J Gastroenterol; 2013; 7048-7054; 19. |
Chen, SC, et al.; Pudendal neuromodulation improvies voiding efficiency in diabetic rats; Neurourol Urodyn; 2013; 293-300; 32. |
Carlson, JJ, et al.; Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States; Clin Ther; 2013; 414-424; 35. |
Cameron, AP, et al.; Battery explanation after sacral neuromodulation in the Medicare population; Neurourol Urodyn; 2013; 238-241; 32. |
Burnstock, G; Introduction and perspective, historical note; Front Cell Neurosci; 2013; 227; 7. |
Brown, SR, et al.; Surgery for faecal incontinence in adults; Cochrane Database Syst Rev; 2013; Cd001757; 7. |
Bleier, JI, et al.; Surgical management of fecal incontinence; Gastroenterol Clin North Am; 2013; 815-836; 42. |
Biemans, JM, et al.; Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review; Neuromodulation; 2013; 25-33; discussion 33; 16. |
Benson-Cooper, S, et al.; Introduction of sacral neuromodulation for the treatment of faecal incontinence; N Z Med J; 2013; 47-53; 126. |
Bartley, JM, et al.; Understanding clinic options for overactive bladder; Curr Urol Rep; 2013; 541-548; 14. |
Bartley, J, et al.; Neuromodulation for overactive bladder; Nat Rev Urol; 2013; 513-521; 10. |
Barroso, U, JR., et al.; Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children; J Urol; 2013; 673-677; 190. |
Barnett, G, et al.; Re: Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation: m. Martinson, S. MacDiarmid and E. Black J Urol 2013; 189; 210-216; J Urol; 2013; 1444-1445; 190. |
Amend, B, et al.; Prolonged percutaneous SNM testing does not cause infection-related explanation; BJU Int; 2013; 485-491; 111. |
Abdel Raheem, A, et al.; Voiding dysfunction in women: How to manage it correctly; Arab J Urol; 2013; 319-330; 11. |
Zhang, F, et al.; Inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; Am J Physiol Renal Physiol; 2012; F1576-1582; 302. |
Worsoe, J, et al.; Turning off sacral nerve stimulation does not affect gastric and small intestinal motility in patients treated for faecal incontinence; Colorectal Dis; 2012; e713-720; 14. |
Van Wunnik, BP, et al.; Cost-effectiveness analysis of sacral neuromodulation for faecal incontinence in The Netherlands; Colorectal Dis; 2012; e807-814; 14. |
Van Wunnik, BP, et al.; Sacral neuromodulation therapy: a promising treatment for adolescents with refractory functional constipation; Dis Colon Rectum; 2013; 278-285; 55. |
Van Ophoven, A, et al., [The future of invasive neuromodulation: new techniques and expanded indications]; Urologe A; 2012; 212-216; 51. |
Tai, C, et al.; Bladder inhibition by intermittent pudendal nerve stimulation in cat using transdermal amplitude-modulated signal (TAMS); Neurourol Urodyn; 2012; 1181-1184; 31. |
Tai, C, et al.; Inhibition of bladder overactivity by stimulation of feline pudendal nerve using transdermal amplitude-modulated signal (TAMS); BJU Int; 2012; 782-787; 109. |
Su, X, et al.; Neuromodulation in a rat model of the bladder micturition reflex; Am J Physiol Renal Physiol; 2012; F477-486; 302. |
Su, X, et al.; Comparison of neural targets for neuromodulation of bladder micturition reflex in the rat; Am J Physiol Renal Physiol; 2012; F1196-1206; 303. |
Steanu, ID, et al,; The Place of the Ice Water Test (IWT) in the Evaluation of the Patients with Traumatic Spinal Cord Injury; Maedica (Buchar); 2012; 125-130; 7. |
Srivastava, D; Efficacy of sacral neuromodulation in treating chronic pain related to painful bladder syndrome/interstitial cystitis in adults; J Anaesthesiol Clin Pharmacol. 2012; 428-435; 28. |
Snellings, AE, et al.; Effects of stimulation site and stimulation parameters on bladder inhibition by electrical nerve stimulation; BJU Int; 2012; 136-143; 110 |
Smits, MA, et al.; [Neuromodulation as a treatment for overactive bladder syndrome]; Ned Tijdschr Geneeskd; 2012; A4135; 156;Abstract. |
Smith, AL, et al.; Contemporary management of overactive bladder; Postgrad Med; 2012; 104-116; 124;Abstract. |
Sivalingam, N, et al.; Concepts in the management of the overactive bladder in women; Med J Malaysia; 2012; 137-141; quiz 142; 67. |
Sievert, KD, et al.; [Unconventional treatment procedures of the bladder in paraplegia and myelomeningocele]; Urologe A; 2012; 1692-1696; 51. |
Schwalenberg, T, et al.; [Sacral neuromodulation in urology—development and current status]; Aktuelle Urol; 2012; 39-48; 43;Abstract. |
Sajadi, KP, et al.; Bladder augmentation and urinary diversion for neurogenic LUTS: current indications; Curr Urol Rep; 2012; 389-393; 13. |
Robinson, D, et al.; Overactive bladder: diagnosis and management; Maturitas; 2012; 188-193; 71. |
Rawashdeh, YF, et al.; International Children's Continence Society's recommendations for therapeutic intervention in congenital neurophatic bladder and bowel dysfunction in children; Neurourol Urodyn; 2012; 615-620; 31. |
Rai, BP, et al.; Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults; Cochrane Database Syst Rev; 2012; Cd003193; 12;Abstract. |
Qin, C, et al.; Is constant current or constant voltage spinal cord stimulation superior for the suppression of nociceptive visceral and somatic stimuli? A rat model; Neuromodulation; 2012; 132-142; discussion 143; 15. |
Peters, KM; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: pro; J Urol; 2012; 2043-2044; 188. |
Penson, DF; Re: Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin a treatment for patients with idiopathic overactive bladder; J Urol; 2012; 2157-2158; 187. |
Otto, W, et al.; [Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a German high-volume clinic]; Aktuelle Urol; 2012; 162-166; 43;Abstract. |
Meurette, G, et al.; Sacral nerve stimulation enhances epithelial barrier of the rectum: results from a porcine model; Neurogastroenterol Motil; 2012; 267-273, e110; 24. |
Mehnert, U, et al.; [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options]; Urologe A; 2012; 189-197; 51. |
Majerus, SJ, et al.; Wireless, Ultra-Low-Power Implantable Sensor for Chronic Bladder Monitoring; ACM J Emerg Technol Comput Syst; 2012;8. |
Madersbacher, H, et al.; What are the causes and consequences of bladder overdistention? ICI-RS 2011; Neurourol Urodyn; 2012; 2012; 317-321; 31. |
Levin, PJ, et al.; The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review; Int Urogynecol J; 2012; 1591-1597; 23. |
Leicht, W, et al.; [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity]; Urologe A; 2012; 348-351; 51. |
Lay, AH, et al.; The role of neuromodulation in patients with neurogenic overactive bladder; Curr Urol Rep; 2012; 343-347; 13. |
Koldewun; EL; [What to do if pills do not work for urge incontinence—still many questions and ambiguities]; Ned Tijdschr Geneeskd; 2012; A5099; 156;Abstract. |
Kessler, TM, et al.; [Sacral neuromodulation for neurogenic bladder dysfunction]; Urologe A; 2012; 179-183; 51. |
Kantartzis, K, et al.; Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder; Curr Opin Obstet Gynecol; 2012; 331-336; 24. |
Hubsher, CP, et al.; Sacral nerve stimulation for neuromodulation of the lower urinary tract; Can J Urol; 2012; 6480-6484; 19. |
Guerci, B, et al.; Gastric electrical stimulation for the treatment of diabetic gastroparesis; Diabetes Metab; 2012; 393-402; 38. |
Groen, LA, et al.; Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms; 15-year experience; J Urol; 2012; 1313-1317; 188. |
Gill, BC, et al.; Improvement of bower dysfunction with sacral neuromodulation for refractory urge urinary incontinence; Int Urogynecol J; 2012; 735-741; 23. |
Ghiselli, R, et al.; Nitric oxide synthase expression in rat anorectal tissue after sacral neuromodulation; J Surg Res; 2012; 29-33; 176. |
Evans, RJ; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: con; J Urol; 2012; 2044-2045; 188. |
Elser, DM; Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management; Postgrad Med; 2012; 42-49; 124;Abstract. |
Elkelini, MS, et al.; Mechanism of action of sacral nerve stimulation using a transdermal amplitude-modulated signal in a spinal cord injury rodent model; Can Urol Assoc J; 2012; 227-230; 6. |
Dwyer, ME, et al.; The dysfunctional elimination syndrome in children—is sacral neuromodulation worth the trouble?; J Urol; 2012; 1076-1077; 188. |
Devroede, G, et al.; Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation; Female Pelvic Med Reconstr Surg; 2012; 103-112; 18;Abstract. |
Denzinger, S, et al.; Does sacral neuromodulation lead to relevant reduction in the need for intermittent catheterization? A single-center experience on patients with chronic urinary retention; Neuromodulation; 2012; 586-591; discussion 591; 15. |
Del Popolo, G, et al.; [Standard pharmacological treatment and new therapies for overactive bladder]; Urologia; 2012; 42534; 79. |
Crock, LW, et al.; Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain; J Neurosci; 2012; 14217-14226; 32. |
Chen, G, et al.; The inhibitory effects of pudendal nerve stimulation on bladder overactivity in spinal cord injury dogs: is early stimulation necessary?; Neuromodulation; 2012; 232-237; discussion 237; 15. |
Cardarelli, S, et al.; Efficacy of sacral neuromodulation on urological diseases: a multicentric research project; Urologia; 2012; 90-96; 79. |
Burnstock, G; Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future; Bioessays; 2012; 218-225; 34. |
Banakhar, MA, et al.; Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem; Ther Adv Urol; 2012; 179-185; 4. |
Arrabal-Polo, MA, et al.; Clinical efficacy in the treatment of overactive bladder refractory to anticholinergics by posterior tibial nerve stimulation; Korean J Urol; 2012; 483-486; 53. |
Arnold, J, et al.; Overactive bladder syndrome—management and treatment options; Aust Fam Physician; 2012; 878-883; 41. |
Allahdin, S, et al.; An overview of treatment of overactive bladder syndrome in women; J Obstet Gynaecol; 2012; 217-221; 32. |
Zullo, MA, et al.; Sacral neuromodulation after stabilization of L2-S1 vertebrae with metallic fixation devices: is it feasbile?; Int Urogynecol J; 2011; 373-375; 22. |
Yazdany, T, et al.; Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women; Int Urogynecol J; 2011; 1549-1554; 22. |
Wu, JM, et al.; Patient preferences for different severities of and treatments for overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 184-189; 17;Abstract. |
Van Wunnik, BP, et al.; Patient experience and satisfaction with sacral neuromodulation: results of a single-center sample survey; Dis Colon Rectum; 2011; 95-100; 54. |
Van Wunnik, BP, et al.; Neuromodulation for constipation: sacral and transcutaneous stimulation; Best Pract Res Clin Gastroenterol; 2011; 181-191; 25. |
Van Koeveringe, GA, et al.; Detrusor underactivity: a plea for new approaches to a common bladder dysfunction; Neurourol Urodyn; 2011; 723-728; 30. |
Van Kerrebroeck, P; Editorial comment re: Killinger et al. “Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation”; Neurourol Urodyn; 2011; 1403; 30. |
Vaarala, MH, et al.; Sacral neuromodulation in urological indications: the Finnish experience; Scand J Urol Nephrol; 2011; 46-51; 45. |
Uludag, O, et al.; Sacral neuromodulation: long-term outcome and quality of life in patients with faecal incontinence; Colorectal Dis; 2011; 1162-1166; 13. |
Ullah, S, et al.; Temporary gastric neuromodulation for intractable nausea and vomiting; Ann R Coll Surg Engl; 2011; 624-628; 93. |
Thoua, NM, et al.; Internal anal sphincter atropy in patients with systemic sclerosis; Rheumatology (Oxford); 2011; 1596-1602; 50. |
Tai, C, et al.; Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats; Am J Physiol Renal Physiol; 2011; F385-392; 300. |
Tai, C, et al.; Irritation induced bladder overactivity is suppressed by tibial nerve stimulation in cats; J Urol; 2011; 326-330; 186. |
Signorello, D, et al.; Impact of sacral neuromodulation on female sexual function and his correlation with clinical outcome and quality of life indexes: a monocentric experience; J Sex Med; 2011; 1147-1155; 8. |
Shepherd, JP, et al.; InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence: A Decision Analysis Comparing Outcomes Including Efficacy and Complications; Female Pelvic Med Reconstr Surg; 2011; 199-203; 17;Abstract. |
Shen, B, et al.; Neuromodulation of bladder activity by stimulation of feline pudendal nerve using a transdermal amplitude modulated signal (TAMS); Neurourol Urodyn; 2011; 1686-1694; 30. |
Sharma, A, et al.; Sacral neuromodulation for the management of severe constipation: development of a constipation treatment protocol; Int J Colorectal Dis; 2011; 1583-1587; 26. |
Sahai, A, et al.; Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management; Curr Urol Rep; 2011; 404-412; 12. |
Richter, EO, et al.; Percutaneous cephalocaudal implantation of epidural stimulation electrodes over sacral nerve roots—a technical note on the importance of the lateral approach; Neuromodulation; 2011; 62-67; discussion 67; 14. |
Possover, M, et al.; Risks, symptoms, and management of pelvic nerve damage secondary to surgery for pelvic organ prolapse: a report of 95 cases; Int Urogynecol J; 2011; 1485-1490; 22. |
Peters, KM, et al.; Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation?; Neurourol Urodyn; 2011; 1489-1492; 30. |
Pena, G, et al.; Cholinergic regulatory lymphocytes re-establish neuromodulation of innate immune responses in sepsis; J Immunol; 2011; 718-725; 187. |
Pascual, I, et al.; Sacral nerve stimulation for fecal incontinence; Rev Esp Enferm Dig; 2011; 355-359; 103. |
Oerlemans, DJ, et al.; Is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?; Neurourol Urodyn; 2011; 1493-1496; 30. |
Miotla, P, et al.; [Sacral nerve stimulation in the treatment of the lower urinary tract function disorders]; Ginekol Pol; 2011; 851-856; 82. |
Marcelissen, TA, et al.; The use of bilateral sacral nerve stimulation in patients with loss of unilateral treatment efficacy; J Urol; 2011; 976-980; 185. |
Marcelissen, TA, et al.; Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment; BJU Int; 2011; 1834-1838; 108. |
Marcelissen, TA, et al.; The effect of pulse rate changes on the clinical outcome of sacral neuromodulation; J Urol; 2011; 1781-1785; 185. |
Marcelissen, T, et al.; Is the screening method of sacral neuromodulation a prognostic factor for long-term success?; J Urol; 2011; 583-587; 185. |
Marcelissen, T, et al.; Sacral neuromodulation as a treatment for chronic pelvic pain; J Urol; 2011; 387-393; 186. |
Majerus, SJ, et al.; Low-power wireless micromanometer system for acute and chronic bladder-pressure monitoring; IEEE Trans Biomed Eng; 2011; 763-767; 58. |
Lombardi, G, et al.; Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury; Spinal Cord; 2011; 629-636; 49. |
Liberman, D, et al.; Concerns regarding sacral neuromodulation as a treatment option for medical-refractory overactive bladder; Can Urol Assoc J; 2011; 285-287; 5. |
Leong, RK, et al.; Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey; J Urol. 2011; 588-592; 185. |
Leong, RK, et al.; PNE versus 1st stage tine lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy; Neurourol Urodyn; 2011; 1249-1252; 30. |
Leong, RK, et al.; Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder; BJU Int; 2011; 558-564; 108. |
Le, NB, et al.; Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery; Curr Bladder Dysfunct Rep; 2011; 25-30; 6. |
Kubota, M, et al.; Effect of neuromodulation with sacral magnetic stimulation for intractable bowel or bladder dysfunction in postoperative patients with anorectal malformation; a preliminary report; Pediatr Surg Int; 2011; 599-603; 27. |
Knupfer, S, et al.; [Therapy-refractory overactive bladder: alternative treatment approaches]; Urologe A; 2011; 806-809; 50. |
Killinger, KA, et al.; Seconary changes in bowel function after successful treatment of voiding symptoms with neuromodulation; Neurourol Urodyn; 2011; 133-137; 30. |
Griffin, KM, et al.; Sacral nerve stimulation increases activation of the primary somatosensory cortex by anal canal stimulation in an experimental model; Br J Surg; 2011; 1160-1169; 98. |
Gill, BC, et al.; Improved sexual and urinary function in women with sacral nerve stimulation; Neuromodulation; 2011; 436-443; discussion 443; 14. |
Ghazwani, YQ, et al.; Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up; Neurourol Urodyn; 2011; 1271-1275; 30. |
George, E, et al.; Use of combined anticholinergic medication and sacral neuromodulation in the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 97-99; 17;Abstract. |
Gajewski, JB, et al.; The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre; BJU Int; 2011; 1258-1264; 107. |
Gaj, F, et al.; [Chronic pelvic pain treatment with posterior tibial nerve stimulation]; Clin Ter; 2011; e111-114; 162;Abstract, |
Duthie, JB, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2011; Cd005493. |
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: optimizing outcome and managing complications; Colorectal Dis; 2011; e196-202; 13. |
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: patient selection, service provision and operative technique; Colorectal Dis; 2011; e187-195; 13. |
Dudding, TC; Future indications for sacral nerve stimulation; Colorectal Dis; 2011; 23-28; 13 Suppl 2. |
De Gennaro, M, et al.; Current state of nerve stimulation technique for lower urinary tract dysfunction in children; J Urol; 2011; 1571-1577; 185. |
Chartier-Kastler, E, et al.; [Sacral neuromodulation with InterStim system: Results from the French national register]; Prog Urol; 2011; 209-217; 21;Abstract. |
Chaabane, W, et al.; Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study; Neurourol Urodyn; 2011; 547-550; 30. |
Burnstock, G, et al.; P2X receptors in health and disease; Adv Pharmacol; 2011; 333-372; 61;Abstract. |
Burnstock, G; Intrductory overview of purinergic signalling; Front Biosci (Elite Ed); 2011; 896-900; 3;Abstract. |
Baeten, CG; Status of sacral neuromodulation for refractory constipation; Colorectal Dis; 2011; 19-22; 13 Suppl 2. |
Atnip, S, et al.; A unique approach to severe constipation; Urol Nurs; 2011; 348-350; 31. |
Arlandis, S, et al.; Cost-effectivenss of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder; Value Health; 2011; 219-228; 14. |
Apostolidis, A; Neuromodulation for intractable OAB; Neurourol Urodyn; 2011; 766-770; 30. |
Al-Zharani, AA, et al.; Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center; J Urol; 2011; 981-986; 185. |
Al-Shaui, TF, et al.; Pelvic electrical neuromodulation for the treatment of overactive bladder syndrome; Adv Urol; 2011; 757454; 2011. |
Zempleni, MZ, et al.; Cortical substrate of bladder control in SCI and the effect of peripheral pudendal stimulation; Neuroimage; 2010; 2983-2994; 48. |
Yoong, W, et al.; Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol; BJU Int; 2010; 1673-1676; 106. |
Wolff, K, et al.; Functional outcome and quality of life after stapled transanal rectal resection for obstructed defecation syndrome; Dis Colon Rectum; 2010; 881-888; 53. |
Wehbe, SA, et al.; Sacral neuromodulations for femal lower urinary tract, pelvic floor, and bowel disorders; Curr Opin Obstet Gyncol; 2010; 414-419; 22. |
Wehbe, SA, et al.; Minimally invasive therapies for chronic pelvic pain syndrome; Curr Urol Rep; 2010; 276-285; 11. |
Watanabe, JH, et al.; Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder; Urology; 2010; 835-840; 76. |
Vasdev, N, et al.; The surgical management of the refractory overactive bladder; Indian J Urol; 2010; 263-269; 26. |
Van Kerrebroeck, PE; Advances in the role of sacral nerve neuromodulation in lower urinary tract symptoms; Int Urogynecol J; 2010; S467-474; 21 Suppl 2. |
Vallet, C, et al.; Sacral nerve stimulation for faecal incontinence: response rate, satisfaction and the value of preoperative investigation in patient selection; Colorectal Dis; 2010; 247-253; 12. |
Uludag, O, et al.; Sacral neuromodulation: does it affect the rectoanal angle in patients with fecal incontinene?; World J Surg; 2010; 1109-1114; 34. |
Thompson, JH, et al.; Sacral neuromodulation: Therapy evolution; Indian J Urol; 2010; 379-384; 26. |
Stoffel, JT; Contemporary management of the neurogenic bladder for multiple sclerosis patients; Urol Clin North Am; 2010; 547-557; 37. |
Starkman, JS, et al.; Surgical options for drug-refractory overactive bladder patients; Rev Urol; 2010; e97-e110; 12. |
Sievert, KD, et al.; Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury; Ann Neurol; 2010; 74-84; 67. |
Sancaktar, M, et al.; The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder; Gynecol Endocrinol; 2010; 729-732; 26. |
Sajadi, KP, et al.; Overactive bladder after sling surgery; Curr Urol Rep; 2010; 366-371; 11. |
Roth, TM; Sacral neuromodulation and cardiac pacemakers; Int Urogynecol J; 2010; 1035-1037; 21. |
Roth, TM; Subcapsular relocation for sacral neuromodulation pulse generator implant revision; Neuromodulation; 2010; 145-146; 13. |
Riguad, J, et al.; [Specific treatments for painful bladder syndrome]; Prog Urol; 2010; 1044-1053; 20;Abstract. |
Ridout, AE, et al.; Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy; J Obstet Gynaecol; 2010; 111-114; 30. |
Reyblat, P, et al.; Augmentation enterocystoplasty in overactive bladder: is there still a role?; Curr Urol Rep; 2010; 432-439; 11. |
Powell, CR, et al.; Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures; J Urol; 2010; 173-176; 183. |
Possover, M; The laparoscopic implantation of neuroprothesis to the sacral plexus for therapy of neurogenic bladder dysfunctions after failure of percutaneous sacral nerve stimulation; Neuromodulation; 2010; 141-144; 13. |
Peters, KM, et al.; Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms; Neurourol Urodyn; 2010; 1267-1271; 29. |
Peters, KM, et al.; Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial; J Urol; 2010; 1438-1443; 183. |
Peters, KM; Alternative approaches to sacral nerve stimulation; Int Urogynecol J; 2010; 1559-1563; 21. |
Peirce, C, et al.; Central representation of the inferior rectal nerve of the rat; Dis Colon Rectum; 2010; 315-320; 53. |
Oom, DM, et al.; Is sacral neuromodulation for fecal incontinence worthwhile in patients with associated pelvic floor injury?; Dis Colon Rectum; 2010; 422-427; 53. |
Occhino, JA, et al.; Sacral nerve modulation in overactive bladder; Curr Urol Rep; 2010; 348-352; 11. |
Nilsson, KF, et al.; Estimation of endogenous adenosine activity at adenosine receptors in guinea-pig ileum using a new pharmacological method; Acta Physiol (Oxf); 2010; 231-241; 199. |
Mayer, R; Neuromodulation—who, what, when, where and why?; J Urol; 2010; 17-18; 183. |
Marcelissen, TA, et al.; Long-term results of sacral neuromodulation with the tined lead procedure; J Urol; 2010; 1997-2000; 184. |
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord-injured patients suffering from neurogenic bowel dysfunctions; Spinal Cord; 2010; 154-159; 48. |
Leong, RK, et al.; Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review; Urol Int; 2010; 245-253; 84. |
Kim, JH, et al.; Sacral nerve stimulation for treatment of intractable pain associated with cauda equina syndrome; J Korean Neurosurg Soc; 2010; 473-476; 47. |
Kavia, R, et al.; A funcational magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler's syndrome; BJU Int; 2010; 366-372; 105. |
Karram, MM; Sacral neuromodulation: emerging technology with expanding indications; Int Urogynecol J; 2010; 1443; 21. |
Kacker, R, et al.; Selection of ideal candidates for neuromodulation in refractory overactive bladder; Curr Urol Rep; 2010; 372-378; 11. |
Indinnimeo, M, et al.; Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness; Dis Colon Rectum; 2010; 1661-1669; 53. |
Hull, TL; Sacral neuromodulation stimulation in fecal incontinence; Int Urogynecol J; 2010; 1565-1568; 21. |
Hoda, MR, et al.; [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine]; Urologe A; 2010; 1254-1259; 49. |
Haddad, M, et al.; Sacral neuromodulation in children with urinary and fecal incontinence: a multicenter, open label, randomized, crossover study; J Urol; 2010; 696-701; 184. |
Gulur, DM, et al.; Management of overactive bladder; Nat Rev Urol; 2010; 572-582; 7. |
French, JS, et al.; What do spinal cord injury consumers want? A review of spinal cord injury consumer priorities and neuroprosthesis from the 2008 neural interfaces conference; Neuromodulation; 2010; 229-231; 13. |
Foon, R, et al.; The overactive bladder; Ther Adv Urol; 2010; 147-155; 2. |
Findlay, JM, et al.; Peripheral neuromodulation via posterior tibial nerve stimulation—a potential treatment for faecal incontinence?; Ann R Coll Surg Engl; 2010; 385-390; 92. |
Fariello, JY, et al.; Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction; Int Urogynecol J; 2010; 1553-1558; 21. |
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2010; 35-48; 57. |
Elneil, S; Urinary retention in women and sacral neuromodulation; Int Urogynecol J; 2010; S475-483; 21 Suppl 2. |
Ellsworth, P, et al.; Update on the pharmacologic management of overactive bladder: the present and the future; Urol Nurs; 2010; 29-38, 53; 30. |
Daniels, DH, et al.; Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction; Neurourol Urodyn; 2010; 578-581; 29. |
Carr, MC; Conservative nonsurgical management of spina bifida; Curr Urol Rep; 2010; 109-113; 11. |
Cardot, V, et al.; [Guidelines for the treatment of urinary incontinence in women with refractory idiopathic vesical hyperactivity using sacral neuromodulation]; Prog Urol; 2010; S161-169; 20 Suppl 2;Abstract. |
Burks, FN, et al.; Neuromodulation and the neurogenic bladder; Urol Clin North Am; 2010; 559-565; 37. |
Brouwer, R, et al.; Sacral nerve neuromodulation is effective treatment for fecal incontinence in the presence of a sphincter defect, pudendal neuropathy, or previous sphincter repair; Dis Colon Rectum; 2010; 273-278; 53. |
Bosch, JL, et al.; What treatment should we use if drugs fail for OAB; and, what really works after drugs?; Neurourol Urodyn; 2010; 658-661; 29. |
Bosch, JL; An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010?; BJU Int; 2010; 1432-1442; 105. |
Amend, B, et al.; [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A]; Urologe A; 2010; 245-252; 49. |
Wyndaele, JJ; Clinical outcomes of sacral neuromodulation in incomplete spinal cord injured patient suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 427; 47. |
Wosnitzer, MS, et al.; The use of sacral neuromodulation for the treatment of non-obstructive urinary retention secondary to Guillain-Barre syndrome; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1145-1147; 20. |
Wooldridge, LS; Percutaneous tibial nerve stimulation for the treatment of urinary frequenc, urinary urgency, and urge incontinence: results from a community-based clinic; Urol Nurs; 2009; 177-185; 29. |
Vignes, JR, et al.; Animal models of sacral neuromodulation for detrusor overactivity; Neurourol Urodyn; 2009; 42594; 28. |
Scaglia, M, et al.; Fecal incontinence treated with acupuncture—a pilot study; Auton Neurosci; 2009; 89-92; 145. |
Roth, TM; Blunt trauma leading to delayed extrusion of sacral nerve implant; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 735-737; 20. |
Rasmussen, NT, et al.; Successful use of sacral neuromodulation after failed bladder augmentation; Can Urol Assoc J; 2009; E49-50; 3. |
Possover, M, et al.; Neuromodulation of the superior hypogastric plexus: a new option to treat bladder atonia secondary to radical pelvic surgery?; Surg Neurol; 2009; 573-576; 72. |
Possover, M; The sacral LION procedure for recovery of bladder/rectum/sexual functions in paraplegic patients after explanation of a previous Finetech-Brindley controller; J Minim Invasive Gynecol; 2009; 98-101; 16. |
Possover, M; Laparoscopic management of endopelvic etiologies of pudendal pain in 134 consecutive patients; J Urol; 2009; 1732-1736; 181. |
Oom, DM, et al.; Anterior sphincteroplasty for fecal incontinence: a single center experience in the era of sacral neuromodulation; Dis Colon Rectum; 2009; 1681-1687; 52. |
Moutzouris, DA, et al.; Interstitial cystitis: an unsolved enigma; Clin J Am Soc Nephrol; 2009; 1844-1857; 4. |
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 486-491; 47. |
Kohli, N, et al.; InterStim Therapy: A Contemporary Approach to Overactive Bladder; Rev Obstet Gyncol; 2009; 18-27; 2. |
Kaufmann, S, et al.; Unilateral vs bilateral sacral neuromodulation in pigs with formalin-induced detrusor hyperactivity; BJU Int; 2009; 260-263; 103. |
Ingber, MS, et al.; Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit?; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1055-1059; 20. |
Herbison, GP, et al.; Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults: Cochrane Database Syst Rev; 2009; Cd004202. |
Hartmann, KE, et al.; Treatment of overactive bladder in women; Evid Rep Techol Assess (Full Rep); 2009; 1-120, v. |
Govaert, B, et al.; Neuromodulation for functional bowel disorders; Best Pract Res Clin Gastroenterol; 2009; 545-553; 23. |
Game, X, et al.; [Alternative treatments for interstitial cystitis]; Prog Urol; 2009; 357-363; 19;Abstract. |
Fu, G, et al.; [Neuromodulation for treatment for neurogenic bowel dysfunction]; Zhonghua Wai Ke Za Zhi; 2009; 128-131; 47. |
Finazzi-Agro, E, et al.; Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials; Neurourol Urodyn; 2009; 320-324; 28. |
Falletto, E, et al.; Is sacral nerve stimulation an effective treatment for chronic idiopathic anal pain?; Dis Colon Rectum; 2009; 456-462; 52. |
Chatoor, D, et al.; Constipation and evacuation disorders; Best Pract Res Clin Gastroenterol; 2009; 517-530; 23. |
Charter-Kastler, E, et al.; [Update on the second line management of idiopathic overactive bladder]; Prog Urol; 2009; 530-537; 19;Abstract. |
Chapple, C, et al.; The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?; BJU Int; 2009; 1188-1190; 104. |
Campbell, JD, et al.; Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence; BMC Urol; 2009; 18; 9. |
Burnstock, G; Purinergic signalling: past, present and future; Braz J Med Biol Res; 2009; 42437; 42. |
Burnstock, G; Purinergic cotransmission; F1000 Biol Rep; 2009; 46; 1. |
Burks, FN, et al.; Neuromodulation versus medication for overactive bladder: the case for early intervention; Curr Urol Rep; 2009; 342-346; 10. |
Bolton, JF, et al.; Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction?; Curr Opin Urol; 2009; 375-379; 19. |
Badlani, GH; Update on lower urinary tract symptoms; ScientificWorldJournal; 2009; 499-500; 9. |
Antolak, SJ, JR., et al.; Therapeutic pudendal nerve blocks using corticosteroids cure pelvic pain after failure of sacral neuromodulation; Pain Med; 2009; 186-189; 10. |
Zabihi, N, et al.; Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 553-557; 19. |
Tjandra, JJ, et al.; Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study; Dis Colon Rectum; 2008; 494-502; 51. |
Starkman, JS, et al.; Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 277-282; 19. |
Starkman, JS, et al.; The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction; J Urol; 2008; 1018-1023; 179. |
Spinelli, M, et al.; Latest techologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety; Eur Urol; 2008; 1287-1296; 54. |
Smaldone, MC, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin; Nat Clin Pract Urol; 2008; 120-121; 5. |
Skobejko-Wlodarska, L; [Non-neurogenic lower urinary tract dysfunctioin]; Pol Merkur Lekarski; 2008; 131-137; 24 Suppl 4;Abstract. |
Seth, A, et al.; What's new in the diagnosis and management of painful bladder syndrome/interstitial cystitis?; Curr Urol Rep; 2008; 349-357; 9. |
Robaina Padron, FJ; [Surgical neuromodulation: new frontiers in neurosurgery]; Neurocirugia (Astur); 2008; 143-155; 19;Abstract. |
Rittenmeyer, H; Sacral nerve neuromodulation (InterStim). Part I: Review of the InterStim system; Urol Nurs; 2008; 15-20; 28. |
Peters, KM, et al.; Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome; Urology; 2008; 634-640; 71. |
Perrigot, M, et al., [Perineal electrical stimulation and rehabilitation in urinary incontinence and other symptoms of non-neurologic origin]; Ann Readapt Med Phys; 2008; 479-490; 51;Abstract. |
Oerlemans, DJ, et al.; Sacral nerve stimulation for neuromodulation of the lower urinary tract; Neurourol Urodyn; 2008; 28-33; 27. |
O'Reilly, BA, et al., A prospective randomised double-blind controlled trial evaluating the effect of trans-sacral magnetic stimulation in women with overactive bladder; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 497-502; 19. |
Nitti, VW; Urodynamics, Incontinence, and Neurourology: Highlights from the Society for Urodynamics and Female Urology Annual Winter Meeting, Feb. 28-Mar. 2, 2008; Miami Fl; Rev Urol; 2008; 229-231; 10 |
Nakib, N, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neuromodulation; Nat Clin Pract Urol; 2008; 118-119; 5. |
Minardi, D, et al.; Activity and expression of nitric oxide synthase in rat bladder after sacral neuromodulation; Int J Immunopathol Pharmacol; 2008; 129-135; 21;Abstract. |
Milne, JL; Behavioral therapies for overactive bladder: making sense of the evidence; J Wound Ostomy Continence Nurs; 2008; 93-101; quiz 102-103; 35;Abstract. |
Mckertich, K; Urinary incontinence-procedural and surgical treatments for women; Aust Fam Physician; 2008; 122-131; 37. |
Lombardi, G, et al.; Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptom (LUTS); J Sex Med; 2008; 1411-1417; 5. |
Lombardi, G, et al.; Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function; J Sex Med; 2008; 2135-2140; 5. |
Liao, KK, et al.; Effect of sacral neuromodulation on the spinal nociceptive reflex of patients with idiopathic overactive bladder; Neuromodulation; 2008; 50-55; 11. |
Kutzenberger, J; [Neurogenic urinary incontinence. Value of surgical management]; Urologe A; 2008; 699-706; 47. |
Kosan, M, et al.; Alteration in contractile responses in human detrusor smooth muscle from obstructed bladders with overactivity; Urol Int; 2008; 193-200; 80. |
Indar, A, et al.; A dual benefit of sacral neuromodulation; Surg Innov; 2008; 219-222; 15. |
Groenendijk, PM, et al.; Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence; BJU Int; 2008; 325-329; 101. |
Game, X, et al.; Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent; Spinal Cord; 2008; 74-77; 46. |
Game, X; [Sacral neuromodulation and sexuality]; Prog Urol; 2008; 167; 18;Abstract. |
Ferhi, K, et al.; [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study]; Prog Urol; 2008; 160-166; 18;Abstract. |
Faucheron, JL; [Anal incontinence]; Presse Med; 2008; 1447-1462; 37;Abstract. |
Fang, Q, et al.; [Morphological study on the role of ICC-like cells in detrusor neuromodulation of rat urinary bladder]; Zhonghua Wai Ke Za Zhi; 2008; 1542-1545; 46. |
Doumouchtsis, SK, et al.; Female voiding dysfuncation; Obstet Gynecol Surv; 2008; 519-526; 63. |
De Seze, M, et al.; [Peripheral electrical stimulation in neurogenic bladder]; Ann Readapt Med Phys; 2008; 473-478; 51;Abstract. |
De Boer, TA, et al.; [Male urinary incontinence]; Ned Tijdschr Geneeskd; 2008; 797-802; 152;Abstract. |
Chartier-Kastler, E; Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience; BJU Int; 2008; 417-423; 101. |
Burnstock, G; The journey to establish purinergic signalling in the gut; Neurogastroenterol Motil; 2008; 42601; 20 Suppl 1. |
Brosa, M, et al.; Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain; Curr Med Res Opin; 2008; 907-918; 24. |
Bannowsky, A, et al.; Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test; World J Urol; 2008; 623-626; 26. |
Vignes, JR, et al.; Sacral neuromodulation as a functional treatment of bladder overactivity; Acta Neurochir Suppl; 2007; 315-322; 97;Abstract. |
Vasavada, SP, et al.; Neuromodulation techniques: a comparison of available and new therapies; Curr Urol Rep; 2007; 455-460; 8. |
Van Voskuilen, AC, et al.; Medium-term experience of sacral neuromodulation by tined lead implantation; BJU Int; 2007; 107-110; 99. |
Van Kerrebroeck, PE, et al.; Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide-clinical study; J Urol; 2007; 2029-2034; 178. |
Van Balken, MR; Percutaneous tibial nerve stimulation: the Urgen PC device; Expert Rev Med Devices; 2007; 693-698; 4. |
Unwala, DJ, et al.; Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?; Curr Urol Rep; 2007; 41-424; 8. |
Starkman, JS, et al.; Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation, Neurourol Urodyn; 2007; 29-35; discussion 36; 26. |
South, MM, et al.; Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation; Int Urogynecol J Pelvic Floor Dysfunct; 2007; 1395-1398; 18. |
Sherman, ND, et al.; Current and future techniques of neuromodulation for bladder dysfunction; Curr Urol Rep; 2007; 448-454; 8. |
Shamliyan, T, et al.; Prevention of urinary and fecal incontinence in adults; Evid Rep Technol Assess (Full Rep); 2007; 1-379; ;Abstract, |
Sevcencu, C; A review of electrical stimulation to treat motility dysfunctions in the digestive tract: effects and stimulation patterns; Neuromodulation; 2007; 85-99; 10. |
Sevcencu, C; Gastrointestinal mechanisms activated by electrical stimulation to treat motility dysfunctions in the digestive tract: a review; Neuromodulation; 2007; 100-112; 10. |
Schreiber, KL, et al.; Evidence for neuromodulation of enteropathogen invasion in the intestinal mucosa; J Neuroimmune Pharmacol; 2007; 329-337; 2. |
Sakas, DE, et al.; An introduction to operative neuromodulation and functional neuroprosthetics, the new frontiers of clinical neuroscience and biotechnology; Acta Neurochir Suppl; 2007; 42439; 97;Abstract. |
Reitz, A, et al.; Topographic anatomy of a new posterior approach to the pudendal nerve for stimulation; Eur Urol; 2007; 1350-1355; discussion 1355-1356; 51. |
Ratto, C, et al.; Sacral neuromodulation in the treatment of defecation disorders; Acta Neurochir Suppl; 2007; 341-350; 97;Abstract. |
Pauls, RN, et al.; Effects of sacral neuromodulation on female sexual function; Int Urogynecol J Pelvic Floor Dysfunct; 2007; 391-395; 18. |
Melenhorst, J, et al.; Sacral neuromodulation in patients with faecal incontinence results of the first 100 permanent implantations; Colorectal Dis; 2007; 725-730; 9. |
Mcachran, SE, et al.; Sacral neuromodulation in the older woman; Clin Obstet Gynecol; 2007; 735-744; 50. |
Lewis, JM, et al.; Non-traditional management of the neurogenic bladder: tissue engineering and neuromodulation; ScientificWorldJournal; 2007; 1230-1241; 7. |
Leong, FC, et al.; Neuromodulation for the treatment of urinary incontinence; Mo Med; 2007; 435-439; 104;Abstract. |
Kuo, HC; Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction; Urology; 2007; 57-61; discussion; 61-52; 69. |
Kessler, TM, et al.; Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland; Eur Urol; 2007; 1357-1363; 51. |
Keppene, V, et al.; [Neuromodulation in the managment of neurogenic lower urinary tract dysfunction]; Prog Urol; 2007; 609-615; 17;Abstract. |
Karsenty, G, et al.; Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux; J Urol; 2007; 1011-1014; 177. |
Iarumov, N, et al.; [Anal incontinence—new methods of surgical treatment using artificial bowel sphincter and sacral nerve stimulation]; Khirurgiia (Soflia); 2007; 40-45;;Abstract. |
Hoque, T, et al.; Validation of internal controls for gene expression analysis in the intestine of rats infected with Hymenolepis diminuta; Parasitol Int; 2007; 325-329; 56. |
Hashim, H, et al.; Novel uses for antidiuresis; Int J Clin Pract Suppl; 2007; 32-36;;Abstract. |
Groenendijk, PM, et al.; Five-Year Follow-up After Sacral Neuromodulation: Single Center Experience; Neuromodulation; 2007; 363-368; 10. |
Glinski, RW, et al.; Refractory overactive bladder: Beyond oral anticholinergic therapy; Indian J Urol; 2007; 166-173; 23. |
Felt-Bersma, RJ, et al.; Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement; Eur J Gastroenterol Hepatol; 2007; 575-580; 19;Abstract. |
Duthie, J, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2007; Cd005493; ;Abstract, |
Dmochowski, R; Neuromodulation and the urinary tract—are we over the rainbow or have we simply stepped through the looking glass?; J Urol; 2007; 1844-1845; 178. |
Deffieux, X, et al.; [Voiding dysfunction after surgical resection of deeply infiltrating endometriosis: pathophysiology and management]; Gynecol Obstet Fertil; 2007; S8-13; 35 Suppl 1;Abstract. |
Yun, AJ, et al.; Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments causes by the global sympathetic bias that emerges with aging; Med Hyptheses; 2006; 392-394; 67. |
Wein, AJ, et al.; Overactive bladder: a better understanding of pathophysiology, diagnosis and management; J Urol; 2006; S5-10; 175. |
Van Voskuilen, AC, et al.; Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study; Eur. Urol; 2006; 366-372; 49. |
Van Der Pal, F, et al.; Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome: 12-Month Follow-up; Neuromodulation; 2006; 163-171; 9. |
Van Der Pal, F, et al.; Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction; Curr Opin Urol; 2006; 261-267; 16. |
Van Balken, MR, et al.; Prognostic factors for successful percutaneous tibial nerve stimulation; Eur Urol; 2006; 360-365; 49. |
Van Balken, MR, et al.; Sexual functioning in patients with lower urinary tract dysfunction improves after percutaneous tibial nerve stimulation; Int J Impot Res; 2006; 470-475; discussion 476; 18. |
Uludag, O, et al.; Sacral neuromodulation; does it affect colonic transit time in patients with faecal incontinence?; Colorectal Dis; 2006; 318-322; 8. |
Sherman, ND, et al.; The current use of neuromodulation for bladder dysfunction; Minerva Ginecol; 2006; 283-293; 58;Abstract. |
Seif, C, et al.; [Use of permanent electrodes in the peripheral nerve evaluation test (PNE-Test) in comparison to conventional wire electrodes]; Aktuelle Urol; 2006; 277-280; 37;Abstract. |
Pelliccioni, G, et al.; External anal sphincter responses after S3 spinal root surface electrical stimulation; Neurourol Urodyn; 2006; 788-791; 25. |
Nyarangi-Dix, JN, et al.; [Overactive bladder syndrome. Are there indications for surgical therapy?]; Urologe A; 2006; 1289-1290; 1292; 45. |
Nordling, J; Surgical treatment of painful bladder syndrome/interstitial cystitis; Womens Health (Lond Engl); 2006; 233-238; 2. |
Ng, CK, et al.; Refractory overactive bladder in men: update on novel therapies; Curr Urol Rep; 2006; 456-461; 7. |
Michelsen, HB, et al.; Rectal volume tolerability and anal pressures in patients with fecal incontinence treated with sacral nerve stimulation; Dis Colon Rectum; 2006; 1039-1044; 49. |
Lazzeri, M, et al.; The challenge of overactive bladder therapy: alternative to antibuscarinic agents; Int Braz J Urol; 2006; 620-630; 32. |
Krivoborodov, GG, et al.; [Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson's disease]; Urologiia; 2006; 42435;;Abstract. |
Kenefick, NJ; Sacral nerve neuromodulation for the treatment of lower bowel motility disorders; Ann R Coll Surg Engl; 2006; 617-623; 88. |
Humphreys, MR, et al.; Preliminary results of sacral neuromodulation in 23 children; J Urol; 2006; 2227-2231; 176. |
Hoch, M, et al.; [Chemical destruction of sacral nerve roots by alcohol injection for the treatment of overactive bladder]; Prog Urol; 2006; 584-587; 16;Abstract. |
Hijaz, A, et al.; Complications and troubleshooting of two-stage sacral neuromodulation therapy; a single-institution experience; Urology; 2006; 533-537; 68. |
Guys, JM, et al.; [Neurogenic bladder in children: basic principles in diagnosis and treatment]; Ann Urol (Paris); 2006; 15-27; 40;Abstract. |
Groen, J, et al.; Sacral neuromodulation women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding; J Urol; 2006; 1005-1009; discussion. |
Elkelini, MS, et al.; Safety of MRI at 1.5Tesla in patients with implanted sacral nerve neurostimulator; Eur Urol; 2006; 311-316; 50. |
Daneshgari, F; Application for neuromodulation of the lower urinary tract in female urology; Int Braz J Urol; 2006; 262-272; 32. |
Corcos, J, et al.; Candian Urological Association guidelines on urinary incontinence; Can J Urol; 2006; 3127-3138; 13;Abstract. |
Blok, BF, et al.; Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators; BJU Int; 2006; 1238-1243; 98. |
Atiemo, HO, et al.; Evaluation and management of refractory overactive bladder; Curr Urol Rep; 2006; 370-375; 7. |
Walter, S; [Duloxetine. A new preparation for patients with urinary incontinence]; Ugeskr Laeger; 2005; 4553-4555; 167;Abstract. |
Vignes, JR, et al.; Sacral neuromodulation in lower urinary tract dysfunction; Adv Tech Stand Neurosurg; 2005; 177-224; 30;Abstract. |
Spinelli, M, et al.; A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data; Neurourol Urodyn; 2005; 305-309; 24. |
Sievert, KD; Neuromodulation; Neurourol Urodyn; 2005; 310; 24. |
Sherman, ND, et al.; Sacral neuromodulation for the treatment of refractory urinary urge incontinence after stress incontinence surgery; Am J Obstet Gynecol; 2005; 2083-2087; 193. |
Seif, C, et al.; [Pudendal nerve stimulation therapy of the overactive bladder—an alternative to sacral neuromodulation?]; Aktuelle Urol; 2005; 234-238; 36;Abstract. |
Riazimand, SH, et al.; Interaction between neurotransmitter antagonists and effect of sacral neuromodulation in rats with chronically hyperactive bladder; BJU Int; 2005; 900-908; 96. |
Park, SH, et al.; Overactive bladder: treatment options for the aging woman; Int J Fertil Womens Med; 2005; 37-44; 50;Abstract. |
Olujide, LO, et al.; Female voiding dysfunction; Best Pract Res Clin Obstet Gynaecol; 2005; 807-828; 19. |
Minardi, D, et al.; Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report; Neuromodulation; 2005; 176-181; 8. |
Miller, JJ, et al.; Diagnosis and treatment of overactive bladder; Minerva Ginecol; 2005; 501-520; 57;Abstract. |
Mazo, EB, et al.; [The role of somatosensory evoked potentials in prognosis of efficacy of tibial neuromodulation in patients with hyperactive urinary bladder]; Urologiia; 2005; 49-52; ;Abstract. |
Leng, WW, et al.; How sacral nerve stimulation neuromodulation works; Urol Clin North Am; 2005; 42692; 32. |
Leclers, F, et al.; [Cystomanometric study of bladder sensation during sacral neuromodulation test]; Prog Urol; 2005; 238-243; 15;Abstract. |
Kocjancic, E, et al.; Sacral neuromodulation for urinary retention in a kidney-transplant patient; Urol Int; 2005; 187-188; 75. |
Kessler, TM, et al.; Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method?; Eur Urol. 2005; 660-665; 47. |
Kavia, R, et al.; Overactive bladder; J R Soc Promot Health; 2005; 176-179; 125;Abstract. |
Karsenty, G, et al.; Understanding detrusor sphincter dyssynergia—significance of chronology; Urology; 2005; 763-768; 66. |
Karademir, K, et al.; A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation; Scand J Urol Nephrol; 2005; 230-233; 39. |
Kapoor, DS, et al.; Combined urinary and faecal incontinence; Int Urogynecol J Pelvic Floor Dysfunct; 2005; 321-328; 16. |
Johnston, TE, et al.; Implantable FES system for upright mobility and bladder and bowel function for individuals with spinal cord injury; Spinal Cord; 2005; 713-723; 43. |
Jarrett, ME; Neuromodulation for constipation and fecal incontinence, Urol Clin North Am; 2005; 79-87; 32. |
Groen, J, et al.; Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mins-stimulator; Neurourol Urodyn; 2005; 226-230; 24. |
Freeman, RM, et al.; Overactive bladder; Best Pract Res Clin Obstet Gynaecol; 2005; 829-841; 19. |
Everaert, K, et al.; Sacral nerve stimulation for pelvic floor and bladder dysfunction in adults and children; Neuromodulation; 2005; 186-187; 8. |
Dasgupta, R, et al.; Changes brain activity following sacral neuromodulation for urinary retention; J Urol; 2005; 2268-2272; 174. |
Daneshgari, F, et al.; Future directions in pelvic neuromodulation; Urol Clin North Am; 2005; 113-115, viii; 32. |
Craggs, MD; Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation; BJU Int; 2005; 29-36; 96 Suppl 1. |
Bernstein, AJ, et al.; Expanding indications for neuromodulation; Urol Clin North Am; 2005; 59-63; 32. |
Benson, JT, et al.; Pudendal neuralgia, a severe pain syndrome; Am J Obstet Gynecol; 2005; 1663-1668; 192. |
Badawi, JK, et al.; [Current diagnosis and therapy of the overactive bladder and urge incontinence]; Dtsch Med Wochenschr; 2005; 1503-1506; 130;Abstract. |
Amundsen, CL, et al.; Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?; Urology; 2005; 746-750; 66. |
Amoroso, L, et al.; Sacral-neuromodulation CT-guided; Radiol Med; 2005; 421-429; 109;Abstract. |
Van Balken, MR, et al.; The use of electrical devices for the treatment of bladder dysfunction: a review of methods; J Urol; 2004; 846-851; 172. |
Uludag, O, et al.; Sacral neuromodulation in patients with fecal incontinence: a single-center study; Dis Colon Rectum; 2004; 1350-1357; 47. |
Svensson, L, et al.; Neuromodulation of experimental Shigella infection reduces damage to the gut mucosa; Microbes Infect; 2004; 256-264; 6. |
Silveri, M, et al.; Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings; J Urol; 2004; 2651-2653; 171. |
Seif, C, et al.; Finding with Bilateral Sacral Neurostimulation: Sixty-two PNE-Tests in Patients with Neurogenic and Idiopathic Bladder Dysfunctions; Neuromodulation; 2004; 141-145; 7. |
Roupret, M, et al.; Sacral neuromodulation for refractory detrusor overactivity in women with an artificial urinary sphincter; J Urol; 2004; 236-239; 172. |
Riazimand, SH, et al.; A rat model for studying effects of sacral neuromodulation on the contractile activity of a chronically inflamed bladder; BJU Int; 2004; 158-163; 94. |
Pelaez, E, et al.; [Epidural spinal cord stimulation for interstitial cystitis]; Rev Esp Anestesiol Reanim; 2004; 549-552; 51;Abstract. |
Qzyalcin, NS, et al.; [Sacral nerve stimulation in fecal incontinence; efficacy and safety]; Agri; 2004; 35-44; 16;Abstract. |
Nijman, RJ; Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children; Urology; 2004; 45-50; 63. |
Madersbacher, H; Overactive bladder—a practical approach to evaluation and management; J Med Liban; 2004; 220-226; 52;Abstract. |
Krames, E, et al.; Spinal cord stimulation reverses pain and diarrheal episodes of irritable bowel syndrome: a case report; Neuromodulation; 2004; 82-88; 7. |
Kessler, TM, et al.; [Urodynamic phenomena in the aging bladder]; Urologe A; 2004; 542-546; 43. |
Hashim H, et al.; Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations; Drugs; 2004; 1643-1656; 64. |
Guys, JM, et al.; Sacral neuromodulation for neurogenic bladder dysfunction in children; J Urol; 2004; 1673-1676; 172. |
Gonzalez-Chamorro, F, et al.; [Neurostimulation and neuromodulation in urinary incontinence]; Rev Med Univ Navarra; 2004; 75-84; 48;Abstract. |
Fowler, CJ; The perspective of a neurologist on treatment-related research in fecal and urinary incontinence; Gastroenterology; 2004; S172-174; 126. |
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2004; 681-689; 46. |
De Gennaro, M, et al.; Percutaneous tibial nerve neuromodulation is well tolerated in children and effective for treating refractory vesical dysfunction; J Urol; 2004; 1911-1913; 171. |
Bower, WF, et al.; A review of non-invasive electro neuromodulation as an intervention for non-neurogenic bladder dysfunction in children; Neurourol Urodyn; 2004; 63-67; 23. |
Abrams, P; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2004; 1116; 93. |
Wein, AJ; Diagnosis and treatment of the overactive bladder; Urology; 2003; 20-27; 62. |
Takahashi, S, et al.; Overactive bladder: magnetic versus electrical stimulations; Curr Opin Obstet Gynecol; 2003; 429-433; 15. |
Spinelli, M, et al.; New sacral neuromodulation lead for percutaneous implantation using lical anesthesia: description and first experience; J Urol; 2003; 1905-1907; 170. |
Shafik, A, et al.; Percutaneous peripheral neuromodulation in the treatment of fecal incontinence; Eur Surg Res; 2003; 103-107; 35. |
Seif, C, et al.; Improved sacral neuromodulation in the treatment of the hyperactive detrusor: signal modification in an animal model; BJU Int; 2003; 711-715; 91. |
Schurch, B, et al.; Electrophysiological recordings during the peripheral nerve evaluation (PNE) test in complete spinal cord injury patients; World J Urol; 2003; 319-322; 20. |
Schonberger, B; [Bladder dysfunction and surgery in the small pelvis. Therapeutic possibilities]; Urologe A; 2003; 1569-1575; 42. |
Scheepens, WA, et al.; Urodynamic results of sacral neuromodulation correlate with subjective improvement in patients with an overactive bladder; Eur Urol; 2003; 282-287; 43. |
Ruffion, A, et al.; [Two indications for bilateral neuromodulation]; Prog Urol; 2003; 1394-1396; 13;Abstract. |
Ruffion, A, et al.; [Sacral root neuromodulation for the treatment of urinary incontinence reported to detrusor hyperactivity]; Neurochirurgie; 2003; 377-382; 49;Abstract. |
Romero Maroto, J, et al.; [Techniques and current practice of urodynamics. Problems and traps]; Actas Urol Esp; 2003; 75-91; 27;Abstract. |
Ratto, C, et al.; Minimally invasive sacral neuromodulation implant technique: modifications to the conventional procedure; Dis Colon Rectum; 2003; 414-417; 46. |
Pannek, J, et al.; [Initial results of Stoller peripheral neuromodulation in disorders of bladder function]; Urologe A; 2003; 1470-1476; 42. |
Oliver, S, et al.; Measuring the sensations of urge and bladder during cystometry in urge incontinence and the effects of neuromodulation; Neurourol Urodyn; 2003; 42567; 22. |
Martin Braun, P, et al.; [Continuous bilateral sacral neuromodulation as a minimally invasive implantation technique in patients with functional bladder changes]; Arch Esp Urol; 2003; 497-501; 56. |
Julius, F, et al.; Catheter tip granuloma associated with sacral region intrathecal drug administration; Neuromodulation; 2003; 225-228; 6. |
Hassouna, M, et al.; Update on sacral neuromodulation: indications and outcomes; Curr Urol Rep; 2003; 391-398; 4. |
Green, BT, et al.; Neuromodulation of enteropathogen internalization in Peyer's patches from porcine jejunum; J Neuroimmunol; 2003; 74-82; 141. |
Fraser, MO, et al.; Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence; BJU Int; 2003; 743-748; 91. |
Fjorback, MV, et al.; A portable device for experimental treatment of neurogenic detrusor overactivity; Neuromodulation; 2003; 158-165; 6. |
Feler, CA, et al.; Sacral neuromodulation for chronic pain conditions; Anesthesiol Clin North America; 2003; 785-795; 21. |
Dasgupta, R, et al.; The management of female voiding dysfunction: Fowler's syndrome—a contemporary update; Curr Opin Urol; 2003; 293-299; 13. |
Comiter, CV; Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1369-1373; 169. |
Bross, S, et al.; [Sacral neuromodulation in patients with nonobstructive, chronic urinary retention: relevance of the carbachol test and influence of associated nerve lession]; Aktuelle Urol; 2003; 157-161; 34;Abstract. |
Bross, S, et al.; The role of the carbachol test and concomitant diseases in patients with nonobstructive urinary retention undergoing sacral neuromodulation; World J Urol; 2003; 346-349; 20. |
Brooks, DR, et al.; The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction; J Biol Chem; 2003; 42795-42801; 278. |
Braun, PM, et al.; Stimulation signal modification in a porcine model for suppression of unstable detrusor contractions; Urology; 2003; 839-844; 61. |
Bouchelouche, K, et al.; Recent developments in the management of interstitial cystitis; Curr Opin Urol; 2003; 309-313; 13. |
Beneton, C, et al.; [The medical treatment of overactive bladder]; Neurochirurgie; 2003; 369-376; 49;Abstract. |
Banyo, T; [The role of electrical neuromodulation in the therapy of chronic lower urinary tract dysfunction]; Ideggyogy Sz; 2003; 68-71; 56;Abstract. |
Bannowsky, A, et al.; [Sacral neuromodulation in treatment of functional disorders of the lower urinary tract. An overview of basic principles, indications, outcomes]; Urologe A; 2003; 1357-1365; 42. |
Antolak, SJ, JR.; Re: Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1956; author reply 1956; 170. |
Amarenco, G, et al.; Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder; J Urol; 2003; 2210-2215; 169. |
Abrams, P, et al.; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2003; 355-359; 91. |
Zhou, Y, et al.; Change of vanilloid receptor 1 following neuromodulation in rats with spinal cord injury; J Surg Res; 2002; 140-144; 107. |
Yamanouchi, M, et al.; Integrative control of rectoanal reflex in guinea pigs through lumbar colonic nerves; Am J Physiol Gastrointest Liver Physiol; 2002; G148-156; 283. |
Whitemore, KE; Complementary and alternative therapies as treatment approaches for interstitial cystitis; Rev Urol; 2002; S28-35; 4 Suppl 1. |
Van Kerrebroeck, PE; Neuromodulation and other electrostimulatory techniques; Scand J Urol Nephrol Suppl; 2002; 82-86. |
Uranga, A, et al.; An integrated implantable electrical sacral root stimulator for bladder control; Neuromodulation; 2002; 238-247; 5. |
Uludag, O, et al.; [Sacral neuromodulation is effective in the treatment of fecal incontinence with intact sphincter muscles; a prospective study]; Ned Tijdschr Geneeskd; 2022; 989-993; 146;Abstract. |
Swinn, MJ, et al.; The cause and natural history of isolated urinary retention in yound women; J Urol; 2002; 151-156; 167. |
Scheepens, WA, et al.; Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction; Urology; 2002; 598-602; 60. |
Scheepens, WA, et al.; Unilateral versus bilateral sacral neuromodulation in patients with chronic voiding dysfunction; J Urol; 2002; 2046-2050; 168. |
Ripetti, V, et al.; Sacral nerve neuromodulation improves physical, psychologica and social quality of life in patients with fecal incontinence; Tech Coloproctol; 2002; 147-152; 6. |
Ramundo, JM, et al.; State of the science: pathology and management of the patient with overactive bladder; Ostomy Wound Manage; 2002; 22-27; 48. |
Pettit, PD, et al.; Sacral neuromodulation: new applications in the treatment of female pelvic floor dysfunction; Curr Opin Obstet Gynecol; 2002; 521-525; 14. |
Ordia, JI, et al.; Continuous intrathecal baclofen infusion delivered by a programmable pump for the treatment of severe spasticity following traumatic brain injury; Neuromodulation; 2002; 103-107; 5. |
Mazo, EB, et al.; [Temporary sacral and tibial neuromodulation in treating patients with overactive urinary bladder]; Zh Vopr Neirokhir Im N N Burdenko; 2002; 17-21; Abstract. |
Malouf, AJ, et al.; Short-term effects of sacral nerve stimulation for idiopathic slow transit constipation; World J Surg; 2002; 166-170; 26. |
Malossi, J, et al.; Sacral neuromodulation for the treatment of bladder dysfunction; Curr Urol Rep; 2002; 61-66; 3. |
Linares Quevedo, AI, et al.; [Posterior sacral root neuromodulation in the treatment of chronic urinary dysfunction]; Actas Urol Esp; 2002; 250-260; 26;Abstract. |
Krivoborodov, GG, et al.; [Afferent stimulation of the tibial nerve in patients with hyperactive bladder]; Urologiia, 2002; 36-39; ;Abstract. |
Kohli, N, et al.; Neuromodulation techniques for the treatment of the overactive bladder; Clin Obstet Gynecol; 2002; 218-232; 45. |
Kirkham, AP, et al; neuromodulation through sacral nerve roots 2 to 4 with a Finetech-Brindley sacral posterior and anterior root stimulator; Spinal Cord; 2002; 272-281; 40. |
Jezernik, S, et al.; Electrical stimulation for the treatment of bladder dysfunction: current status and future possibilities; Neurol Res; 2002; 413-430; 24;Abstract. |
Hedlund, H, et al.; Sacral neuromodulation in Norway: clinical experience of the first three years; Scand J Urol Nephrol Suppl; 2002; 87-95; ;Abstract. |
Ferulano, GP, et al.; [Sacral neuromodulation in fecal continence disorders]; Recenti Prog Med; 2002; 403-409; 93;Abstract. |
Braun, PM, et al.; [Chronic sacral bilateral neuromodulation. Using a minimal invasive implantation technique in patients with disorders of bladder function]; Urologe A; 2002; 44-47; 41. |
Braun, PM, et al.; Alterations of cortical electrical activity in patients with sacral neuromodulation; Eur Urol; 2002; 562-566; discussion 566-567; 41. |
Amundsen, CL, et al.; Sacral neuromodulation in an older, urge-incontinent population; Am J Obstet Gynecol; 2002; 1462-1465; discussion 1465; 187. |
Wyndaele, JJ, et al.; Conservative treatment of the neuropathic bladder in spinal cord injured patients; Spinal Cord; 2001; 294-300; 39. |
Walsh, IK, et al.; Non-invasive antidromic neurostimulation: a simple effective method for improving bladder storage; Neurourol Urodyn; 2001; 73-84; 20. |
Scheepens, WA, et al.; [Neuromodulation and neurostimulation in urology]; Ned Tijdschr Geneeskd; 2001; 1730-1734; 145;Abstract. |
Mauroy, B, et al.; [Long-term results of interferential current stimulation in the treatment of bladder instability]; Prog Urol; 2001; 34-39; 11; Abstract. |
Maher, CF, et al.; Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis; J Urol; 2001; 884-886; 165. |
Krolczyk, G, et al.; Effects of continuous microchip (MC) vagal neuromodulation on gastrointestinal function in rats; J Physiol Pharmacol; 2001; 705-715; 52. |
Kirkham, AP, et al.; The acute effects of continuous and conditional neuromodulation on the bladder in spinal cord injury; Spinal Cord; 2001; 420-428; 39. |
Jarvis, JC, et al.; Functional electrical stimulation for control of internal organ function; Neuromodulation; 2001; 155-164; 4. |
Hohenfellner, M, et al.; Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants; Urology; 2001; 887-892; 58. |
Hoebeke, P, et al.; Transcutaneous neuromodulation for the urge syndrome in children: a pilot study; J Urol; 2001; 2416-2419; 166. |
Hindley, RG, et al.; The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate; BJU Int; 2001; 217-220; 88. |
Groen, J, et al.; Computerized assessment of detrusor instability in patients treated with sacral neuromodulation; J Urol; 2001; 169-173; 165. |
Groen, J, et al.; Neuromodulation techniques in the treatment of the overactive bladder; BJU Int; 2001; 723-731; 87. |
Govier, FE, et al.; Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study; J Urol; 2001; 1193-1198; 165. |
Ganio, E, et al.; Neuromodulation for fecal incontinence: outcome in 16 patients with definitive implant. The initial Italian Sacral Neurostimulation Group (GINS) experience; Dis Colon Rectum; 2001; 965-970; 44. |
Dorflinger, A, et al.; Voiding dysfunction; Curr Opin Obstet Gynecol; 2001; 507-512; 13. |
Carey, M, et al.; Sacral nerve root stimulation for lower urinary tract dysfunction: overcoming the problem of lead migration; BJU Int; 2001; 15-18; 87. |
Bugee, M, et al.; An implant for chronic selective stimulation of nerves; Med Eng Phys; 2001; 29-36; 23. |
Buback, D; The use of neuromodulation for treatment of urinary incontinence; Aorn J; 2001; 176-178, 181-177, 189-190; uiz 191-176; 76;Abstract. |
Bower, WF, et al.; A pilot study of the home application of transcutaneous neuromodulation in children with urgency or urge incontinence; J Urol; 2001; 2420-2422; 166. |
Benson, JT; New therapeutic options for urge incontinence; Curr Womens Health Rep; 2001; 61-66; 1;Abstract. |
Alo, KM, et al.; Selective Nerve Root Stimulation (SNRS) for the Treatment of Intractable Pelvic Pain and Motor Dysfunction: A Case Report; Neuromodulation; 2001; 19-23; 4. |
Alo, KM, et al.; Sacral nerve root stimulation for the treatment of urge incontinence and detrusor dysfunction utilizing a cephalocaudal intraspinal method of lead insertion: a case report; Neuromodulation; 2001; 53-58; 4. |
Wyndaele, JJ, et al.; Influence of sacral neuromodulation on electrosensation of the lower urinary tract; J Urol; 2000; 221-224; 163. |
Weil, EH, et al.; Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial; Eur Urol; 2000; 161-171; 37;Abstract. |
Wang, Y, et al.; Neuromodulation reduces urinary frequency in rats with hydrochloric acid-induced cystitis; BJU Int; 2000; 726-730; 86. |
Wang, Y, et al.; Neuromodulation reduces c-fos gene expression in spinalized rats: a double-blind randomized study; J Urol; 2000; 1966-1970; 163. |
Sun, Y, et al.; Effects of neural blocking agents on motor activity and secretion in the proximal and distal rat colon: evidence of marked segmental differences in nicotinic receptor activity; Scand J Gastroenterol; 2000; 380-388; 35. |
Shaker, H, et al.; Role of C-afferent fibres in the mechanism of action of sacral nerve root neuromodulation in chronic spinal cord injury; BJU Int; 2000; 905-910; 85. |
Rovner, ES; Treatment of urinary incontinence; Curr Urol Rep; 2000; 235-244; 1. |
Nijman, RJ; Classification and treatment of functional incontinence in children; BJU Int; 2000; 37-42; discussion 45-36; 85 Suppl 3. |
Mazo, EB, et al., [Temporary sacral neuromodulation in patients with urge incontinence]; Urologiia; 2000; 42-46; ;Abstract. |
Klingler, HC, et al.; Use of peripheral neuromodulation of the S3 regions for treatment of detrusor overactivity: a urodynamic-based study; Urology; 2000; 766-771; 56. |
Hohenfellner, M, et al.; [Sacral neuromodulation of the urinary bladder]; Urologe A; 2000; 55-63; 39. |
Hohenfellner, M, et al.; Sacral neuromodulation for treatment of lower urinary tract dysfunction; BJU Int; 2000; 10-19; discussion 22-13; 85 Suppl 3. |
Grill, WM; Electrical activation of spinal neural circuits: application to motor-system neural prostheses; Neuromodulation; 2000; 97-106; 3. |
Dahms, SE, et al.; Sacral neurostimulation and neuromodulation in urological practice; Curr Opin Urol; 2000; 329-335; 10. |
Costa, JA, et al.; Spinal cord neuromodulation for voiding dysfunction; Clin Obstet Gynecol; 2000; 676-688; 43. |
Chancellor, MB, et al.; Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions; Neuromodulation; 2000; 16-26; 3. |
Bosch, JL, et al.; Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study; J Urol; 2000; 1219-1222; 163. |
Bosch, JL; Sacral neuromodulation: treatment success is not just a matter of optimal electrode position; BJU Int; 2000; 20-21; discussion 22-23; 85 Suppl 3. |
Van Der Aa, HE, et al.; Sacral anterior root stimuation for bladder control: clinical results; Arch Physiol Biochem; 1999; 248-256; 107. |
Vaizey, CJ, et al.; Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence; Gut; 1999; 407-412; 44. |
Sullivan, J, et al.; Overactive detrusor; Curr Opin Urol; 1999; 291-296; 9. |
Sullivan, J, et al.; The overactive bladder: neuropharmacological basis of clinical management; Curr Opin Obstet Gynecol; 1999; 477-483; 11. |
Shaker, H, et al.; Sacral root neuromodulation in the treatment of various voiding and storage problems; Int Urogynecol J Pelvic Floor Dysfunct; 1999; 336-343; 10;Abstract. |
Ishigooka, M, et al.; Sacral nerve stimulation and diurnal urine volume; Eur Urol; 1999; 421-426; 36;Abstract. |
Craggs, M, et al.; Neuromodulation of the lower urinary tract; Exp Physiol; 1999; 149-160; 84. |
Braun, PM, et al.; Tailored laminectomy: a new techniqu for neuromodulator implantation; J Urol; 1999; 1607-1609; 162. |
Bemelmans, BL, et al.; Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction; Eur Urol; 1999; 81-91; 36;Abstract. |
Anton, PA; Stress and mind-body impact on the course of inflammatory bowel diseases; Semin Gastrointest Dis; 1999; 14-19; 10;Abstract. |
Zvara, P, et al.; An animal model for the neuromodulation of neruogenic bladder dysfunction; Br J Urol; 1998; 267-271; 82. |
Wallace, JL, et al.; Lack of beneficial effect of a tachykinin receptor antagonist in experimental colitis; Regul Pept; 1998; 95-101; 73. |
Van Kerrebroeck, PE; The role of electrical stimulation in voiding dysfunction; Eur Urol; 1998; 27-30; 34 Suppl 1;Abstract. |
Shaker, HS, et al.; Sacral root neuromodulation in idiopathic nonobstructive chronic urinary retention; J Urol; 1998; 1476-1478; 159. |
Shaker, HS, et al.; Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence; J Urol. 1998; 1516-1519; 159. |
Schultz-Lampel, D, et al.; Experimental results on mechanisms of action of electrical neuromodulation in chronic urinary retention; World J Urol; 1998; 301-304; 16. |
Schmidt, RA, et al.; Neurostimulation and neuromodulation: a guide to selecting the right urologic patient; Eur Urol; 1998; 23-26; 34 Suppl 1;Abstract. |
Jiang, CH; Modulation on the micturition reflex pathway by intravesical electrical stimulation: an experimental study in the rat: Neurourol Urodyn; 1998; 543-553; 17. |
Hohenfellner, M, et al.; Bilateral chronic sacral neuromodulation for treatment of lower urinary tract dysfunction; J Urol; 1998; 821-824; 160. |
Hasan, ST, et al.; Neuromodulation in bladder dysfunction; Curr Opin Obstet Gynecol; 1998; 395-399; 10. |
Grunewald, V; Neuromodulation/neurostimulation; World J Urol; 1998; 299-300; 16. |
Chapple, CR, et al.; Surgery for detrusor overactivity; World J Urol; 1998; 268-273; 16. |
Brown, DR, et al.; Delta-opioid receptor mRNA expression and immunohistochemical localization in porcine ileum; Dig Dis Sci; 1998; 1402-1410 ;43. |
Bower, WF, et al.; A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency; J Urol; 1998; 2133-2136; 160. |
Bosch, JL, et al.; Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperflexia; Behav Brain Res; 1998; 141-150; 92. |
Bosch, JL; Sacral neuromodulation in the treatment of the unstable bladder; Curr Opin Urol; 1998; 287-291; 8. |
Turner, WH, et al.; Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment; Pharmacol Ther; 1997; 77-110; 75. |
Sutherland, RS, et al.; Vesicourethral function in mice with genetic disruption of neuronal nitric oxide synthase; J Urol; 1997; 1109-1116; 157. |
Gottwald, T, et al., [Sex differences in neuromodulation of mucosal mast cells in the rat jejunum]; Langenbecks Arch Chir. 1997; 157-163; 382;Abstract. |
Gonzalez-Chamorro, F, et al.; [Current status of neurostimulation and neuromodulation for vesicourethral dysfunction]; Arch Esp Urol; 1997; 687-694; 50;Abstract. |
Everaert, K, et al.; The urodynamic evaluation of neuromodulation in patients with voiding dysfunction; Br J Urol; 1997; 702-707; 79. |
Sheriff, MK, et al.; Neuromodulation of detrusor hyper-reflexia by functional magnetic stimulation of the sacral roots; Br J Urol; 1996; 39-49; 78;Abstract. |
Hasan, ST, et al.; Surface localization of sacral foramina for neuromodulation of bladder funtion. An Anatomical study; Eur Urol; 1996; 90-98; 29;Abstract. |
Hasan, ST, et al.; Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability; J Urol; 1996; 2005-2011; 155. |
Bristow, SE, et al.; TENS: a treatment option for bladder dysfunction; Int Urogynecol J Pelvid Floor Dysfunct; 1996; 185-190; 7. |
Traynor, TR, et al.; Neuromodulation of ion transport in porcine distal colon: NPY reduces secretory action of leukotrienes; Am J Physiol; 1995; R426-431; 269;Abstract. |
Kinder, MV, et al.; Neuronal circuitry of the lower urinary tract central and peripheral neuronal control of the micturition cycle; Anat Embryol (Berl); 1995; 195-209; 192. |
Hassouna, M, et al.; Dog as an animal model for neurostimulation; Neurourol Urodyn; 1994; 159-167; 13. |
Duve, H, et al.; Distribution and functional significance of Leu-callatostatins in the blowfly Calliphora vomitoria; Cell Tissue Res; 1994; 367-379; 276. |
Wiklund, CU et al.; Modulation of cholinergic and substance P-like neurotransmission by nitric oxide in the guinea-pig ileum; Br J Pharmacol; 1993; 833-839; 110. |
Tanagho, EA; Concepts of neuromodulation; Neurourol Urodyn; 1993; 487-488; 12. |
Katsuragi, T, et al.; Possible transsynaptic cholinergic neuromodulation by ATP released from ileal longitundinal muscles of giunea pigs; Life Sci; 1993; 911-918; 53. |
Dijkema, HE, et al.; Neuromodulation of sacral nerves for incontinence and voiding dysfunctions. Clinical results and complications; Eur Urol; 1993; 72-76; 24;Abstract. |
Tanagho, EA; Neuromodulation in the management of voiding dysfunction in children; J Urol; 1992; 655-657; 148;Abstract. |
Dijkema, HE, et al.; [Initial experiences with neuromodulation as treatment for incontinence and micturition disorders in The Netherlands]; Ned Tijdschr Geneeskd; 1992; 88-90; 136;Abstract. |
Collins, SM; Is the irritable gut an inflamed gut?; Scand J Gastroenterol Suppl; 1992; 102-105; 192;Abstract. |
Parija, SC, et al.; Adenosine- and alpha,beta-methylene ATP-induced differential inhibition of cholinergic and non-cholinergic neurogenic responses in rat urinary bladder; Br J Pharmacol; 1991; 396-400; 102. |
Kachur, JF, et al.; neuromodulation of guinea pig intestinal electrolyte transport by cholecystokinin octapeptide; Gastroenterology; 1991; 344-349; 100;Abstract. |
Katsuragi T, et al.; Involvement of dihydropyridine-sensitive Ca2+ channers in adenosine-evoked inhibition of acetylcholine release from guinea pig ileal preparation; J Neurochem; 1990; 363-369; 55. |
Burnstock, G; Innervation of bladder and bowel, Ciba Found Symp; 1990; 2-18; discussion 18-26; 151;Abstract. |
Wiklund, NP, et al.; Cholinergic neuromodulation by endothein in guinea pig ileum; Neurosci Lett; 1989; 342-346; 101. |
Carey, HV, et al.; Neuromodulation of intestinal transport in the sucking mouse; Am J Physiol; 1989; R481-486; 256;Abstract. |
Wiklund, NP, et al.; Neuromodulation by adenine nucleotides, as indicated by experiments with inhibtors of nucleotide inactivation; Acta Physiol Scand; 1986; 217-223; 126;Abstract. |
Hoyle, CH, et al.; Ethylcholine mustard aziridinium ion (AF64A) impairs cholinergic neuromuscular transmission in the guinea-pig ileum and urinary bladder, and cholinergic neuromodulation in the enteric nervous system of the guinea-pig distal colon; Gen Pharmacol; 1986; 543-548; 17. |
Katsuragi, T, et al.; Cholinergic neuromodulation by ATP, adenosince and its N6-substituted analogues in guinea-pig ileum; Clin Exp Pharmacol Physiol; 1985; 73-78; 12;Abstract. |
Barroso U Jr et al.; Electrical nerve stimulation for overactive bladder in children;Nature Reviews Urology; 2011; 402-407; 8. |
M. Matsushita et al.; Primary somatosensory evoked magnetic fields elicited by sacralsurface electrical stimulation; Neuroscience Letters; 2008; 77?80; 431. |
N. Patidar et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactivebladder: A preliminary report; Journal of Pediatric Urology; 2015; 351.e1-351.e6; 11. |
Perissinotto et al.; Transcutaneous Tibial Nerve Stimulation in the Treatment of Lower UrinaryTract Symptoms and Its Impact on Health-Related Quality of Life in Patients With ParkinsonDisease; J Wound, Ostomy and Continence Nurses Society; 2015; 94-99; 42. |
Tomonori Yamanishi et al.; Neuromodulation for the Treatment of Lower Urinary TractSymptoms; Low Urin Tract Symptoms; 2015; 121-132; 7. |
Christopher J. Chermansky et al., “MP68-15 Electrical Stimulation of Afferent Nerves in the Foot NITH Transcutaneous Adhesive Pad Electrodes Improves Overactive Bladder Symptoms in Women”, The Journal of Urology, vol. 195, No. 4S, Supplement, Monday, May 9, 2016, 2 pages. |
Christopher J. Chermansky, “Foot/Hand Neuromodulation for Overactive Bladder (OAB) (FootStim)”; First Posted: Oct. 30, 2013; http://clinicaltrials.govict2/show/NCT01972061; pp. 1-5. |
Tai et al., “FootStim: Neuromodulation therapy for overactive bladder”; http://www.engineering.pitt.edu/Sub-Sites/Programs/Coulter/Projects/2013---FootStim/: retrieved on Sep. 26, 2017. |
Oliver_et_al—2003—Neurourology_and_Urodynamics. |
J. Groen and J.L.H.R. Bosch; Neuromodulation techniques in the treatment of the overactive bladder; BJU International (2001), 87, 723-731. |
Michael Craggs and Jonathon McFarlane; Neuromodulation of the lower urinary tract; Experimental Physiology (1999), 84, 149-160. |
Yogi A. Patel; Kilohertz Electrical Stimulation Nerve Conduction Block: Effects of Electrode Surface Area; IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. 25, No. 10, Oct. 2017. |
Number | Date | Country | |
---|---|---|---|
20170281938 A1 | Oct 2017 | US |
Number | Date | Country | |
---|---|---|---|
62119134 | Feb 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14893946 | Nov 2015 | US |
Child | 15048760 | US |